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CD23, the low affinity IgE receptor, is a trimeric C-type lectin (45 kDa) expressed on 
the surface of several haematopoetic cells. Several soluble CD23 fragments, monomeric 
and trimeric, are produced by endogenous proteases and by the dust mite allergenic 
protease, Der p 1. These fragments have many ligands resulting in a variety of 
functions; including the regulation of IgE production by B-cells (via CD21) and 
triggering the release of pro-inflammatory mediators from monocytes (by binding 
CD11b/c integrins). A recombinant version of the monomeric CD23 fragment produced 
by Der p1 (Der-CD23) was expressed in E. coli and was able to bind an IgE-Fc mutant 
(KA = 9.0 x 106 M-1). Two chimeric proteins were assessed for their ability to form 
stable, trimeric CD23. A fusion protein comprising the neck region of surfactant 
protein-D and CD23 formed trimers, but was unstable and had low affinity for IgE. 
When extracellular CD23 sequence was fused with an isoleucine zipper (LZ-CD23), 
dimeric or trimeric CD23 formed, which did not degrade as readily and had wild type 
affinity for an IgE-Fc mutant (KA = 5.3 x 107 M-1). LZ-CD23 was shown to be more 
effective at binding IgE and CD21 than Der-CD23 by ELISA, presumably because of 
its ability to form trimers. An attempt at expressing recombinant soluble integrin, 
CD 11 b/CD 18, in insect cells lead to both subunits being sequestered within the cell. 
Using soluble integrins expressed by mammalian cells, specific interactions between 
Der-CD23 and CD1lb/CD18 and the vitronectin receptor ((cvß5) were demonstrated. 
Preliminary experiments indicated a suppressive effect of Der-CD23 and LZ-CD23 
upon in vitro IgE synthesis. Thus, Der-CD23 and LZ-CD23 are useful molecular tools 
to study the biological roles of monomeric and trimeric sCD23. Furthermore, NMR 
techniques are currently being employed to elucidate the 3D structure of the lectin 
domain and identification of ligand binding sites. 
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CHAPTER 1: INTRODUCTION 
1.1 Introduction to IgE and its Receptors 
IgE is one of five classes of antibody (IgM, IgG, IgE, IgA and IgD), distinguished by its 
heavy chain (CE). When a foreign antigen is recognised by the variable regions of the 
antibody, it is the constant region of the antibody (Fc) that determines its `effector' 
response through ligation to Fc receptors (FcERI and FcsRII) on a variety of cells 
(Figure 1.1). IgE is present in the serum at very low concentrations (50-300 ngml) and 
has a short half life (2 days) when compared to other antibody classes (IgG 1 at 10 
mg/ml, 3 week half life) but is effective in providing protection from parasites. Aberrant 
production of IgE is characteristic of allergic diseases affecting 20% of Western 
populations. Thus, there is much interest to understand the mechanisms of IgE 
production and the interactions with its receptors. 
The high affinity IgE receptor is expressed on the surface of mast cells and basophils. 
IgE binds to FccRJ with a very high affinity (KA = 1010 M-1) through residues in the Cc2 
and CF3 3 domains (reviewed by Sutton and Gould, 1993). The receptor is a complex of 
four transmembrane subunits, a43y2. The a chain belongs to the immunoglobulin (Ig) 
superfamily, consisting of two Ig-like domains al and a2 which form the IgE binding 
site (Figure 1.1). The 0 and y chains are not involved directly in IgE binding but 
mediate a transmembrane signal on allergen binding. 
IgE can bind to FccRI on mast cells even in the absence of antigen, thus `sensitising' the 
cell. On re-introduction of antigen/allergen the receptors are cross-linked, which signals 
the release of mediators. This process is very rapid as the antigen-specific antibody is 
already bound to the effector cell (hence, the immediate hypersensitivity response). The 
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signal transduction pathway leads to the degranulation of the effector cell, releasing 
histamine and a number of lymphokines, including IL-4, to recruit and activate 
inflammatory cells. IL-4 is an important multifunctional cytokine involved in the up- 
regulation of IgE synthesis, and notably is a potent stimulator of FceRII (CD23) 
expression on B cells. 
Cross-linking of FctRII by IgE-allergen complexes also triggers effector functions of 
inflammatory cells e. g. facilitating phagocytosis or cytotoxicity by macrophages, 
eosinophils, monocytes and platelets. Cross-linking membrane CD23 induces activation 
of a tyrosine kinase, leading to a cascade through IKK and IkBa leading to NF-KB 
activation and gene transcription (Ten et al., 1999). FccRII exists as a membrane 
protein, from which a soluble form is released. Both have several other biological 
functions, IgE dependent and independent (section 1.5), mediated by other counter 
structures (CD21, CD1lb/CD 18). To clarify its role in functions distinct from effector 
mechanisms, it will be referred to as CD23. 
1.2 CD23 
1.2.1 Expression 
CD23, is present on populations of B-lymphocytes and a variety of haematopoietic 
cells. These include macrophages, monocytes, eosinophils, platelets, follicular dendritic 
cells in the light zone of the lymph node, Langerhans cells and T lymphocytes 
(reviewed by Delespesse et al., 1991). CD23 has also been detected on some epithelial 
cells (Billaud et al., 1989). CD23 is expressed on a subset of resting B cells, and can be 
induced following antigen activation, and lost on differentiation into plasma cells. In 
addition to the expression on cell surfaces, it has been detected in bodily fluids as a 
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soluble form (sCD23). Pathologically, a high level of sCD23 is regarded as a disease 
marker in conditions such as chronic lymphocytic leukaemia, allergy and in chronic 
inflammatory diseases such as rheumatoid arthritis. 
1.2.2 Structure of CD23 
The gene encoding CD23 was identified on Chromosome l 9p 13, adjacent to the 
recently discovered DC-SIGN and DC-SIGNR (Trask et al., 1993; Soilleux et al., 
2000). CD23 cDNA was cloned by 3 different groups (Kikutani et al., 1986; Ludin et 
al., 1987; Ikuta et al., 1987) from human lymphocytes and B-cell lines. The nucleotide 
sequence predicted a protein of 321 amino acids, with residues Cysl6l to Cys288 
showing homology with the carbohydrate recognition domain (CRD) of animal 
calcium-dependent (C-type) lectins, e. g. human and rat asialoglycoprotein receptor, 
chicken hepatic lectin and CD72. This makes CD23 an unusual Fc receptor, as all other 
known Fc receptors belong to the Ig superfamily (Figure 1.2). To date, a high resolution 
structure of CD23 has not been obtained; instead much is inferred from modelling based 
on the crystal structures of Mannose Binding Protein (Weis et al., 1991) and E-selectin 
(Graves et al., 1994). The atomic structure of several (>9) C-type lectins have been 
solved by crystallography and show that the CRD to contains equal proportions of alpha 
helices and beta sheet but contain a significant amount of `random coil'. One or two 
calcium binding sites are co-ordinated by this backbone. Stable coordination of the 
calcium ion is provided by the ligand (hydroxyl groups of terminal sugar groups). The 
sugar specificity of CD23 was defined as galactose, particularly glycoproteins 
terminating in Gal-GalNac (Kijimoto et al., 1994). As will be described in section 1.4, 
additional, or accessory, protein binding sites in the CRD are important for CD23 ligand 
binding. Indeed, interaction with IgE is not through carbohydrate recognition (Richards 
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CD23 is a type II membrane protein with 2 isoforms, a and b, differing in N-terminal 
residues. The `stalk' region contains leucine rich heptad repeat sequences that are predicted 
to form alpha helical coiled coil associations. Hydrophobic residues are coloured cyan. 
Along the stalk are several sites of proteolysis and a N-linked glycosylation site (green). 
Sequence in the `head' region has homology to animal C-type lectins and is modeled on the 
crystal structure of rat mannose binding protein A (inset). Highlighted regions have been 
identified to form interactions with IgE (Bettler et al., 1992). The C-terminal `tail' is of 
unknown structure but contains an inverse RGD motif (red). Circled residues indicate the 
start and end points of the recombinant proteins described in this thesis (Chapters 3 and 4). 
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CD23 is a type II membrane protein that contains a single transmembrane domain and 
an N-terminal cytoplasmic domain. The cytoplasmic domain contains a short sequence 
of 20 amino acids rich in arginine and glutamate residues. There are two splice variants 
expressed on B cells, CD23a and CD23b differing by 6 or 7 amino acids at the N- 
terminus. CD23a is present only on B cells and contains the motif YSEI, which is 
utilized in proteins targeted to coated pits, and so supports its role in antigen 
endocytosis (section 1.5.2). CD23b expression is induced by IL-4 and confers FccRII 
effector function (Yokota et al., 1992). 
The extracellular sequence between the membrane and lectin domain consists of a series 
of heptad repeat sequences. The first and fourth residue is hydrophobic so that in an 
alpha helix, a hydrophobic side promotes the association of an alpha helical coiled-coil. 
From structure prediction, this coiled coil region is 10 nm long, with little flexibility, 
and continues to the boundary of the lectin domains that are, as a result, probably 
closely packed. Beavil et al. (1995) confirmed, with chemical cross-linking evidence, 
that CD23 can form trimers at the cell surface and in solution. 
At the base of the stalk is a N-linked glycosylation site conserved in human and mouse 
which may stabilise the associated trimer in the membrane (Letellier et al., 1990). 0- 
linked glycosylation containing sialic acid has been reported to exist in lectin domain 
but has not been characterised or any function assigned (Letellier et al., 1988). Finally, 
there is a short C-terminal sequence (tail) of unknown structure but contains an inverse 
RGD motif, a common requirement in the binding sites of several ligands of integrins. 
The C-terminal tail may be important in association with MHC-II (HLA-DR) in the 
membrane (Kijimoto-Ochiai and Noguchi, 2000). 
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CD23 cDNA has also been cloned from mouse (Kondo et al., 1994) rat, horse and 
partially from cattle (Watson et al., 2000). Although the key structural features are 
present in these species, i. e. lectin domain and stalk region, some vital differences are 
apparent, notably the length of stalk region and the sequence and length of the C- 
terminal tail. These structural contrasts could account for the differences in CD23 ligand 
binding and function, particularly evident between the better characterised human and 
mouse systems, for instance, the murine CD23-CD21 interaction has yet to 
demonstrated. 
1.3 Production of Soluble CD23 
Fragments of extracellular CD23 (37 kDa, 33 kDa, 29 kDa, 25 kDa and 16 kDa) can be 
detected in B cell cultures and body fluids (Figure 1.3) and were previously referred to 
as IgE Binding Factors (Delepesse et al., 1989). The 29-37 kDa fragments are short 
lived and contain varying lengths of the alpha helical stalk region and have been shown 
to exist as trimers in solution (Beavil et al., 1995). The serine/cysteine protease 
inhibitor, tosyl-L-lysyl chloromethanhydrochloride ketone (TLCK) appears to prevent 
degradation along the stalk region and release of CD23 from membranes (Cairns et al., 
1990). The stable 25 kDa fragment contains only lectin domain and C-terminal tail and 
is monomeric. Its production can be inhibited by iodoacetamide (Letellier et al., 1990). 
A further cleavage site is present in the tail resulting in a monomeric 16 kDa fragment 
that Sarfati et al., (1984) were able to purify from human colostrum. Production of 16 
kDa CD23 can not be inhibited by iodoacetamide thus, a different protease again is 
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1.3.1 Endogenous Proteases 
Initially it was thought CD23 was being cleaved by an auto-proteolytic activity, as it 
was being specifically degraded by a factor present in CD23+ cells and recombinant 
CD23 preparations (Letellier et al., 1990). Recently, metalloproteinase inhibitors 1,10, 
phenanthroline, imidazole and batimastat were found to inhibit 33 kDa sCD23 release 
from solubilised membranes (Marolewski et al., 1998). Further characterisation of the 
protease showed it to be membrane anchored (approximately 63 kDa), pH dependent 
(optimal at pH 7) with a Km of 220 nM and present in most cell lines except T-cells. 
These characteristics were similar to the matrix metalloproteinases (MMP) responsible 
for the shedding of L-selectin. This finding was supported by Gu et al., 1998, who 
demonstrated the hydroxamic acid based inhibitor of zinc dependent MMPs, Ro31- 
9790, was able to inhibit ATP-induced shedding of CD23 (and L-selectin) from the 
surface of B-chronic lymphocytic leukaemia cells. Also, GI 129471, another 
hydroxamate based Zn 2+ MMP inhibitor, prevented sCD23 production by IL-4, CD40L 
stimulated tonsillar B-cells (Wheeler et al., 1998). Thus, evidence suggests the protease 
responsible for CD23 shedding is a neutral Zn2+ dependent MMP. The endogenous 
proteases responsible for 25 kDa and 16 kDa CD23 remain unknown. 
1.3.2 Allergenic Protease, Der p1 
The dust mite allergen Der p1 is a cysteine protease that was shown to cleave 
membrane CD23 in vitro. Schultz et al. (1995) demonstrated Der p1 incubated with 
RPMI 8866 cells released a soluble 17 kDa CD23 fragment and can be inhibited by a-1 
antitrypsin. This fragment has been characterised at both termini and identified as 
Ser156-G1u298, encompassing the lectin domain. Shakib et al. (1998) hypothesise that 
Der p1 is able to cross the mucosal barrier and remain active suggesting CD23 
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proteolysis may occur in vivo. In addition to CD23 proteolysis Schultz et al. (1998) also 
showed Der p1 was able to cleave the alpha subunit of the IL-2R (CD25) on TH 1 cells. 
Inactivation of these receptors is speculated to bias immune response toward TH2 cells, 
typical of an allergic response. 
1.4 CD23 Ligand Interactions 
1.4.1 CD23-IgE Interaction 
Consistent with other classes of Immunoglobulin, IgE comprises of two heavy and two 
light chains (Figure 1.1). Unlike IgG, the heavy chain contains an extra immunoglobulin 
domain (Cs2) where the hinge region would be. A number of biophysical experiments 
suggest the IgE molecule assumes a bent conformation (Zheng et al., 1991; Beavil et 
al., 1995). A high resolution structure has been obtained for IgE Fc (Cc3-Cc4) and in a 
complex with its high affinity receptor (Garman et al., 2000; Wurzburg et al., 2000). 
However, no crystallography data describes the IgE-CD23 interaction. 
Despite being referred to as the low affinity IgE receptor, CD23 has a fairly high 
affinity for IgE, KA = 3-7 x 10-7 M-1 (Anderson and Spielgelberg, 1981, Bettler et al., 
1992; Sato et al., 1997). Ultracentrifugation data suggests that the stoichiometry of the 
interaction is 2 lectin domains binding one IgE Fc molecule (Shi et al., 1997) Figure 
1.1b). It is believed that 2 sites on IgE interact with the CD23 trimer, one being on the 
CO3 domain close to the N371 glycosylation site. Despite this proximity, CD23 does not 
require carbohydrate for binding. Indeed, the absence of exposed carbohydrate allows 
IgE Fc to bind FceRII with a 10 fold higher affinity than the wild type IgE-Fc (Young et 
al., 1995). Thus, CD23 is not utilising its lectin activity in the IgE interaction. The 
interaction sites are contained within the lectin domain alone. Homologue scanning 
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mutagenesis (Bettler et al., 1992) identified discontinuous regions of lectin domain that 
potentially interact with IgE (Figure 1.2) that are located around the calcium ion binding 
sites. This would account for the calcium dependent binding observed. 
1.4.2 CD21, Complement Receptor 2 (CR2) 
CD21 (CR2) binds inactivated forms of C3b that opsonise pathogenic surfaces and is 
important in B cell activation and the alternative pathway of activation of the 
complement system (reviewed by Fearon and Carroll, 2000). CR2 was identified as the 
ligand for CD23 on B-cells (Aubry et al., 1992) that participates in the IL-4 induced IgE 
up-regulation, and B-cell growth and differentiation (section 1.5). CD21 is present on 
mature B cells (IgM+/IgD+), until activated, and follicular dendritic cells (FDC) in 
germinal centres. CD21 has also been found at low levels on epithelial cells and some T 
lymphocytes (Timens et al., 1991). 
The structure of CD21 (approximately 145 kDa) is composed of 15 or 16 short 
consensus repeat (SCR) domains found in several complement proteins e. g. CRI, C2, 
Factor B and Factor H. These domains of 60-75 amino acids are arranged like a `string 
of beads'. Monoclonal antibodies have helped to identify the SCR domains involved in 
CD21 ligand binding to C3d (SCR 1-2), CD23 (SCR 1-2 and 5-8), EBV (SCR 1-2) and 
interferon-a (SCR 3-4; Figure 1.4). There are 11 N-linked glycosylation sites but no 
apparent O-linked glycosylation. Unlike C3d binding, carbohydrate is required for the 
interaction with CD23 (Aubry et al., 1994). The sugar specificity of the CD23-CD21 
interaction is unknown; galactose was unable to inhibit the interaction, and reports of 
fucose 1 phosphate inhibition are contradictory (Pochon et al., 1992, Sato et al., 1997). 
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Figure 1.4: Schematic diagram of CD21 Structure and Ligand Binding Sites 
This diagram shows the results of epitope mapping anti-CD21 monoclonal antibodies 







A single transmembrane domain anchors the receptor to the cell surface, and a 
cytoplasmic domain of 34 amino acids is responsible for signal transduction via a 
potential Protein Kinase C motif (TSQK) and/or a sequence common to tyrosine kinase 
substrates. CD21 is part of a large signal transduction complex involving the association 
of CD 19, CD81 and Leu 13. 
In addition to the membrane bound form CD21 is shed from the surface of B-cells and 
still retains iC3b and CD23 binding capabilities (Fremeaux-Bacchi et al., 1996). The 
soluble form of CD21 (135 kDa and 90 kDa) was shown to circulate in complexes with 
C3, CD23 and IgE. Biological relevance of sCD21 is unknown but could inhibit sCD23 
enhanced IgE synthesis (Fremeaux-Bacchi et al., 1998; section 1.5.1). 
1.4.3 CDllb/CD18 and CDllc/CD18 (CR3 and CR4) 
Both CR3 (Mac-1, CD11b/CD18, aMß2) and CR4 (p150, p95, CD11c/CD18 (xXß2) 
belong to the integrin superfamily. Integrins comprise two non-covalently associated 
subunits a (-150 kDa) and ß (- 90 kDa). To date, 14 alpha and 8 beta chains have been 
identified which are able to form up to 21 distinct heterodimers. Some subunits are 
promiscuous (e. g. (W) whereas some pair exclusively with one other subunit, e. g. aM. 
Integrins can be grouped according to their beta subunit. Both CR3 and CR4 belong to 
the leukocyte ß2 family expressed on monocytes, granulocytes, NK cells and a subset of 
B cells and T cells. 
CD 11 b and CD 11 c are type I transmembrane proteins with a short cytoplasmic domain 
of 19 and 26 residues, respectively. The structure of the extracellular region is only 
partially understood. Structure predictions suggest seven repeating sequences assume a 
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ß-propeller fold similar to that found in the trimeric G protein ß subunit (Springer, 
1997). 
In between the second and third repeat is a domain homologous to the von Willebrand 
A domain called the I (inserted) domain. Crystallography studies of CDllb I domain 
shows this domain resembles a dinucleotide binding `Rossman' fold of a beta sheet 
surrounded by 7 alpha helices (Lee et al., 1995). Many of the receptor's ligands have 
been mapped to this domain, which contains a Metal Ion Dependent Adhesion Site 
(MIDAS). Divalent cations in particular, Mn2+, Mgt+, and Ca 2+ regulate the binding at 
this site. The (32 integrins have many ligands: cell surface, matrix and soluble proteins, 
endogenous and foreign (Table 1.1). 
Ligand binding requires the presence of both subunits. The beta subunit (CD18) has an 
`I' -like domain and a cytoplasmic domain that contains an actin-binding site, thereby 
linking cellular and extracellular adhesions to the cytoskeleton. Through the 
cytoplasmic domains an `inside-out' signal can be transmitted to alter the adhesive 
states of the extracellular domains. Resting cells are in a low adhesive state until an 
intracellular signal can rapidly activate the cell to a high adhesive state, e. g. during 
transmigration of leukocyte through endothelium. (32 integrins also serve as classic 
signal transduction receptors for several soluble ligands, e. g. Factor X, C3 and CD23. 
The interaction of CD23 with CD 11 b/CD 18 and CD 11 c/CD 18 was partly characterised 
by Lecoanet-Henchoz et al. (1995). The CD23 binding site on the integrin was mapped 
to the alpha subunit by blocking monoclonal antibodies. Factor X was the most potent 
inhibitor of CD23 binding of the ß2 ligands tested, suggesting their binding sites are in 
close proximity. If this was the case, it is likely that CD23 form contacts with regions 
outside of the I domain as well (Zhou et al., 1994). The interaction was calcium 
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dependent as it was inhibited by EDTA and was also sensitive to deglycosylation by 
tunicamycin. This would be indicative of C-type lectin activity, however, EDTA could 
be disrupting metal ion dependent binding of either CD23 or the integrin. Activation of 
monocytes via CD11b and CD11c was achieved using monomeric 25 kDa sCD23 
(Aubry et al., 1995). Therefore, this putative lectin-carbohydrate interaction does not 
rely on avidity effects to improve affinity. 
A common motif found in some integrin ligands is Arg-Gly-Asp (RGD) found in 
fibronectin, vitronectin, von Willebrand factor and the foot and mouth virus, and is used 
in the integrin interaction. Human CD23 contains an inverse RGD sequence in its C- 
terminal tail. However, RGD peptide and antibodies failed to inhibit CD23 binding to 
CD1 lb and CD11c. Furthermore, the absence of such a motif in murine CD23 (which 
also exhibits monocyte activation via CD11b) suggests the integrin binding site is 
elsewhere on CD23. 
Table 1.1: Ligands of the 02 Integrins and Vitronectin Receptors 
Integrin Other names Li ands CD23 Binding 
aLß2 LFA-1, ICAM-1,2,3,4 No 
CD ll a/CD 18 
äM132 CR3, Mac-1, ICAM-1,2, iC3b, LPS, Fibronectin, Lecoanet-Henchoz et 
CD 1l b/CD 18 Factor X, sCD 16, sCD23 al., 1995 
aXI32 CR4, Fibronectin, iC3b, LPS, sCD16, Lecoanet-Henchoz et 
pl 50, p95, sCD23 al., 1995 
CD ll c/CD 18 
äDß2 ICAM-3 Not determined 
ävß1 Vitronectin Vitronectin, fibronectin, von Not determined 
receptor Willebrand factor, fibrinogen 
äv133 Vitronectin Vitronectin, PECAM-1, Laminin, Hermann et al., 1999 
receptor, Fibrinogen, Fibronectin, Von 
CD51/CD61 Willebrand Factor, Collagen, 
osteopontin, Thrombospondin 
ävß5 Vitronectin Vitronectin, Fibrinogen, Matheson et al., 
receptor Fibronectin 1999 
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Figure 1.5: Structure of Integrin Subunits 
The alpha subunits of integrin superfamily are type I glycoproteins with a short cytoplasmic 
domain. There are seven N-terminal repeat sequences believed to fold into aß propeller 
domain (Springer, 1997). Some alpha subunits (al, a2 aL aM aX aD aE a9) have a 
conserved I domain between the 3rd and 4th repeat, where most ligands bind. Other alpha 
subunits are proteolytically processed in the extracellular domain which remains attached 
by disulphide bridge (a3, a5, a6, a7, a8 allb and av). The beta subunits form intracellular 
protein contacts. An I-like domain and 4 EGF-like cysteine rich domains are present in the 
extracellular domain but are ofunknown structure and function. 
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1.4.4 Vitronectin Receptors, ocvß3 and ocvf35 
Hermann et al. (1999) provided evidence for another CD23-integrin interaction. CD23 
mediated pro-inflammatory cytokine release (TNF(x, IL- 12, IENy) was inhibited by 
antibodies to the av(33/CD47 complex on monocytes. CD23 binding to av(33+ cell lines 
was inhibited by anti-ocv. Furthermore, CD23 (25 kDa) was demonstrated to bind 
purified av and av transfected CHO cells. Binding to avß3 was improved by the 
presence of CD47. The authors propose that sCD23 binds directly to the av of the 
av(33/CD47 complex mediating an inflammatory response. Matheson et at. (1999) 
isolated c v135 chains from pre B cell like lymphocytic cell line as the receptor for 
sCD23. Antibodies to CD23, av and ß5 were able to inhibit CD23 binding to these 
cells. CD47 was present but not ß3, ß2 or CD21. The significance of this interaction 
may be the prevention of pre B cells going into apoptosis (White et al., 1997). 
Structurally, the notable difference between the ß2 integrin and avß3 and av15, is that 
av contains no I domain. RGD peptides have been chemically cross-linked to a region 
comprising repeat 2-7 of av (Smith and Cheresh, 1990) that forms part the putative 0 
propeller structure (Springer, 1997). In this model, a Mg 2+ ion binds to the upper cavity 
of the propeller, providing a binding site similar to the MIDAS in the I domain. 
Functionally, av integrins which are widely expressed also have a large repertoire of 
ligands in addition to vitronectin and fibronection (Table 1.1). av133 and avß5 and are 
implicated in, tumour invasion, bone resorption and transendothelial migration. The 
interaction of av(33 and avß5 with CD23 has yet to be confirmed and the biological 
significance remains unclear. 
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1.5 Biological Functions of CD23 
1.5.1 Regulation of IgE Synthesis 
Several lines of in vitro evidence have implicated CD23 in the up-regulation and down- 
regulation of IgE synthesis, using recombinant CD23, B-cell line cultures, anti-CD23 
monoclonal antibodies and CD23 processing inhibitors (summarised in Table 1.2). 
Furthermore, inhibition of CD23 processing in vivo also resulted in IgE suppression 
(Mayer et al., 2000). CD23 regulation of IgE occurs in IgE committed (i. e. IL-4 
dependent) B cells (Saxon et al., 1990). Furthermore, CD21 was identified as a ligand 
for CD23, also involved in the enhancement of IgE production (Aubry et al., 1992). 
Figure 1.6 illustrates a hypothetical model of a molecular mechanism for IgE regulation 
proposed by Sutton and Gould (1993). Down regulation or up regulation of IgE 
production is attributed to whether CD23 is in its membrane or soluble form, 
respectively. CD23 on the surface of B cells binding IgE or IgE-immune complexes 
transduces an inhibitory signal that prevents further IgE synthesis. This is supported by 
observations that IgE-CD23 blocking antibodies stimulate IgE synthesis (Sherr et al., 
1989) and that CD23 knockout mice have constantly increased IgE levels (Yu et al., 
1994). IgE binding appears to prevent CD23 being shed from the surface, presumably 
by stabilising the trimer (Munoz et al., 1998). In the absence of IgE, the CD23 is 
cleaved terminating the negative feedback and allows the B cell to increase IgE 
synthesis. 
In the human system, sCD23 is thought to up-regulate IgE synthesis either through 
ligation to membrane expressed CD21 or possibly by trapping IgE in the medium 
preventing it binding to membrane CD23 and triggering the negative signal, or both. 
The hypothetical cross-linking of IgE-CD23-CD21 to trigger IgE up-regulation (Figure 
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1.6) attempts to consolidate the wealth of in vitro results (Table 1.2). Certain evidence, 
e. g. enhancement by monomeric 25 kDa CD23 (Mayer et al., 2000) and the 
contradictory effects of anti-CD23 Fab, IgG 1 and IgG4 molecules (Sarfati et al., 1988, 
Natamura et al., 2000), suggest other mechanisms or receptors are responsible in these 





IgE Synthesis I IgE Synthesist 
Figure 1.6: Hypothetical Molecular Mechanism For IgE regulation by CD23. 
IgE, CD23 and CD21 are expressed on the surface of antigen activated B cells. In the 
presence of antigen and soluble IgE, a negative feedback signal is transduced on binding 
IgE. In a situation where membrane CD23 remains unligated, sCD23 is released and 
triggers a stimulatory signal possibly through the cross-linking of surface IgE and CD21 
(Sutton and Gould, 1993). 
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Table 1.2: Evidence for role of CD23 in IgE Regulation 
Culture Additive Effect on IgE 
Production 
Reference 
Cell line supernatants 
RPMI 8866 (sCD23) ENHANCED Sarfati et al., 1984 
EBV (sCD23) ENHANCED Sarfati et al., 1984 
Recombinant sCD23 
33 kDa sCD23 ENHANCED Chretien et al., 1990 
29 kDa sCD23 ENHANCED Aubry et al., 1992, Sarfati et al., 1992 
25 kDa sCD23 
(degradation product) 
ENHANCED Mayer et al., 2000 
16 kDa sCD23 (& native) SUPPRESSED Sarfati et al., 1992 
16 kDa + 29 kDa sCD23 SUPPRESSED Sarfati et al., 1992 
Monoclonal Antibodies 
IgE blocking anti-CD23 SUPPRESSED Wakai et al., 1993 
EBVCS-1 (anti-CD23) ENHANCED Wakai et al., 1993 
Anti-CD23 Fab SUPPRESSED Sarfati et al., 1988 
Anti-CD23 Fab NO EFFECT Natamura et al., 2000 
Anti-CD23-chimeras SUPPRESSED 
(IgG1 > IgG4) 
Natamura et al., 2000 
Others 
EBV peptide SUPPRESSED Henchoz et al., 1996 
Anti-CD21 ENHANCED Aubry et al., 1992 
Soluble CD21 SUPPRESSED Fremeaux-Bacchi et al., 1996 
MMP Inhibitors SUPPRESSED Mayer et al., 2000, Christie et al., 
1998, Wheeler et al., 1998 
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1.5.2 IgE-CD23 Facilitated Antigen Presentation 
Antibodies IgM, IgG and IgE have the ability to enhance or suppress an immunological 
response to their specific antigen. IgE is able to upregulate specific IgM, IgG1, IgG2 
and IgE. Mice immunised with haptenated protein plus a monoclonal IgE specific for 
the hapten group gave a 100 fold increase in serum levels of specific IgG than with 
haptenated protein alone (Heyman et al., 1993). Through the use of blocking antibodies 
and knockout mice, CD23 was identified as the receptor for this IgE mediated 
enhancement of specific antibody production. Furthermore, CD23 expressed on B cells, 
not follicular dendritic cells, is responsible in the murine system and requires the 
presence of T cells (reviewed by Heyman, 2000). In humans CD21 is also implicated in 
CD23 facilitated antigen presentation (Grosjean et al., 1994). 
A plausible mechanism is an increase in antigen binding, processing and presentation. 
CD23a expressed on the surface of B cells has been shown to be effective at 
internalising IgE-antigen complexes for processing and presentation of peptides by 
MHC II to antigen specific CD4+ T helper cells in vitro. CD23 has been shown to be 
spatially associated with MHC II (HLA-DR) in human B cell membranes (Bonnefoy et 
al., 1988), which could be a result of antigen processing but also CD23 may be acting as 
a co-stimulatory or cell-cell adhesion molecule with CD21 at the immunological 
synapse. Alternatively, the binding of IgE-antigen complexes by CD23 may focus 
antigen on B-cells. Bound antigen could readily activate the B-cell through surface 
immunoglobulin and complement receptor. 
1.5.3 Growth and Differentiation Factor 
CD23 acts as a growth factor for antigen activated (or phorbol ester treated) B cells in 
culture. Soluble CD23 (25 kDa) in conjunction with IL-1 is able to rescue germinal 
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centre B cells (centrocytes) from apoptosis in vitro (Liu et al., 1991). In vivo CD23 
would allow those centrocytes primed with antigen to survive, presumably because 
sCD23 upregulates Bcl-2. This mechanism is thought to occur through IgE and CD21 
cross-linking (Sutton and Gould, 1993; Reljic et al., 1997). In this way expression of 
CD23 (induced by IL-4) might promote the survival of IgE switched centrocytes. CD23 
and IL-1 (also in vitro) promotes the differentiation of centrocytes to antibody 
synthesising plasma cells, pro-thymocytes into T-cells (Bertho et al., 1991) and myeloid 
precursors into basophils (Arock et al., 1991). 
1.5.4 Monocyte Activation. 
Armant et al. (1994) demonstrated that sCD23 alone was able to stimulate the release of 
inflammatory cytokines TNP-a, IL-6, IL-1(x and IL-10 from PBMC, typical of 
activated monocytic cells. Armant et al., 1995 went further to show that sCD23 plus 
IL-2 co-stimulation of monocytes upregulates accessory molecules (CD40, B7) which 
induces the release of IFNy by resting T-cells (in the absence of TCR occupancy). 
This activity of sCD23 could not be attributed to binding to IgE or CD21. Lecoanet- 
Henchoz et al. (1995) identified the 02 integrins CD 11 b/CD 18 (CR3) and CD 11 c/CD 18 
(CR4) as the monocyte receptors for recombinant CD23 in fluorescent liposomes. 
Interaction of recombinant soluble CD23 (25 kDa) with CD 11 b or CD 11 c triggers a 
transient calcium ion influx that activates a membrane bound, constitutively expressed, 
nitric oxide synthase (NOS). Nitric oxide is produced; cGMP accumulates ultimately 
leading to the production of TNF-a and other pro-inflammatory mediators (Aubry et al., 
1997). Two mitogen activated protein kinase pathways were identified as essential for 
the induction and control of IL-1 ß synthesis triggered by the sCD23-CD 11b/CD 18 and 
CD 11 c/CD 18 interaction (Rezzonico et al., 2000). CD 11b, CD 11 c ligation with sCD23 
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was also shown to activate NF-KB leading to the expression of macrophage 
inflammatory protein, MIP 1a and MIP 1(3 (Rezzonico et al., 2001). Activation of 
monocytes through 132 integrins is likely to influence adherence to endothelial cells in 
transmigration, monocyte-T-cell interactions, chemotaxis of other immune cells to site 
of inflammation, phagocytosis and cytotoxicity. 
1.5.5 Other Possible Roles for CD23 
Homotypic B-cell adhesion as observed with EBV transformed cells has been attributed 
to CD23 interactions with galactose glycoproteins (Kijimoto-Ochaia et al., 1994) 
suggests CD23 could act as a cell adhesion molecule. CD23 may even play a role in cell 
migration. Stimulating anti-CD23 monoclonal antibodies have been reported to enhance 
eosinophil migration towards the chemokine, C5a (Lantero et al., 2000). In studies with 
a monocytic cell line, U937, purified soluble CD23 was a potent inhibitor of monocyte 
migration which could be reversed by anti-CD23 monoclonal antibodies (Flores-Romo 
et al., 1989). With the discovery of CD 11b and CD 11 c as the receptor for sCD23 on 
monocytes, it remains to be seen whether inhibition of spontaneous migration was a 
result of blocking these adhesion molecules. 
1.6 Implications of Soluble CD23 in Disease 
It is established that overproduction of IgE is a hallmark of allergic disease. Serum 
sCD23 is also significantly increased in atopic patients as compared to normal controls. 
With the mounting in vitro evidence that sCD23 (in addition to IL-4) is capable of 
enhancing IgE synthesis, and that anti-CD23 monoclonal antibodies, and CD23 
processing inhibitors can suppress IgE production, makes CD23 a potential target for 
therapeutics (Sutton et al., 2000; Riffo-Vasquez et al., 2000). 
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High levels of sCD23 are found in the serum of patients with B-chronic lymphocytic 
leukaemia. Levels indicate the extent of tumour load and clinic stage of the disease and 
are therefore used as a prognostic marker. CD21 is also upregulated and it is speculated 
that the CD21-sCD23 interaction underlies the B cell proliferation aspect of this disease 
(Lopez-Matas et al., 2000). CD23 levels are also elevated in other diseases 
characterised by aberrantly proliferating B-cells: in certain immunocytomas and low- 
grade non-Hodgkin's lymphomas and EBV infections. 
Elevated sCD23 levels are reported in a variety of chronic inflammatory diseases 
(reviewed by Bonnefoy et al., 1996) e. g. systemic lupus erythematosus, inflammatory 
bowel, Sjogren's syndrome glomerulonephritis and rheumatoid arthritis (RA). In RA 
patients, sCD23 levels are high in serum but even greater in the synovial fluid of the 
joint. Within the synovial compartment there are very few B-cells (CD21+ or IgE+), 
quiescent T-cells but macrophages (CD1lb+ CD1lc+) are plentiful and are considered 
responsible for joint damage (Huissoon et al., 2000). The importance of CD23 in the 
pathology of joint disease was shown by the suppression of collagen-induced arthritis in 
mice by anti-CD23 monoclonal antibodies (Plater Zyberk et al., 1995). Thus, it is 
tempting to speculate that increased sCD23 contributes to the on-going inflammatory 
damage through continued activation of synovial macrophages. Prevention of sCD23 
binding to CD11b and CD11c would be a valid target for anti-inflammatory therapies 
and justifies further investigation of the interaction. 
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1.7 Objectives of the Thesis 
This thesis describes the expression and characterisation of two recombinant sCD23 
fragments. The first, Der-CD23 comprises the sequence of the lectin domain produced 
by proteolysis by the house dust mite protease, Der p 1. This recombinant 16 kDa CD23 
was used for NMR structural determination of the CD23 C-type lectin domain. The 
second CD23 fragment produced was a chimeric recombinant protein designed to 
stabilise the trimeric association of CD23. Two motifs for chimeric CD23 were 
compared; the surfactant protein D neck region and an isoleucine rich leucine zipper. 
Both the CD23 lectin domain and trimeric sCD23 were included in ligand binding 
assays with recombinant IgE, CD21 and its integrin ligands in order to characterise their 
interactions in a cell free system. Kinetic data was obtained by surface plasmon 
resonance for the interactions between the novel proteins and IgE-Fc. Finally, the 
recombinant 16 kDa CD23 and trimeric CD23 were included in preliminary in vitro IgE 
synthesis assays utilising human peripheral blood mononuclear cells so that the 
mechanism of IgE suppression and enhancement could be investigated. 
Thus, by the use of recombinant components, the structure and function of the l6kDa 
and trimeric soluble CD23 can be understood in more detail. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Buffers, Solutions and Media 
Carbonate-Bicarbonate Buffer (pH 9.8): 22 ml 0.2 M anhydrous sodium carbonate, 
28 ml 0.2 M sodium hydrogen carbonate, d. H20 to 200 ml. 
Coomassie Blue Stain: 0.25% Coomassie Brilliant Blue, 7.5% acetic acid, 5% 
methanol 
Coomassie De-stain: 10% Acetic Acid, 40% methanol in d. H20 
DNA loading Buffer: 0.25% Bromophenol Blue, 0.25% xylene cyanol, 30% glycerol 
Extraction Solution 1: 10 mM Tris-C1 pH 7.9,25% sucrose, 0.1 M KCl, 10 mM DTT, 
2 mM PMSF (in isopropanol) 
Extraction Solution 2: 0.3 M Tris-Cl pH 7.9,100 mM EDTA, 0.1 g Lysozyme 
Extraction Solution 3: 20 mM EDTA, 1M LiCI, 0.5% Igepal 
Extraction Solution 4: 10 mM Tris-Cl pH 7.9,2.5 mM EDTA, 1M LiCI, 0.5% Igepal, 
10 mM DTT, 1 mM PMSF 
Extraction Solution 5: 10 mM Tris-Cl pH 7.9,2.5 mM EDTA, 2% Igepal, 10 mM 
DTT, 2 mM PMSF 
Extraction Solution 6: 10 mM Tris-Cl pH 7.9,2.5 mM EDTA, 0.5% Igepal, 10 mM 
DTT, 2 mM PMSF 
HBS-Ca: 10 mM HEPES, 150 mM NaCl, 2 mM CaC12,0.05% NaN3,0.002% SP20 
Luria-Bertani media (1 1): 10 g Bactotryptone, 5g Yeast extract, 10 g NaCl pH 7.5 
(with NaOH) 
M9 salts (10X): 10 g NH4C1,30 g KH2PO4,60 g Na2HPO4 -7H20 
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M9 minimal media (500 ml): 50 ml lOX M9 salts, 450 ml d. H20 autoclave. 
12.5 ml 20% casamino acids, 25 ml 20% glucose, 0.5 ml 0.1 M CaC12,0.5 ml 1M 
MgSO49 0.5 ml 10 mg/ml thiamine (all additives are filter sterilised) 
PBS: 0.14 M NaCl, 2.7 mM KC1,1.5 mM KH2PO4,8.1 mM Na2HPO4, pH 7.4 
Plasmid Preparation Solution 1 (P1): 50 mM Tris-Cl pH 8.0,10 mM EDTA, 0.1 
mg/ml RNase I 
Plasmid Preparation Solution (P2): 1% SDS, 0.2 M NaOH 
Plasmid Preparation Solution 3 (P3): 5M Potassium Acetate pH 5.5 
SDS Loading Buffer (4X): 0.25 M Tris-Cl pH 6.8,0.01% Bromophenol Blue, 40% 
glycerol, 8% SDS (plus 10% (3-mercaptoethanol for reducing buffer) 
SDS Running Buffer (10X): 30.2 g Tris, 114 g Glycine, 10 g SDS up to 11 with d. H20 
SDS Tris Glycine Separation Gel Buffer: 1.5 M Tris-Cl, 0.4% SDS, pH 8.8 
SDS Tris Glycine Stacking Gel Buffer: 0.5 M Tris-Cl, 0.4% SDS, pH 6.8 
Semi-Dry Western Blot: Cathode Buffer: 25 mM Tris-Ci, pH 9.4,40 mM 
s-aminocaproic acid, 20% methanol 
Semi-Dry Western Blot: Anode Buffer: 0.3 M Tris-Cl, pH 10.4,20% methanol 
Silver Diamine Solution: 21 ml 0.36% NaOH, 1.4 ml ammonia, 4 ml 20% silver 
nitrate, d. H20 to 100 ml 
Silver Stain Reducing Solution: 2.5 ml 1% citric acid, 0.26 ml formaldehyde, d. H20 
to 500 ml 
Silver Stain Stop Solution: 10% Acetic Acid, 45% methanol 
Silver Stain Farmer's Reducer: 0.3% (w/v) potassium ferricyanide, 0.6% (v/v) 
sodium thiosulphate, 0.1 % (w/v) sodium carbonate 
SOC: 2g bactotryptone, 0.55 g yeast extract, 10 mM NaCl, 10 mM KCl autoclave in 
97 ml d. H20. Add 10 mM MgSO4,10 mM MgCl2 and 20 mM glucose, filter sterilise. 
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TAE (10X): 48.4 g Tris, 11.4 ml glacial acetic acid, 20 ml 0.5 M EDTA, d. H20 up toll 
TBE: 90 mM Tris, 90 mM orthoboric acid, 2 mM EDTA 
TBS-Ca: 25 mM Tris-Cl pH 7.5,137 mM NaCl, 2 mM CaC12 
TE: 10 mM Tris-Cl, pH 8.0,1 mM EDTA 
Wet transfer Western Blot Buffer: 3g Tris, 14 g glycine, 20% methanol, d. H20 to 11 
2.1.2 Antibodies, Recombinant Proteins and Peptides 
Anti-CD23 Antibodies: rb55, rabbit polyclonal (Glaxo) was used in Western blotting. 
A variety of monoclonal antibodies recognising epitopes on the lectin domain were used 
in ELISA (Table 2.1), EBV-CS 1 being the exception as it binds to residues in the stalk 
domain (epitope mapping by Wakai et al., 1993). MHM6 used in Western Blotting only 
recognises CD23 under non-reducing conditions. 
Table 2.1: Details of Monoclonal anti-CD23 Antibodies. 
Monoclonal 
Antibody 
Source CD23 epitope Isotype 
B6 Coulter Immunotech Lectin Domain IgG2b 
BU38 Hybridoma (also Binding Site) Lectin Domain IgGl 
EBV-CS1 W. Sugdon, WI, USA Stalk IgGI 
EBV-CS2 W. Sugdon, WI, USA Lectin Domain IgG1 
EBV-CS4 W. Sugdon, WI, USA Lectin Domain IgM 
EBV-CS5 W. Sugdon (also BD) Lectin Domain IgGl 
IOB 8 Coulter Immunotech Lectin Domain IgG 1 
mAb 25 Coulter Immunotech, Glaxo Lectin Domain IgG 1 
MHM6 Hybridoma (also Dako) Lectin Domain IgG 1 
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Anti-CD21 Antibodies: HB5 (hybridoma culture); BU33 (Binding Site, Birmingham, 
UK); IF8 (DAKO) 
Anti-Integrin Antibodies: KIM87 (CD 18), KIM 127 (CD 18), 6. E (CD 18) mapped by 
Stephens et al., 1995; Ab44 was obtained from Serotec; L230 ((xvß5), Ab1961 ((xv(35), 
Ab1980 (av(35), were all obtained from Celltech (Slough, UK). 
Other Antibodies: M2 anti-FLAG (Kodak), donkey anti-rabbit immunoglobulin-HRP 
(DAKO); rabbit anti-mouse immunoglobulin-HRP (DAKO); G anti-CD40; goat anti- 
IgE (DAKO); goat anti-IgE-HRP (DAKO). 
Recombinant proteins: rCD23 (3lkDa) E. coli expression and purification described 
by R. Reljic (1996); sCD21 recombinant baculovirus (gift of VM Holers, Colorado, 
USA); anti-NIP IgE (JW8 hybridoma culture), IgE-Fc bIIgII (NSO culture, Young et al., 
1995) recombinant soluble integrin (Fc fusions) aMß2, avßl, av133 and avß5 were 
produced at Celltech (Stephens et al., 2000); iC3b (Calbiochem); IL-4 (R&D), 
Fibronectin, Fibronectin RGD peptide and Vitronectin RGD peptide (Sigma). 
2.2 DNA Manipulation Techniques 
2.2.1 Plasmid Vectors 
The cloning of PCR products and engineering of DNA constructs were carried out in 
either pBluescript KS II (Stratagene) or in pSP73 (Promega). Both shuttle vectors are 
high copy and can be selected through their resistance to Ampicillin. Plasmid vectors 
for expression in E. coli and insect cells by baculovirus: pET5a (Novagen), pFastBac 
and pFastBacDUAL (GibcoBRL). 
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2.2.2 PCR 
1 pmol of each primer was used in 50 µl PCR using 1 ng of cDNA template. 1-3 mM 
magnesium chloride, 20 µM dNTP and 1U of Taq polymerase (all Promega) or Pwo 
polymerase (Expand, Boehringer Mannheim, for longer PCR products) were included in 
the reaction. The annealing temperatures of the primers were estimated by (4n[G/C] + 
2n[A/T]) from Suggs et al. (1981) and was used in a 25 cycles of: 95 °C, 1 minute; 
annealing temperature 4 °C, 1 min; 72 °C, 1-1.5 minutes on a Biometra Trio- 
thermoblock PCR machine. 5 µl of PCR products were analysed on a TBE-agarose gel. 
Pooled PCR products were precipitated by adding sodium acetate, pH 3.5 to 0.1 M and 
then 3 volumes of 100% ethanol, incubating on ice for 30 minutes and spun down at 
13,000 rpm for 10 minutes. The DNA pellet was washed with 70% ethanol, dried in air 
for 10 minutes and resuspended in 50 µl of the appropriate restriction digest buffer. 
2.2.3 Agarose Gel Electrophoresis of DNA 
0.5-1.5% agarose was melted in TBE or TAE buffer, cooled, 0.5 µg/ml ethidium 
bromide added and set in a gel tray with plastic comb. Once set, the gel was placed into 
electrophoresis apparatus and covered in buffer. 5 µl samples in DNA Loading Buffer 
were placed in the wells alongside appropriate DNA Molecular weight markers (A- 
HindIII, pBS-HpaII) and a voltage of 100 V was applied across the gel until the 
fragments were separated, viewed by UV radiation. 
2.2.4 Restriction Digest 
1-5 U of restriction enzyme (or Promega or NEB recommendation) was used per 
microgram of DNA (PCR product or plasmid vector) and incubated at 37 °C for 1-2 
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hours in manufacturers' recommended reaction buffer. The reaction was stopped by 
heating to 60 °C for 15 minutes. DNA loading buffer was added and the digested PCR 
fragment and vector were separated on an agarose-TAE gel. The band was excised and 
the DNA purified by QIAGEN gel extraction kit. Concentration of insert and vector 
were estimated by comparison of similar sized DNA of known concentration on a TBE- 
agarose gel. 
2.2.5 Ligation 
Relative quantities of vector to insert were calculated by the following equation using 
100 ng of vector per ligation: 
Mass of insert (ng) = 100 x size of insert (kb) x molar ratio of insert: vector 
size of vector (kb) 
Ligation in 10 µl was carried out with 10 U T4 ligase and buffer (New England Biolabs) 
for 24 hours at 16 T. Reactions containing a molar ratio of insert: vector of 1 and 3 
were performed alongside a negative control containing no insert to give an indication 
of the effectiveness of the vector digestion. 
2.2.6 Transformation 
100 ng plasmid or 5 p1 of ligation product was used to transform chemically competent 
E. soli cells (Xli Blue) prepared by P. Marsh. 50 µl cells were added on ice and 
incubated for 15 minutes; heat shock at 42 °C for 2 minutes was followed by addition of 
200 41 SOC and 30 minutes at 37 °C. 100 µl was spread onto LB-agar plate containing 
100 p g/ml ampicillin (and also 40 µg/ml IPTG and 100 µg/ml X-gal for blue/white 
colony selection of pBluescript) and incubated overnight at 37 °C 
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2.2.7 Plasmid purification 
Single colonies (white if selected on IPTG/X-gal plates) were picked and cultured in 2 
ml LB (plus 100 ig/m1 Ampicillin) overnight at 37 T. 1.5 ml of the culture was spun at 
10,000 rpm for 2 minutes and the plasmid DNA from the bacterial pellet was extracted 
by the method of Birnboim, 1983. Cultures of positive colonies were used to produce 
larger, purer quantities of plasmid DNA using the QIAGEN plasmid purification MIDI- 
kit following the manufacturers instructions. Concentrations of purified plasmid were 
estimated by spectrophotometry, where A260 of 1 is the equivalent of 50 µg/ml double 
stranded DNA. 
2.2.8 Colony Screening 
Identification of colonies containing the insert of interest was carried out by either 
restriction digest or a PCR screen. Restriction digest was performed using 3 µl of 
purified plasmid in a 10 t1 reaction. For the PCR screen, 20 µl reactions were spiked 
with cells picked from a single colony with NUNC inoculating needles. Clones were 
also spotted onto a fresh agar plate labelled with colony numbers. Up to 94 colonies 
could be analysed by PCR using a 96 well plate in a Hybaid PCR machine. DNA 
loading dye was added to the digests or PCR reactions and analysed by TBE-agarose 
gel electrophoresis. Colonies screened as positives were confirmed by sequencing 
2.2.9 Sequencing 
Oligonucleotides of 20 bases, of 50/50 AT/GC content, were designed along both 
strands of the insert at 350-400 bp staggered intervals. Primers outside the cloning site 
were also designed or provided by the vector's supplier. The insert was sequenced by a 
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dideoxy termination method using the Big Dye Terminator cycle Sequencing kit (PE 
biosystems). Following a 7.5 µl cycling reaction (including 0.5-1.0 p. g DNA, 3.2 pmol 
primer) the products were analysed using ABI Prism Technology (PE biosystems) by A. 
Lyons (Celltech). Clones with the no sequence errors were used in further construct 
assembly rounds or the insert was excised and transferred to the expression vector. 
2.2.10 Sequence Analysis 
Sequencing data from each primer were overlapped and edited by the Autoassembler 
software (Perkin Elmer). The sequence obtained was then compared to the original 
sequence using Mac Vector 6.5 software (Oxford Molecular). The sequence of the 
cDNAs were obtained from Genbank databank available on the internet (listed in Table 
2.2). Any point mutations found were checked to see whether they were silent (and 
therefore acceptable) by translating the sequence data by Mac Vector and comparing it 
to the correct protein sequence. 
Table 2.2: Genbank Names and Numbers of Construct Sequences 
DNA Genbank Name Accession Number Author reference 
Human CD23 HUMFCERA M14766 Kikutani, H. 1986 
Human CDl lb HUMLAPA M18044 Arnaout, M. A. 1988 
Human CD 18 HUMLAP M15395 Kishimoto, T. 1987 
Human SPD HUMSPD02 L05484 Rust, K. 1991 
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2.3 Protein Expression Systems 
2.3.1 Escherichia. coli 
2.3.1.1 Expression Conditions 
100 ng of recombinant expression plasmid was used to transform either BL21 (DE3) or 
BL21 (DE3) (pLysS) supplied by P. Marsh, KCL, or Invitrogen. 
Genotypes: 
BL21 (DE3): F ompT hsdSB (rB-mB-) gal dem (DE3) 
BL21 (DE3) pLysS: F ompT hsdSB (rB-mB-) gal dem (DE3) pLysS (CamR) 
Transformation into these cells differs from the standard protocol as heat shock stage at 
42 °C only needed 40 seconds. Cells containing the target plasmid (pET5a) were 
selected by 50 µg/ml ampicillin (or 50 µg/ml carbenicillin). When using the E. coli host 
strain containing pLysS, 34 pg/ml chloramphenicol was also required. 
A single colony was picked and grown in 2 ml M9 media containing antibiotics for 8 
hours. An overnight culture of 100 ml was inoculated with 1 ml. The following day, 500 
ml M9 media containing antibiotics was inoculated with 10 ml of overnight culture in a 
21 conical flask. The culture was incubated at 37 °C, with orbital agitation at 200 rpm 
until the A600 reached 0.6-1.0. Expression of the target was induced with 0.4 mM IPTG. 
The cells were harvested after further incubation at 3 hours by centrifugation at 5000 
rpm for 10 minutes in a GSA rotor (Sorvall). The pellets were stored frozen at -20 °C. 
2.3.1.2 Purification of Der-CD23 from Inclusion Bodies 
Inclusion bodies from at least 1 litre of culture were extracted and purified by the 
method of Bohmann and Tjian (1989) using the extraction solutions listed in 2.1. The 
pellet was resuspended in 72 ml of Solution 1 with DNase I (Sigma) to break up viscous 
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cellular DNA. The cells lyre on thawing if using BL21 (DE3) (pLysS) strain, even so, 
18 ml Solution 2 was added containing lysozyme and incubated on ice for 10 minutes. 
90 ml solution 3 was added, vortexed and sonicated on ice for up to 10 minutes to 
disperse clumps of material, then centrifuged for 10 minutes at 10,000 rpm in a GSA 
rotor at 4 °C. The inclusion body pellet was resuspended in 200 ml Solution 4, sonicated 
and pelleted as before. This washing step was repeated using Solutions 5 and 6. The 
final purified preparation of inclusion bodies was resuspended in 5 ml 6M Guanidine 
and incubated at room temperature for 1 hour. Soluble proteins are separated from 
insoluble material by centrifugation at 10,000 rpm, 4 °C for 5 minutes. The protein 
concentration was measured by A280 adjusted to 10 mg/ml and stored at 4 T. 
2.3.1.3 Refolding 
This was the method used by Taylor et al., 1992, involving the reduction of cysteine 
residues with glutathione to facilitate refolding by dilution into cysteine buffer. 20 mg 
of protein in 6M Guanidine was reduced by 10 mM DTT, 100 mM Tris-Acetate, pH 
8.6, and left standing at room temperature for 1 hour. The reduced protein was diluted 
ten-fold in 6M Guanidine, 0.5 M Tris-Acetate pH 8.6 and 100 mM glutathione 
(oxidised form, Sigma). The glutathione intermediate was formed at 4 °C for 24 hours. 
The protein was further diluted 100-fold into a refolding buffer containing 100 mM 
Tris-Acetate pH 8.6,3 mM cysteine and 2 mM CaC12. This addition was made slowly to 
avoid precipitation. The protein was allowed to refold at 4 °C, in the dark for 48 hours. 
2.3.2 Baculovirus Expression System 
Expression in insect cells was carried out with the pFastBac baculovirus expression 
system. Methods for virus production were adapted 
from the manufacturers handbook 





10 ng of pFastBac containing the cloned construct was placed in sterile 15 ml 
polypropylene tubes and 100 µl of DH1oBac competent cells were added. After 30 
minutes incubation on ice, the cells were heat shocked at 42 °C for 45 seconds then 
chilled on ice for 2 minutes. 900 µ1 SOC medium was added and the mixture placed at 
37 °C with medium agitation for 4 hours. 100 µl and a dilution of 1 in 1000 of the 
transposed cells were plated on agar plates (containing 50 µg/ml Kanamycin, 7, µg/ml 
Gentamycin, 10 , g/m1 Tetracyclin, plus 100 µg/m1 Bluo-gal and 40 µg/ml IPTG for 
blue/white colony selection). The plates were left to incubate at 37 °C for at least 24 
hours. 10 white colonies were picked, streaked onto fresh plates and incubated at 37 °C 
for another 24 hours. 
2.3.2.2 Isolation of Recombinant Bacmid DNA. 
3 colonies were picked and grown at 37 °C for 24 hours in 2 ml LB (containing 
antibiotics). 1.5 ml of the culture was used to produce a preparation of the bacmid DNA 
by standard plasmid purification: resuspension in 250 µl Buffer P1; lysis 3-4 minutes 
with the addition of 250 µl Buffer P2; and neutralisation at room temperature on gentle 
mixing with 250 µl Buffer P3. The suspension was centrifuged for 10 minutes at 13,000 
rpm and the supernatant carefully transferred to an equal volume of isopropanol. The 
DNA was precipitated by incubation on ice for 10 minutes. After centrifugation 13,000 
rpm, 10 minutes, the pellet was washed with 0.5 ml 70% ethanol, dried, resuspended in 
50 µl TE and stored at -20 °C. The samples of the DNA preparation were run on a 0.5% 
agarose gel in TAE buffer to confirm the presence of the bacmid DNA by its 
characteristic pattern. 
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2.3.2.3 Transfection of Sf9 Cells with Recombinant Bacmid DNA. 
9x 105 Sf9 cells in mid-log phase were seeded in a6 well plate in 2 ml sf-90011 serum 
free media (JRH) or excell 420 (JRH). After the cells had been left to attach for an hour 
at 27 °C, the media removed and washed with fresh media. A mixture of 5 µI bacmid 
DNA in 100 µl media and 6 µl of the lipid suspension CELLFECTIN in 100 µl media 
were gently mixed and incubated at room temperature for 30 minutes and then diluted 
to 1 ml with media. The lipid-DNA complexes was used to overlay the cells and 
incubated for 5 hours or overnight. The transfection mixture was removed and 2 ml of 
media added and incubated at 27 °C for 48 hours. Between 48-72 hours the virus 
infected cells had died and the cells and media were assayed for protein by Western 
blot. 
2.3.2.4 Estimating Virus Titre by Plaque Assay. 
The culture was centrifuged at 4000 rpm for 5 minutes and the supernatant (viral 
fraction) was stored in the dark at 4 °C. 1.2 x 106 Sf9 cells in 1.8 ml media were seeded 
in 6 well trays and left to attach for 1 hour. A serial dilution of the virus 
(10-1,10-2... 10-9) were made in the wells and left to adsorb onto the cells by incubating 
at 28 °C. After 2 hours the media was removed and to the wells 2 ml of a 1: 1 mixture of 
media and 3.2% low gelling temperature agarose in PBS was added. Once set, 1 ml of 
media was placed on top of the agarose overlay. The trays were incubated at 28 °C for 7 
days. To detect the plaques, the live cells were stained by the addition of 1 ml of a1 in 
20 dilution of Neutral Red (Sigma) in PBS for 1 hour. The stain was removed and the 
wells left in the dark for a couple of hours or overnight before estimating the virus titre 
by the number of clear plaques (dead, infected, cells from a single virus). 
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2.3.2.5 Amplifying the viral titre. 
To amplify the viral titre a monolayer or suspension of Sf9 cells of density 0.8 x 106 per 
ml were infected with the stock virus. 400 ml and 800 ml suspensions could be 
produced in flat bottomed round flasks with agitation by a magnetic bar stirrer at 180 
rpm at 28 °C. The following formula was applied where the multiplicity of infection 
(MOI) for viral amplification was 0.1 (i. e. the ratio of plaque forming units of virus to 
host cell number). Higher densities of cells could be used with excell 420 as this richer 
media could support growth to 4x 106 cells/ml therefore could be infected at 2x 106 
cells/ml. 
Inoculum required (ml) = MOI (pfu/ml) x (total number of cells) 
titre of Inoculum (pfu/ml) 
2.3.2.6 Infection of Sf9 Insect Cells for Protein Expression 
The MOI for protein expression was between 5 and 10. Up to 800 ml culture could be 
infected in a suspension, or a large scale (5 1) fermenter was used to produced large 
quantites of protein conditions described in Chapter 4. The culture was harvested after 3 
days when expressing a secreted recombinant protein. 
2.4 Protein Purification Methods 
All chromatography steps were carried out using either an HPLC system (Gilson) for 
size exclusion chromatography or peristaltic pump apparatus (Gilson) for other 
methods. 
2.4.1 Affinity Chromatography 
Antibody was coupled to Affiprep-10 through primary amines (Biorad). 5 ml matrix 
was washed with 30-50 volumes 10 mM sodium acetate pH 
4.5 in a Buchner funnel. 10 
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mg of purified antibody dialysed into acetate buffer was added to the matrix, transferred 
to a 50 ml tube and incubated at 4 °C for 4 hours on a rotating wheel. Free active esters 
were blocked with 0.1 M ethanolamine, washed with 4 volumes 0.5 M NaCl. The 
coupled matrix was packed into an Econo-column (Biorad) and washed with PBS until 
no more uncoupled protein was eluted. A mock-elution step with 5 volumes 0.1 M 
glycine pH 2.5 was also performed on the newly made column. 
For purification, the column was equilibrated with TBS-Ca (+ 0.05% NaN3) at 1 mumm 
at 4 °C using a peristaltic pump, the sample loaded then washed with at least 10 column 
volumes (CV) of TBS-Ca. The protein was eluted with 3-5 CV 0.1 M glycine, pH 2.5, 
into tubes containing 1/10 volume 1M Tris-Cl, pH 8.0. The column was immediately re- 
equilibrated with 5 CV TBS-Ca 
2.4.2 Hydrophobic Interaction Chromatography 
25 ml phenyl sepharose 6 (high substituted) HIC matrix was packed into a 16 x 30 cm 
column (both Amersham Pharmacia Biotech) and equilibrated with 25 mM Tris-Cl pH 
7.5,1.5 M ammonium sulphate. The sample was adjusted to 1.5 M ammonium sulphate 
and filtered through a 43 mm cellulose acetate filter (0.8 µm pore; Sattorius). The 
sample was loaded at 5 ml/min at 4 °C using a peristaltic pump, then washed with 5 CV 
equilibration buffer. The bound proteins were eluted by a gradient to low salt (25 mM 
Tris-Cl, pH 7.5) over 10 CV and separated according to increasing hydrophobicity. 
Tightly bound proteins were removed by 3 CV 30% isopropanol, followed by 10 CV 
d. H20. Further sanitization was carried out with 3 CV 0.1 M NaOH. 
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2.4.3 Size Exclusion Chromatography 
Superdex 75 or Superdex 200 column (Amersham Pharmacia Biotech) were 
equilibrated with 0.5 M Tris-Cl, 0.25 M NaCl, pH 7.2,0.05% NaN3 at a flow rate of 
0.75 ml/min. 200 µl samples were injected onto the column and was separated 
according to size. Higher molecular weight components elute first, not being impeded 
by diffusion into the pores in the beads. The columns were calibrated by injecting 
proteins of known molecular weight obtained from the Molecular Weight Standards Kit 
(Sigma). By plotting log(Mw) against time of elution, the Mw of the sample protein can 
be estimated from the linear section of the plot. 
2.4.4 Concentration Techniques 
Proteins in solution were concentrated using ultrafiltration through 10 kDa cut off 
YM10 cellulose membranes (Millipore) in Amicon Stirred cells (300 ml, 50 ml or 10 ml 
sizes). Ultrafiltration was carried out at 4 °C under pressure provided by compressed 
air. Smaller volumes for analysis were concentrated by microcon- l0 (Millipore) spun in 
a cooled micro-centrifuge at 8 000 rpm for 20 minutes at 4°C. 
2.4.5 Buffer Exchange 
The buffer of the protein sample was changed either during concentration or by dialysis. 
Dialysis membrane (MW cut off 8 kDa, Medicell) was prepared by boiling with EDTA 
for 10 minutes. The sample inside the dialysis tubing was placed into at least 200 
volumes of the desired buffer and stirred at 4 °C. The dialysis buffer was changed twice 
in the course of 24 hours. Buffer exchange was also performed using PD 10 ion 
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exchange columns (Amersham Pharmacia Biotech) using 
instructions. 
2.5 Protein Characterisation 
2.5.1 Estimating Protein Concentration 
the manufacturer's 
Total protein in a supernatant was approximated using the Biorad protein assay (based 
on the Bradford protein test) using BSA for a standard curve as instructed in the 
manual. The concentration of a specific protein in a heterogeneous solution was crudely 
estimated by comparing the signal density in a Western blot against a titration of the 
same protein of known concentration. A quantitative ELISA for CD23 was designed 
(see 2.5.8.2) for the same purpose. 
Pure protein was more accurately calculated by UV spectrophotometry. A spectrum 
measuring wavelengths between 240 nm and 340 nm was recorded on a Cary Varian 
UV-visible spectrophotometer using an appropriate buffer blank as baseline. A 
concentration of the protein sample was calculated from Beer's Law: 
A=ccl 
Where A is the absorbance at a specified wavelength, c is the molar concentration, c is 
the molar extinction coefficient and 1 is the path length of the cell (1 cm for quartz 
spectrometer cuvette manufactured by Hellmann). Concentrations in mg/ml can be 
calculated multiplying the molar concentration with the molecular weight. The molar 
extinction coefficient and the Mw of protein from E. coli can be estimated from the 
sequence by the peptidesort programme in the GCG Wisconsin package (Table 2.3). 
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Table 2.3: Data of commonly used recombinant proteins. 




Der-CD23 E. coli 16145 45430 
H-CD23 NSO / E. coli 15774 45430 
LZ-CD23 E. coli 37638 63300 
rCD23 E. coli 30991 51120 
sCD21 Baculovirus 120000 84730 
SPD-CD23 Baculovirus 22325 46710 
2.5.2 SDS-PAGE 
SDS-PAGE was employed to judge the presence, purity and molecular weight of a 
protein in a sample. The methods are based on Laemmli (1970) and carried out in Atta 
or Novex mini gel apparatus. Gels were either purchased from Novex or created using 
the solutions listed in Table 2.4, where Acylamide refers to 30% w/v acrylamide bis- 
acrylamide 37.5: 1, and APS, ammonium persulphate. Gradient gels were also made 
using a gradient maker attached to a peristalic pump. 
The gel was placed in the tank and filled with running buffer, the samples were loaded 
after boiling in reducing or non-reducing sample buffer for 6 minutes alongside 
molecular weight markers: See-Blue, Mark-12 (both Novex) or full range Rainbow 
markers (Amersham Life Sciences). A voltage of 150 mV was applied and the proteins 
separated until the dye reached the bottom of the plate. 
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Acyrlamide 1.00 1.68 3.33 4.18 5.00 6.65 
Gel Buffer 1.25 2.50 2.50 2.5 2.50 2.50 
d. H20 3.18 5.68 4.03 3.18 2.36 0.70 
10% APS 0.05 0.05 0.05 0.05 0.05 0.05 
TEMED 0.025 0.0075 0.0075 0.0075 0.0075 0.0075 
2.5.3 Staining Protein on SDS Gels 
The choice of stain depended on the amount of protein loaded onto the gel. Coomassie 
was used for samples containing 5-10 µg and silver staining for less than 0.5 µg. Gels 
were removed from the plates and covered with Coomassie stain and incubated at room 
temperature overnight on an orbital shaking platform. Background staining was 
removed with De-stain Solution for several hours until protein bands were visible. 
The silver stain protocol was adapted from Wray et al. (1981). After electrophoresis, the 
gel was fixed in 20% TCA for at least 1 hour. The gel was then washed twice in 50% 
methanol for 30 minutes then in d. H20 twice for 20 minutes. The Silver Diamine 
Solution was added for 15 minutes (neutralised with HCl before disposal) then washed 
in d. H20 twice for 5 minutes. Protein bands appear after 5-10 minutes in Reducing 
Solution, the solution was poured away, rinsed and Stop Solution added. Partial de- 
staining could be achieved in Farmer's Reducer and returned to Stop Solution. 
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2.5.4 Western Blotting 
Following electrophoresis, the protein on the gel were transferred to either 
nitrocellulose (0.4 µM pore, Schleicher and Schuell) or 0.45 µm pore Immobilon-P 
(Millipore) which requires activation in methanol for 30 seconds. Protein could be 
transferred by a semi-dry or a wet method. 
For semi-dry transfer, 2 pieces of thick Whatman blotting paper adsorbed with Anode 
and Cathode Buffer and was used to sandwich the gel and dry nitrocellulose between 
graphite electrode plates. The nitrocellulose, free of air bubbles, was placed at the anode 
side of the assembled blot. Transfer was usually complete after 20 minutes at 20 V. 
Wet transfer involved all components of the blot being soaked in cold Wet Transfer 
Blotting Buffer and assembled as above in a Novex Western Blot apparatus. The tank 
was completely filled with buffer and a current of 220 mA was applied for 1 hour. 
Following transfer, the immunoblot was blocked 1 hour (or overnight) in 5% BSA in 
TBS-Ca. CD23 was detected by the polyclonal antibody rb55 in 1% BSA TBS-0.05% 
azide (which was reused) and incubated for 1 hour at room temperature with gentle 
agitation. The blot was washed 3 times for 10 minutes with TBS-Ca 0.05% Tween 20. 
Goat anti rabbit immunoglobulin HRP (Dako) was added as a1 in 2000 dilution in 1% 
BSA TBS-Ca-T and incubated for one hour. The blot was washed again, and developed 
with SuperSignal (Pierce) chemoluminescence reagents. The blot was wrapped in cling 
film and used to expose autoradiography film (Kodak) initially for 1 minute. The film 
was developed by an X-ornat machine. 
Alternatively, following blocking with 10% Marvel PBS, monoclonal antibodies were 
used at 1 µg/ml in 2% Marvel PBS-Tween and revealed with rabbit anti-mouse 
immunoglobulin HRP conjugate (Dako). 
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2.5.5 Chemical Crosslinking 
2.5.5.1 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Hydrochloride (EDC) 
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Hydrochloride (EDAC or EDC) is a 
water soluble condensing reagent. The method employed was that described by Beavil 
et al., 1995. Cross-linking was performed in a 15 minute reaction at room temperature 
with 1 , µg of protein 
in 20 µl 25 mM acetate buffer pH 5 and 25 mM EDC. Non- 
reducing SDS loading buffer was added to stop the reaction. The cross-linking reactions 
were loaded onto a 5-15% Tris-glycine gel alongside non-cross linked protein and 
visualised by silver staining or western blot (using rb55 polyclonal antibody). 
2.5.5.2 Di-fluoro di-nitrobenzene (DFDNB) 
50 mM stock solution of DFDNB was made in ethanol. 1 , gm1 protein was incubated 
with 1 mM DFDNB (or a titration of concentrations) in 100 mM carbonate buffer, pH 
10 for 2 hours at room temperature. The reaction was stopped on addition of reducing 
SDS loading buffer and resulting crosslinked products were analysed by western blot. 
2.5.6 Mass Spectrometry 
50 µg of sample was run by positive ion electrospray, scanning 1000 - 2000 amu 
performed by L. King (Celltech). The sample was injected onto a5 cm C18 column at 
5: 95 MeCN: H20,0.1 % formic acid, at 0.1 mumm. After 1 min, the solvent was ramped 
quickly up to 70: 30, and the eluting protein was acquired, after approximately 10 
minutes. 
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2.5.7 N-terminal Protein sequencing 
30 pmol of pure protein was prepared using Prosorb Sample Preparation Cartridge and 
analysed in a Procise 492 Protein Sequencer (PE biosystems) by B. Smith (Celltech). 
2.5.8 Enzyme-Linked Immunosorbent Assay (ELISA) 
2.5.8.1 Preparation of Biotinylated Proteins for ELISA 
Protein at 1 mg/ml in PBS was incubated for 1 hour at room temperature in the dark 
with a 1: 20 molar ratio of protein to 6-(Biotinamidocaproylamido) caproic acid 
succinamide ester (Biotin-X-X-NHS, Sigma) dissolved in DMSO. Free biotin was 
dialysed away in PBS. For purposes such as preparing ligand for streptavidin coated 
SPR sensorchips, a ratio of 1: 5 was employed. 
2.5.8.2 Quantitative sCD23 ELISA 
The quantification of soluble CD23 was carried out using Nunc maxi-sorb 96 well flat 
bottomed plates (GibcoBRL). 100 µl EBVCS-4 anti-CD23 capture antibody at 2 µg/ml 
was coated in bicarbonate-carbonate buffer, pH 9, overnight at 4 °C. The coating 
solution was discarded and free binding sites on the plate were blocked with 2% Marvel 
in PBS for 1 hour at room temperature. The plate was washed 4 times with 200 µl PBS 
0.05% Tween 20. 
A standard CD23 protein (e. g. H-CD23 from NSO cell cultures) of known concentration 
was serially diluted (x2) in triplicate across the plate (from 0.5 µg/ml). Proteins of 
unknown concentration were added in triplicate at a couple of dilutions as were an 
appropriate negative control and an internal control of known concentration. These 
100 µl samples in assay buffer (1% Marvel, PBS, 0.02% Tween 20) were incubated at 
room temperature for 1-2 hours. The plate was washed as before. 
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The next step involved incubation of 1µg/ml biotinylated BU38 in assay buffer for 1-2 
hours as before. Following washing, a1 in 2000 dilution of streptavidin-horse radish 
peroxidase conjugate (Amersham Life Sciences) in assay buffer was added and 
incubated for one hour at room temperature. 
After a final washing procedure, the ELISA was developed using 5 mg/ml OPD in 
phosphate-citrate buffer plus 0.8 ptVml hydrogen peroxide. 50 µl of OPD solution was 
added to each well and allowed to develop in the dark for 10 minutes. The enzyme 
reaction producing colour development was terminated on addition of 50 ml of 3M 
HCI. The A492 of the wells were recorded by a Titertek micro-plate reader. The A492 
readings of the standards were plotted against log concentration. A sigmoidal curve was 
fitted to the data points using Ascent software. The concentration of the sample 
triplicates were estimated from the linear part of the curve. 
EBVCS-2 and biotinylated MHM6 was another combination of anti-CD23 monoclonal 
antibodies, that could be reliably used in this ELISA. 
2.5.8.3 Quantitative IgE ELISA 
Microtitre plates were coated with a1 in 7000 dilution of anti-IgE (Dako, A0094) in 
carbonate buffer, overnight at 4 °C. 2% Marvel PBS-T was used to block the wells for 
one hour at room temperature. The wash buffer (PBS-T) used 5x 400 µl between each 
step. Anti-NIP IgE was serially diluted by two (from 200 ng/ml) to produce 11 
triplicates on the standard curve. Samples were also applied in triplicate and incubated 
overnight at 4 °C. A1 in 500 dilution of anti-IgE-HRP (Dako, P0295) was applied for 4 
hours at room temperature. OPD was used to develop the enzyme reaction and 
quantification calculated as above. 
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2.5.8.4 CD23 - IgE ELISA 
Plates were coated with 3 µg/ml CD23 in TBS containing 2 mM CaC12, overnight at 
4 °C. 5% BSA in TBS-Ca was used as blocking buffer and TBS-Ca 0.05% Tween 20 
used as a wash buffer between each step (4 x 200 µl). 1 µg/m1 biotinylated IgE or IgE- 
Fc (or a serial dilution) in 0.5% BSA-TBS-Ca-T was incubated for 3 hours at room 
temperature. Interactions were revealed by 1 in 2000 dilution of streptavidin-HRP (Life 
Technologies) for 1 hour at room temperature. OPD was used to develop the enzyme 
reaction. 
2.5.8.5 Sandwich CD23-IgE ELISA 
Microtitre plates were coated in 2 µg/ml mAb25 (Immunotech) overnight at 4 °C in 
carbonate buffer. The blocking buffer, wash buffer and assay buffer were the same as 
used in the direct ELISA. CD23 samples were applied for 2 hours at room temperature. 
1 µg/ml biotinylated NIP IgE or IgE Fc were added for a3 hour incubation at room 
temperature. The interaction was detected by streptavidin-HRP (1 in 2000) as before 
and visualised with OPD. 
2.5.8.6 CD23 - CD21 ELISA 
Based on the ELISA described by Fremeaux-Bacchi et al., 1996,10 tg/ml CD23 was 
coated in TBS-Ca (using iC3b as a positive control). 1% BSA in hypotonic phosphate 
buffer (10 mM sodium phosphate, 25 mM NaCl) was used as a blocking buffer and 
hypotonic phosphate buffer with 0.1% Tween as a wash buffer. Serial dilutions of 
sCD21 (baculovirus) from 10 pg/ml in 0.1% BSA hypotonic phosphate-T were 
incubated for 3 hours at room temperature. 1.5 tg/m1 anti-CD21 antibody HB5 was 
added for 2 hours at room temperature. A rabbit anti-mouse immunoglobulin -HRP 
conjugate (1 in 2000) was added for 1 hour, then developed with OPD. 
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2.5.8.7 CD23 - recombinant soluble integrin ELISA 
5 µg/ml Der-CD23 in TBS-Ca and positive controls were coated (unless otherwise 
stated) overnight at 4 °C. 5% BSA in TBS-Ca was used as a blocking buffer (1 hour 
room temperature) and TBS-Ca-T plus 1 mM MnC12 as a wash buffer. Dilutions of 
culture supernatants containing integrin-Fc chimeras in wash buffer were to used 
establish optimum concentration (detailed in Chapter 6). Following incubation for 2 
hours at room temperature the plates were washed and a1 in 5000 dilution of anti 
mouse (or human) IgG Fc-HRP in 1% BSA in wash buffer added for 1 hour. TMB 
substrate was added and absorbance at 630 nm measured after 15-20 minutes. 
2.5.9 Surface Plasmon Resonance 
Surface Plasmon Resonance (SPR) was performed using a Biacore Biosensor apparatus 
(Pharmacia Biosensor) at 25 °C using HBS-Ca buffer. The ligand was lightly 
biotinylated (2.5.9.1) at molar ratio 1: 5 protein: biotin reagent so that it would bind the 
streptavidin coated SA sensor chip. The ligand, IgE-Fc bIIgII (diluted in HBS-Ca) was 
passed over the conditioned flow cell at 5 µg/min until approximately 450 response 
units (RU) and 900 RU were obtained. A control protein (rCD23) was used to select the 
optimum regeneration conditions (3 x2 minute injections of HBS, 50 mM EDTA). To 
obtain data for kinetic analysis, the analyte (soluble CD23) was injected at various 
concentrations at a flow rate of 10 dJmin. The association phase and dissociation 
phases were measured for 6 minutes, then the ligand was regenerated. A conditioned 
flow cell with no ligand bound to the streptavidin was used as a negative control. The 
data obtained was analysed using BiaEvaluation 3.0 (Pharmacia Biosensor) using the 
1: 1 Langmuir association/dissociation model. 
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2.5.10 Culturing Human Peripheral Blood Mononuclear Cells (PBMC) 
PBMC preparations were performed by N. McCloskey and D. Fear. 60 ml of blood 
containing anti-coagulant were diluted 1: 1 in PBS. 20 ml of the diluted blood was 
layered onto 15 ml of Ficoll-paque (apb) and centrifuged for 2000 rpm for 20 minutes 
(brake off). The interface was pipetted off and washed in PBS by a further 
centrifugation at 200 rpm for 10 minutes at room temperature. Pelleted cells were 
resuspended in 10 ml culture media: RPMI 1640,10 gg/ml penicillin, 100 µg/ml 
streptomycin, 2 mM glutamine (all GibcoBRL) and 10% FCS (HI clone). 10 µl cells, 
40 µl culture media and 50 µl 0.4% trypan blue (Sigma) were mixed to count the cells 
which were then adjusted to 3x 106 ml-1 
A 4x stock of anti-CD40 (G28.5) at 4 µg/m1 and IL-4 at 800 IU/ml were made in 
culture media. 4x stocks of filter sterilised recombinant CD23 in PBS and batimastat 
(donated by Ruth Mayer, SKB, MA, USA) were also made. Thus, 0.5 ml of cells and 
additives were placed in sterile 24 well Nunclon plates (Nunc) and made upto 2 ml with 
culture media. Each additive (CD23 and Batimastat) was cultured with IL-4/anti-CD40 
or culture media alone. Duplicates or triplicates of each condition were made depending 
on the yield of cells. PBMC cultures were incubated for 12 days at 37 °C with 5% 
enriched CO2 atmosphere. Cells and supernatants were harvested on day 12 or 13 by 
centrifugation and stored at -20 °C. 
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CHAPTER 3: PRODUCTION OF A RECOMBINANT CD23 C-TYPE 
LECTIN DOMAIN 
3.1 Introduction 
At the time of writing, the molecular structure of CD23 is undefined. The CD23 lectin 
domain has been modelled through homology to the carbohydrate recognition domain 
(CRD) of rat mannose binding protein and E-selectin (Bajorath and Aruffo, 1996; 
Padlan and Helm, 1993) whose structures have been solved by x-ray crystallography. 
Models are informative, but are insufficient to provide insights at the atomic level of 
ligand binding sites. Indeed, all known ligands to CD23 (IgE, CD21, certain integrins) 
interact with residues in the lectin domain. Clearly, structural information would benefit 
biochemical understanding of relevant biological interactions and, long term, could aid 
design of potential therapies for diseases in which CD23 may be a factor, e. g. 
rheumatoid arthritis (Plater-Zyberk and Bonnefoy, 1995). 
The lack of diffracting CD23 crystals in this laboratory has lead to the investigation of 
nuclear magnetic resonance (NMR) as a method to determine the structure of the CD23 
lectin domain (reviewed by Bax, 1989 and Wuthrich, 1989). In addition, NMR 
experiments are able to determine the atoms involved in ligand binding sites and any 
conformational changes occurring during binding. 
The mass of the CD23 lectin domain (approximately 16 kDa) made it a good candidate 
for NMR structure determination, as it is within the size limits of these techniques. Two 
possible versions of the lectin domain were investigated, differing in start and end 
positions but each containing the complete lectin domain (Table 3.1). A characterised 
recombinant CD23 lectin domain H-CD23,16 kDa, has been previously expressed in 
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mammalian cells (Shi et al., 1997). Furthermore, H-CD23 gave well resolved, 1D 'H- 
NMR spectra. The second candidate, denoted Der-CD23, is the recombinant equivalent 
of the CD23 fragment formed by the allergenic protease Der p1 (Schultz et al., 1995). 
Little is known about the activity of this fragment, so in addition to NMR studies Der- 
CD23 could be included in biological assays (Chapter 5). 
The intention was to produce H-CD23 and Der-CD23 using a bacterial expression 
system and refold and purify them using techniques established for the full length CD23 
(R. Reljic, 1996). Expression in bacteria would allow the recombinant proteins to be 
easily labelled with 15N and 13C isotopes using minimal media. This strategy would 
satisfy the criteria for NMR experiments assuming large enough yields could be 
obtained. 
Table 3.1: Proposed recombinant CD23 constructs for expression in E. coli. 
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The lectin domain constructs were sub-cloned from CD23 cDNA by PCR. The primers 
HF, HR and DF, DR (Appendix I) were used to produce H-CD23 and DerCD23 DNA, 
respectively, using the following cycle conditions: 95 °C, 1 min; 52 °C, 1 min; 72 °C, 1 
min; 25 cycles, and were of the correct size -450 bp when analysed by gel 
electrophoresis. The PCR products were digested and ligated into the Hindill and 
BamHI sites of the shuttle vector, pBluescript KS. In this vector, positive colonies were 
blue/white colony selected, analysed by restriction digest of plamid DNA and 
sequenced using T3 and T7 primers. The constructs were excised using Ndel and 
BamHI and ligated into the multiple cloning site of the E. coli expression vector pET5a 
(Figure 3.1). 
Ndel has a palindromic cleavage site (CATATG) which provides the recombinant 
construct an initiation codon when inserted in phase. The resulting methionine is either 
preserved or cleaved in expression in E. coli, depending on the following residue as 
outlined by Ben-Bassat, 1990. The initiation methionine of H-CD23 remains uncleaved, 
whereas in the Der-CD23 peptide it is cleaved. Therefore, this vector is able to produce 
recombinant peptides with no unnatural residues. 
3.3 Expression 
3.3.1 Expression of H-CD23 in Bacteria. 
The target gene cloned into the pET vector is under the control of a strong T7 
bacteriophage promoter. Expression of a T7 RNA polymerase, coded in the 
chromosomal DNA of the E. coli host cell, is induced by IPTG (controlled by a lacUV5 









Figure 3.1: Vector map of the Der-CD23 Expression Vector. 
Ndel 
BgIII 
Both H-CD23 and Der-CD23 (shown) DNA constructs were ligated into the Ndel/BamHI 
cloning sites of the bacterial expression vector pET5a (Novagen). The plasmid contains a T7 
promoter from which transcription is induced on addition of IPTG. The plasmid also contains 
an ampicillin resistance gene (AmpR) 
r-CD23 DNA 
69 
expression of the recombinant protein, the majority of the cells' resources are used and 
large amounts of product can accumulate in a few hours. 
Initial expression was carried out in the BL21 (DE3) E. coli strain. A time course of 
expression following induction with 0.4 mM ITPG was analysed by Western blot 
(Figure 3.2a). 100 
,1 aliquots at time 
1,4,6 hours were taken, spun down and 
resuspended in 10 t1 SDS-loading buffer. The presence of H-CD23 in total protein of 
the extract was detected by Western blot using the polyclonal antibody Rb55. 
It was apparent that the recombinant protein was being degraded within the cells after 1 
hour of culture (Figure 3.2a). The background signal was particularly bad because so 
much protein needed to be loaded to obtain signal, suggesting yields were very low. 
Comparison with 1 pg H-CD23 (obtained from NSO cell line) on a western blot showed 
expression levels approximated 1 mg/l at 1 hour. 
There was a possibility that the construct was toxic to the cells. To minimise any 
toxicity effects, the expression plasmid was transferred to another host strain, BL21 
(DE3) (pLysS). The pLysS plasmid expresses low levels of T7 lysozyme that binds any 
T7 RNA polymerase before induction and therefore prevents `leaky' transcription of 
toxic product. However, the peptide was still being lost with time and was undetectable 
at 5 hours (Figure 3.2b). H-CD23 must be unstable and being degraded, because if 
soluble it would still be detected in the total protein extract. 
It was decided that the poor yields made H-CD23 from E. coli an unsuitable candidate 
for NMR isotopic labelling because large volumes of culture would require too much 
expensive glucose isotope. No further work was done with H-CD23 in E. coli because 
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Figure 3.2: Western Blot Analysis of H-CD23 Expression in E. coli 
a) 50µ1 of BL2l (DE3) culture and b) 100µl sample of BL2l (DE3)(pLysS) culture 
was analysed by Western blot using rb55. Expression was induced by 0.4mM IPTG, 
aliquots taken at intervals(hours). Total cell protein (soluble and insoluble fractions 
was loaded under non reducing conditions. H-CD23 (16 kDa) was detected in the 
first hour but was undetectable after 4 hours. 
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3.3.2 Expression of Der-CD23 in Bacteria 
A time course of expression after induction showed the Der-CD23 to be stable three 
hours after induction (Figure 3.3). The amount of peptide expressed was estimated to be 
about 50 mg/l on an immunoblot. At this yield, less than 51 of culture would provide 
enough material for NMR experiments at 2 mM. 
Mock labelling conditions were carried out on a large scale i. e. 500 ml. 15N labelling 
was carried out in M9 media containing no casamino acids. The media for 
15N/ 13C 
labelling also has a reduction of glucose from 10 g/1 to 2 g11. Care was taken to remove 
traces of complete M9 media from the overnight culture by pelleting the cells and re- 
suspending in labelling media. Rate of growth, final cell density and amounts of 
expressed Der-CD23 were compared to the normal M9 media. 
Under labelling conditions, cultures took longer to reach optimum cell density for 
induction (A600 >0.6), 7 hours as compared to 3 hours for casamino acid complemented 
M9 media (Figure 3.4a). The final cell density in labelling media was lower, A600 of 1.0 
compared to A600 2.3 for casamino acid supplemented M9 media. By inoculating pre- 
warmed media with more cells (10 ml overnight culture into 500 ml) the time needed to 
reach an inducible cell density was reduced to 6 hours in label media and reached a final 
A600 of 1.3. 
The amount of expressed recombinant protein was similar in all media taking into 
account cell numbers (Figure 3.4b). Therefore, with cell densities being approximately 
half of that under normal media conditions, the total protein yielded would also be 
halved. This was taken into consideration when determining the volume of culture to 
use for isotopic labelling. 
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Labelling was carried out once the whole purification procedure had been optimised, 
activity assessed and preliminary 1D NMR experiments on unlabelled Der-CD23 were 
satisfactory. 51 of labelled culture were prepared, which would cover subsequent losses 
during extraction and purification. Final yields in bacterial cells were 200 mg of 15N 
labelled protein and also for 15N/13C labelled material from 51 cultures. For a 300 µl 
NMR experiment at 2 mM (32 mg/ml) approximately 10 mg of protein is required. 
Accounting for losses during purification (expecting yields of around 10%) this culture 
volume is sufficient. Expression results are summarised in Table 3.2. 
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Figure 3.3: Expression of Der-CD23 in the E. coli host strain BL21 (DE3) (pLysS) 
Western blot analysis of Der-CD23 expression at hourly intervals after induction with 
0.4 mM IPTG. 17 kDa CD23 was detected in 50 µl cell lysates by a polyclonal antibody 
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Figure 3.4: Expression of Der-CD23 with Labelling Conditions 
500m1 cultures of BL21 (DE3) (pLysS) transformed with pET5a-Der-CD23 were grown in 
M9 (supplemented) media or mock label media (no additional casamino acids and reduced 
glucose). a) The growth curve of the cultures were compared by assessing cell density (A600). 
Cells grown in label media (bold line) took 6 hours to reach optimal density for induction 
(A600>0.6) as compared to 3 hours for cells grown in supplemented M9 media (dashed line). 
Labelled cultures reached a lower maximum density (equivalent to 108 cells/ml). b) Western 
blot analysis using Rb55 showed no difference in yields of recombinant protein after induction 
when samples were corrected for cell number. 
02468 
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Table 3.2: Summary of Expression in E. coli. 
Construct E, coli strain Media Harvest Time 
(hrs after IPTG) 
CD23 yield 
(mg/1) 
H-CD23 BL21 (DE3) M9 1 1 
H-CD23 BL21 (DE3)(pLysS) M9 1 10 
Der-CD23 BL21 DE3 L sS M9 3 80 
Der-CD23 BL21 (DE3)(pLysS) 1N 
- 
3 40 
Der-CD23 BL21 (DE3)(pLysS) /1 3C 1 3N 3 40 
3.4. Purification of Der-CD23 
3.4.1 Inclusion Body Extraction 
Over-expression of recombinant proteins in bacterial cells often leads to the formation 
of inclusion bodies, insoluble aggregates of protein. Inclusion bodies are advantageous 
for purification, especially for untagged proteins, as they are easily separated from 
soluble bacterial proteins by centrifugation. 
Der-CD23 was expressed as inclusion bodies as shown by SDS-PAGE of total, soluble 
and insoluble fractions of protein from cell lysate (Figure 3.5). The extraction method 
(from Bohnmann and Tjian, 1989, see Chapter 2) yielded moderately pure recombinant 
protein from inclusion bodies due to the multiple washing steps. The yield was 
estimated by A280 once the final product was solublised in 6M Guanidine-HCI. 
Approximately 200 mg extracted protein was recovered routinely from 51 cultures in 
M9 media. 
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Figure 3.5: Extraction of Der-CD23 from Inclusion Bodies 
Total insoluble and soluble protein fractions of bacterial cell lysates loaded onto a 4- 
20% SDS gel stained by Coomassie. `0' represents protein before induction with 0.4 
mM IPTG, protein samples taken 3 hours after induction are labelled 'I'. `X' is the final 
inclusion body extract, prepared from 6M Guanidine by TCA precipitation (Methods 
and Materials 2). `P' is 2 µg final purified Der-CD23. Der-CD23 is present in the 
insoluble fraction. 
3.4.2 Gel Filtration Chromatography under Denaturing Conditions 
A denatured gel filtration step on an Sephacryl S 100 column (3 cm x 90 cm dimensions) 
in 6M Guanidine was used to further purify the protein according to size. The step 
appeared unnecessary because there was only one major peak resolved (Figure 3.6a) 
whose fractions were still contaminated by higher molecular weight E. coli proteins 
(Figure 3.6b). Omitting this procedure saved on time for the column run, fraction 
analysis, fraction concentration, protein losses and the use of several hundred millilitres 
of 6M Guanidine. Instead, the extracted protein was adjusted to 10 mg/ml in 
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Figure 3.6: Purification of Extracted Der-CD23 by Gel Filtration 
Solubilised Der-CD23 in 6M Guanidine from inclusion bodies was loaded onto a 
Sephacryl S 100 column and run at 1 ml/ml at room temperature using 6M Guanidine 
running buffer. a) The A280 profile of the fractions shows the eluted protein to be poorly 
resolved, a second peak (fractions 80-100) contained other small molecules with 
absorbance at 280 nm. b) A 15% SDS gel stained with coomassie shows fractions 60-64 
contains 16 kDa Der-CD23, but are still contaminated by higher molecular weight E. coli 
proteins. 
0 20 40 60 80 100 120 
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3.4.3 Refolding 
Using the method from Taylor et al., 1992, (Chapter 2), 10 mg of extracted Der-CD23 
was reduced, a glutathione intermediate formed and renatured by dilution to 10 µg/ml in 
cysteine buffer. Refolded product was concentrated to 1 mg/ml and run on a size 
exclusion column, Biosep 2000 in 0.5 M Tris-HC1,0.25 M NaCl, 0.05% NaN3 buffer 
(Figure 3.7a). There were three peaks assigned `A' at 6 minutes (presumably aggregated 
protein), at `B' at 8 minutes and `C' at 11 minutes. Fractions containing these peaks 
were pooled. An SDS gel indicated the majority of Der-CD23 was present in pools A 
and B (Figure 3.7b). An IgE Fc binding assay by ELISA clearly showed pool B was 
active. Pool C was likely to be small molecules, e. g. glutathione and cysteine which 
absorb strongly at 280 nm. The amount of aggregate formed was reduced by careful, 
slow, dilution in refolding buffer and therefore, better yields of refolded product were 
obtained. 
Size exclusion was initially used as means for purification of active Der-CD23. 
However, it was observed during the procedure, huge losses were occurring; during 
concentration by ultrafiltration and during the column run itself. In addition, there was 
no evidence that all of the mis-folded protein would aggregate or what proportion of the 
purified CD23 is correctly renatured. An alternative method for isolating active refolded 






















Figure 3.7: Gel Filtration analysis of Refolded Der-CD23. 
(a) Refolded, concentrated Der-CD23 was applied to a Biosep 2000 size exclusion column 
in 0.5 M Tris pH 7.2,0.25 M NaCl, 0.05% NaN3. The fractions collected were pooled 
according to the peaks A, B and C observed in the elution profile. (b) The pools A, B and C 
were loaded onto a 15% SDS gel, under reducing conditions and stained with Coomassie 
Blue. 1 6kDa CD23 is present in the high molecular weight pool, A, (aggregated Der- 
CD23) and in pool B (monomeric Der-CD23). Pool C contains low molecular weight 
molecules e. g. cysteine and glutathione that absorb at 280 nm. Lane Ha control sample of 
H-CD23 (derived from mammalian cells). 
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3.4.4 Hydrophobic Interaction Chromatography (HIC) 
Hydrophobic interaction chromatography separates proteins according to 
hydrophobicity in a salt solution. The theory behind this chromatography has been 
debated. One thermodynamic explanation suggests that the driving force of adsorption 
is the entropy gained arising from the displacement of ordered water molecules around 
the interacting hydrophobic groups. Alternatively, the Van der Waals forces between 
protein and immobilised ligand increase as the ordered structure of water increases in 
the presence of salt. 
It was envisaged that unfolded protein would be more hydrophobic than correctly folded 
active material and therefore could be separated according to hydrophobicity. 
Experimentally, HIC involves protein sample in a high concentration of a non- 
chaotropic salt (usually 1M ammonium sulphate) binding to a hydrophobic matrix (with 
aliphatic or phenyl side chains). The protein is eluted with a decreasing ammonium 
sulphate concentration gradient, with tightly bound hydrophobic proteins being eluted in 
a water wash. 
3.4.4.1 Matrix Selection 
First it was established that Der-CD23 remained soluble in 1M ammonium sulphate. 
The proportion of aggregate in the sample was reduced on addition of 1M ammonium 
sulphate as shown by analytical size exclusion on Superdex 75 (results not shown) 
presumably because it has precipitated and been removed on filtering. 
There are several different HIC media available each varying in hydrophobicity of the 
aromatic or alkyl substitutions on Sepharose matrix. The surface of a protein can be up 
to 50% non-polar that can bind hydrophobic adsorbents, although it is difficult to 
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predict which matrix is optimal. Interactions between protein and HIC matrices must be 
screened, in this experiment with a HIC test kit (Amersham Pharmacia Biotech). 300 µg 
of concentrated refolded Der-CD23 was made up to 1M ammonium sulphate, filtered, 
and loaded onto the HIC columns (listed in Table 3.3). The column was eluted with a 
decreasing ammonium sulphate gradient and any eluted protein was detected by a A280 
trace. The percentage eluted was estimated the integration of `flow through' maxima 
and that observed during the gradient (Table 3.3). 
Only Phenyl Sepharose 6 (high substituted) bound Der-CD23 which could be removed 
upon a decrease in ammonuim sulphate concentration. The experiment was repeated 
with this matrix with 10 mg refolded protein on 25 ml of matrix but only 0.1 mg was 
eluted. To improve binding to hydrophobic surfaces, the initial salt concentration can be 
increased which is believed to increase the `salting out' effect that promotes interaction. 
Table 3.3: HIC Matrix Selection for Der-CD23 Purification 
Hydrophobic Interaction Column Matrix % Total Der-CD23 Eluted 
Phenyl Sepharose 6 (low substituted) 0 
Phenyl Sepharose 6 (high substituted) 40 
High Performance Phenyl Sepharose 0 
Butyl Sepharose 0 
Octyl Sepharose 0 
3.4.4.2 Optimising Ammonium Sulphate Concentration 
Further tests were carried out with the Phenyl Sepharose 6 (high substitution) matrix at 
1 M, 1.25 M, 1.5 M and 2M ammonium sulphate. 10 mg of refolded protein at varying 
salt concentration were loaded onto 25 ml matrix and eluted by decreasing salt 
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concentration gradient. The amount of recovered protein was estimated by A280 
readings. A marked increase in binding occurs when ammonium sulphate concentration 
is increased from 1M to 1.25 M. No further increase in Der-CD23 yield was observed 
with 1.5 M ammonium sulphate. 1.25 M was selected to have maximum yields using 
least salt (Table 3.4). 
Only -25% of the total refolded protein bound. When the flow through was loaded onto 
the regenerated column, no further protein eluted suggesting that the binding capacity of 
the column was not exceeded and that this proportion represented the folded Der-CD23 
in solution. Moreover, the eluted protein was non-aggregated, pure, the correct size and 
bound IgE-Fc as described in the characterisation section of this chapter (3.5). The rest 
of the protein is likely to be contaminants (unbound), mis-folded protein (tightly bound, 
removed with H20 or isopropanol) and protein that precipitated on the addition of 
ammonium sulphate. 
Table 3.4: Optimisation of Ammonium Sulphate Concentration for Purification of 
Der-CD23 by Hydrophobic Interaction Chromatography 






3.4.6 Final Protein Preparation 
HIC fractions were concentrated to 1 mg/ml using stirred cell ultrafiltration using a 
regenerated cellulose membrane (10 kDa low molecular weight cut off). It was noted 
that the recovery of CD23 from concentration was improved in the presence of 
ammonium sulphate in the elution due to decreased interaction with the cellulose 
membrane. The protein was dialysed into the final buffer of TBS, 2 mM CaCl2 and 
0.05% sodium azide. To remove ammonium sulphate the dialysis buffer was changed 
several times over 2 days. 
Table 3.5: Summary of Der-CD23 Purification 
STEP ORIGINAL METHOD YIELD MODIFIED METHOD YIELD 
1 EXTRACTION 100mg EXTRACTION 100mg 
2 S 100 GEL FILTRATION, 
FRACTION CONCENTRATION 63mg 
RENATURATION & 
HIC SAMPLE PREPARATION 68mg 




4 SIZE EXCLUSION FRACTIONS 9mg CONCENTRATION & DIALYSIS 20mg 




A silver-stained reducing SDS gel gave an indication of the purity of Der-CD23.50 ng 
of contaminant can be detected with this method and no apparent bands were detected 
when 1µg was loaded, therefore this preparation of Der-CD23 was particularly pure 









14 wº Der-CD23 
Figure 3.8: Silver Stained SDS gel of refolded Der-CD23 Purified by Hydrophobic 
Interaction Chromatography 
1 µg of purified Der-CD23 was loaded onto a 12% SDS gel under reducing conditions. 
A single band at approximately 17 kDa was visualised by silver staining. 
3.5.2 Analytical Gel Filtration HPLC 
Analytical gel filtration HPLC was carried out in order to assess whether the sample 
contained aggregate or oligomers which would be detrimental to NMR data collection. 
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The final protein sample derived from HIC was run analytically on a calibrated 
Superdex G75 (Appendix III). Figure 3.9 shows the resulting A280 trace which gave a 
single peak. When extrapolated on the standard curve (log Mw vs elution volume) to be 
approximately 16 kDa (theoretically 16,145 Da). The experiment was unable to detect a 











Figure 3.9: Analytical Gel Filtration HPLC of Purified Der-CD23. 
0 
Approximately 10 µg of purified Der-CD23 was loaded onto a Superdex G75 size 
exclusion column and run at 0.75 ml/min in 0.5 M Tris-HCI, pH7.2,0.25 M NaCl, 
0.05% NaN3. Der-CD23 eluted as a single peak at 15.7 minutes (-16.6 kDa, Appendix 
IIIa) and there was little evidence of higher molecular weight oligomers or aggregate. 
3.5.3 Mass Spectrometry 
Positive ion electrospray spectrometry was performed by L. King, Celitech, on 
unlabelled Der-CD23 (Figure 3.10). One major peak at 16137 amu (referring to the 
calculated masses listed in the top right hand corner) was identified representing the 
16.6 kDa 
processed fragment (minus the first Methionine) with 4 disulphide bridges. Another 
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peak occurs 16,179, -40 mu greater than the desired construct and is most likely to be a 
Calcium ion bound product. The motif C-X-C, which is present in the Der-CD23 
sequence, has been known to chelate positive ions (usually sodium) observed in electron 
spray mass spectrometry. A small proportion of the protein is 16,266 and 16,295 which 
represents the full length polypeptide (+ Methionine) with and without the putative 
calcium ion. No degradation product is apparent. 
An NMR sample that had been at 25 °C for 2 days and stored at 4 °C for several months 
was also analysed by mass spectrometry (by J. McDonnell, Rockefeller University). The 
products found in this experiment were all smaller than expected, the largest having a 
mass equivalent to having the 3 carboxyl-terminal residues cleaved. With time and 
moderate temperatures, degradation of Der-CD23 sequence exterior to the lectin domain 
was occurring. 
3.5.4 N-terminal Sequencing 
The results of N terminal sequencing from B. Smith, Celltech (Materials and Methods 
2.5.7), showed the major peptide in the final preparation of Der-CD233 had the 
predicted sequence: SGFV_NT_PEKWINF. A minor fraction of the protein was 
sequenced as TPPASEGSAE, this represents C-terminal sequence following the final 
Cys of the lectin domain. 
3.5.5 Detection by anti-CD23 antibodies 
In addition to detection by polyclonal anti-CD23 in immunoblotting, Der-CD23 was 
detected by a variety of monoclonal antibodies in a sandwich ELISA format (2.5.8.2). 
EBVCS-2, EBVCS-4, EBVCS-5, B6, IOB8, mAb25, BU38 and MHM6 which all map 
to the lectin domain. EBVCS-1, which binds an epitope in the neck region, was also 
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tested and, predictably, showed no binding to Der-CD23. These results (not shown) 
suggest the domain was folded into the correct conformation. 
3.5.6 Ligand Binding Assay by ELISA 
In an IgE binding assay, Der-CD23 bound IgE-Fc albeit at a lower affinity to that of a 
molar equivalent of full length rCD23 (Chapter 5). Design and further description of 
this assay is included in Chapter S. This result has also been demonstrated by Shi et al., 
1990, with the mammalian expressed lectin domain (H-CD23). 
3.5.7 Chemical Cross-linking with EDC 
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Hydrochloride (EDAC or EDC) is a 
water soluble condensing reagent that can assess the oligomeric state of proteins in 
solution by linking amide and carboxyl groups of adjacent protein molecules with a zero 
length spacer. The method employed is described in Materials and Methods (2.5.5.1) 
was used to demonstrate CD23 oligomerisation by Beavil et al., 1995. 
1 µg of purified Der-CD23 was cross-linked alongside a full length recombinant CD23 
positive control and visualised by non reducing SDS PAGE. Figure 3.11 shows a broad 
band around 20 kDa (monomeric), some evidence of a dimeric and very small amounts 
of trimeric protein. The control full length CD23 gave the expected trimeric result, 
showing the conditions of the cross-linking were similar to those observed by Beavil et 
al., 1995. They observed that the lectin domains can associate, but the cross-linking 
sites are found mainly in the stalk. Thus, the stalk region forms the trimeric a-helical 
coiled coil which is stabilised by weaker interactions in the lectin domain. 
88 
















Figure 3.11: EDC cross-linking of Purified Der-CD23 
wT 
fM 
Silver stained non-reducing, 12% SDS gel of 1 tg protein cross-linked with 25 mM 
EDC for 15 minutes at room temperature. Full length CD23 (B) runs as a trimer (T) 
whereas the lectin domain (A, Der-CD23) exists predominantly as a monomer (M) 
when cross-linked (X). Some dimeric (D) and trimeric (T) cross-linked Der-CD23 is 
also observed. 
3.6 NMR 
J. McDonnell (Oxford Univerisity) carried out all NMR experiments with the 
unlabelled, 15N-labelled and 15N-13C-labelled material provided. 
3.6.1 One dimensional 1H-NMR Spectra 
Comparison of the 1H spectra of H-CD23 (expressed by a mammalian cell line, spectra 
not shown) and the E. coli derived Der-CD23 (Figure 3.12) showed the two lectin 
domain constructs gave similar spectra. This result indicated that the purified Der-CD23 
was folded in a similar way to native CD23. The up-field chemical shifts observed at 0 
to -1 ppm results from residues within the folded core of the domain also suggest the 
























3.6.2 NMR studies using the 15 N Der-CD23 Sample 
The proportion of label incorporation of the 15N sample was assessed by electrospray 
mass spectroscopy (spectra not shown). The heavier nitrogen isotope results in a protein 
with higher mass than the unlabelled sample (14N). Der-CD23 contains 201 nitrogen 
atoms, the 15N sample was +202 mu therefore approximately 100% isotope 
incorporation was achieved. 
A number of different experiments can be performed on the single labelled sample, 
providing a range of structural and ligand binding information, e. g. coupling constant 
experiments, hydrogen-deuterium exchange and relaxation studies, and eventually the 
ligand mapping experiments. For instance, the 1H 15N HSQC (heteronuclear single 
quantum-coherence) spectra (Figure 3.13) shows the protons attached to nitrogen atoms 
thus representing the backbone of the protein. At the sample concentrations used, the 
2D spectra was well resolved allowing accurate data to be extracted. The most 
important information will require full assignment, which requires the double labelled 
sample. 
3.6.3 15N/13C labelled DerCD23 
Evidence of aggregation was observed during the data collection of the double labelled 
sample. The high concentration of sample needed for the 3D experiment was promoting 
the dimerisation of the lectin domains and therefore producing poorly resolved spectra. 
Improvements were made at higher temperatures as the low affinity interaction were 
reduced and the tumbling time was increased. Experiments and assignments are on- 
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Figure 3.13: 1H-15N HSQC Fingerprint of Der-CD23 
1.2 mM Der-CD23 labeled with 15N. Each residue represents protons attached to 'N atoms, 
thus giving details of the protein backbone. Virtually all of the peaks are well resolved and 
the difference in intensity indicates a varying amount of flexibility within the molecule. 
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3.7 Discussion 
H-CD23 and Der-CD23 were expressed in E. coli for use NMR structural analysis and 
interaction studies. H-CD23 was found to be unstable in the bacterial expression system 
whereas Der-CD23 was stable and expressed in high yields (80 mg/1). The slight 
difference in sequence of the two similar constructs may account for the difference in 
stability within the cell. H-CD23 RNA or polypetide ends may be susceptible to 
exonuclease or exoprotease activity. 
Der-CD23 was expressed as inclusion bodies and extracted to moderate purity. 
Following refolding, the purification procedure was improved on methods used for full 
length recombinant CD23. Hydrophobic interaction chromatography was used to purify 
active Der-CD23 in a single step. Final recovery of protein was optimised to 20% (as 
compared to less than 10% in a previous method). 
Hydrophobic interaction chromatography greatly benefits the purification of refolded 
proteins expressed as inclusion bodies. This procedure is able to separate different 
folded species of the protein on account of the exposure of hydrophobic surfaces. 
Purification methods such as gel filtration that separate according to size of the 
molecules are sufficient to separate grossly mis-folded aggregates but are poor at 
discriminating the numerous folds a domain like the CD23 lectin domain may assume. 
The CD23 lectin domain contains 8 cysteine residues, which is relatively high for an 
extracellular domain of that size. Assuming all cysteine pairings are possible, there 
would be 24 combinations of disulphide bridges and this does not include any folds 
with free sulphide groups. The refolding method used assumes the disulphide 
bonding 
occurs after the formation of secondary structures and favours 
folds of least energy, so 
certain folded species will be less likely because cysteine residues are 
in the wrong 
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orientation, too far apart, sterically hindered or the pairing may create an unfavourable 
torsion. Realistically, eight cysteines may stablise only a few different folded species if 
the domain contains a high percentage secondary structure. The CD23 lectin domain is 
approximately 26% alpha helix, 34% beta sheet, and the large remainder being `other' 
(although coordinate bonding of the metal ion will account for some of this random 
coil). With this in mind, to be able to remove wrongly folded recombinant protein 
during purification is necessary to obtain accurate structural and binding data. 
Data from antibody binding, and more convincingly, ligand binding assays and 1H 
NMR spectra comparisons to H-CD23 (from NSO) suggest the Der-CD23 purified was 
correctly folded and assumed a conformation able to bind IgE, albeit at a lower affinity 
to full length CD23, as previously reported (Sarfati et al., 1992). 
Analysis of purified Der-CD23 showed that it was more than 95% pure. The majority 
was the correct sequence and predicted molecular weight. Some degradation was 
occurring over time, with evidence of the C-terminal 3,6 and 10 residues being cleaved, 
but with the lectin domain remaining intact. 
Der-CD23 satisfied the requirements for NMR experiments in that millimolar quantities 
could be purified and were soluble, consequently 15N and 15N13C labelled preparations 
were produced. Incorporation of isotope was complete and initial NMR 1D and 2D 
spectra were well resolved which will aid resonance assignment and ultimately structure 
determination. Unfavourable dimerisation of the lectin domain during 3D NMR 
experiments (at 1.5 mM) was perhaps foreseen with chemical cross-linking experiments 
but overcome with an increased experimental temperature. This interaction could 
stabilise the trimeric form of CD23 and, in addition to the CD23 ligands binding sites, 
can be identified in future experiments using NMR techniques. 
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CHAPTER 4: PRODUCTION OF STABLE, TRIMERIC sCD23 
4.1 Introduction 
CD23 expressed in the membrane forms trimers, through non covalent association of 
the alpha helical stalk region (Beavil et al., 1995). However, much of the biophysical 
and in vitro biological assays previously carried out with soluble CD23 have used either 
monomeric (16 kDa or 25 kDa) or readily degradable, unstable trimeric fragments (29- 
37 kDa). Thus, a recombinant, stable trimeric CD23 would a very useful tool to 
investigate the properties and function of soluble CD23 as a trimer. 
Recombinant, soluble CD23 tends to form unstable trimers for several reasons. Firstly, 
without the two dimensional constraint of the membrane the long helical stalk is less 
likely to associate in the correct orientation in solution. Secondly, proteolysis along the 
stalk region would releases monomeric 25 kDa fragments which, in turn, could interfere 
with the formation of other trimers. The design of a stable, trimeric CD23 chimera must 
therefore contain a structural motif that will form a stronger association in solution and 
omit proteolytic sites. 
This criteria could be achieved by fusion with oligomerisation sequences of other stable, 
soluble trimers, e. g. those with alpha helical coiled coils, particularly the collectin 
family of C-type animal lectins that includes mannose binding protein, surfactant 
proteins A and D (Hakansson and Reid, 2000). A heptad repeat sequence in the neck 
region of SPD was chosen because it forms tightly associated trimers in solution and 
has been well characterised (Hoppe et al., 1995). Thus the strategy was to produce a 
chimeric protein comprising of the lectin domain and C-terminal tail of CD23 with the 
heptad sequence of the SPD. Thus, the ligand binding sites are retained and the CD23 
stalk that easily degrades is omitted. 
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Some success has been achieved in creating recombinant trimeric versions of murine 
CD23 (Kelly et al., 1998) and CD40L (Morris et al., 1999). The extracellular sequence 
of murine CD23 (with a point mutation at the site of proteolysis) was fused to a 
modified leucine zipper motif (lz) that forms trimers when leucines are replaced by 
isoleucines (Harbury et al., 1993 and 1994). This chimera was less labile and had a 
greater affinity for IgE than any other recombinant form of murine CD23. Indeed, it was 
able to inhibit IgE binding to the high affinity IgE receptor. In a collaboration with the 
laboratory of D. Conrad, a human version of this chimera has been provided for folding, 
oligomerisation and activity studies. 
Consequently, the two human CD23 fusion constructs have been investigated and 
compared: one with the neck region of surfactant protein D (SPD-CD23); and the other 
with an engineered isoleucine zipper region (LZ-CD23). Production of a stable trimeric 
CD23 was hoped to enhance the affinity of recombinant CD23 for its ligands (IgE and 
CD21). Previous recombinant extracellular CD23 had a tenfold lower affinity for IgE 
than membrane bound oligomeric CD23 (KA = 106 M-1 and 107 M-1, respectively; Reijic, 
1996). 
4.2 Cloning of Chimeric SPD-CD23 
The fusion of SPD and CD23 DNA (coding for M150 to S321, as indicated in Figure 
1.2) was achieved by a two-stage strategy, as illustrated in Figure 4.1. The polymerase 
chain reactions were implemented using the primers and oligonucleotides 
listed in 
Appendix I. The fusion junction was designed so the hydrophobic residues a and d of 
the heptad repeats of SPD and the substituted and remaining CD23 stalk were 
in phase. 
i. e. SPD neck CD23 
head 
VAS LRQQ VEA LQGQ VQH LQAA FSQ YKME LQV ... 
adadadada 
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4.2.1 Construction of Leader-SPD DNA for Chimera Production 
Four long, overlapping oligonucleotides (01-04) were synthesised to contain the 
sequence of VK light chain leader sequence (Ml to 122; Whittle et al., 1997) and the 
neck region of surfactant protein D (coding P222 to K249; numbering by Rust et aL, 
1991). Overhang primers (PF I and PR1) with BamHI and Xhol restriction sites were 
included with the oligonucleotides (0.02 µM of each) in a PCR using an annealing 
temperature of 56 °C (Figure 4.1 a). The resulting leader-SPD PCR product (162 bp) 
was digested, purified by electrophoresis and ligated into BamHI/Xhol sites of 
pBluescript KS. 
Xli Blue cells were transformed and positive colonies identified, amplified and 
sequenced using T3 and T7 vector primers (full sequence data in Appendix II). This 
pBluescript Vk-SPD vector could then be used for any trimeric chimeras that may be 
designed in the future. The Xmal site was included in the 5' end of the construct for 
potential ligation of SPD chimeras into the mammalian expression vector, pEE 12. 
4.2.2 Fusion of Leader-SPD and CD23 Sequences by PCR 
Two primers were designed to contain the sequence encompassing the fusion junction, 
one on each strand (CD23FF and SPDFR). Together with PF2 and PR2 the PCR 
produces intermediate fragments that in turn act as overhang primers to produce the 
completed fusion product (Figure 4.1b). A 700 bp product was obtained using an 
annealing temperature of 51 °C. The fusion product was purified, digested and ligated 
into pBluescript (BamHI and EcoRI sites). Positive clones were identified by analytical 
restriction digestion of purified plasmid DNA. One positive clone was sequenced using 
T3, T7 primers and a couple of insert specific primers (Appendix I). No coding errors 






























Figure 4.1: Schematic Diagram of the Cloning Strategy for the Construction of SPD- 
CD23 
a) The leader of Immumoglobulin V kappa light chain (encoding M 1-I22, Whittle et al., 
1997) and the neck region of surfactant protein D (encoding P222-K249, Rust et al., 1991) 
were synthesised from 4 long oligomers (01-04). This sequence was ligated into the shuttle 
vector pBluescript KS. b) Fusion of the leader-SPD and CD23 sequence (encoding M 150- 
S321, i. e. 25 kDa fragment illustrated in Figure 1.2) was achieved using primers that 
overlap the 3' SPD and 5' CD23 sequence, so that the heptad repeats were in phase The PCR 





5' reaction that results 
in sequence fusion 
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BamHI 
Vx leader SPDneck CD23 head 
BamHI EcoRI 
pPolh SV40 
poly A ., ý 
Tn7L 








3 stop codons 
Figure 4.2: Expression Vector for the Production of SPD-CD23 Baculovirus 
a) The completed SPD-CD23 construct, including the Vx leader sequence, SPD-CD23 
fusion and stop codons, was inserted into the BanHI and EcoRl sites of pFastBac. b) The 
insert was downstream of a polyhedron promoter (pPolh) which, in addition to gentamycin 
resistance (Gm) was transferred to the bacmid DNA by homologous recombination of the 
TO elements. The plasmid was also selected by ampicillin resistance (Apr) 
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4.3 Production of SPD-CD23 by the Baculovirus Expression System 
The 37 kDa and 25 kDa CD23 fragments have been expressed previously by the 
baculovirus expression system (Graber et al., 1992 and Rose et al., 1992). The 
advantage of expression in insect cells is that the recombinant molecule will be 
correctly folded by the cellular machinery and secreted into a relatively pure, serum free 
media. 
4.3.1 Production of Recombinant Baculovirus 
The SPD-CD23 DNA was excised using the BamHI and EcoRI sites, purified and 
ligated into pFastBac, the baculovirus expression vector (Figure 4.2). A plasmid 
preparation of a positive colony was used to transform DH 1 OBAC, an E. coli strain 
containing bacmid DNA and helper DNA (plasmids encoding only the essential 
baculovirus components). Within the bacterial cell, a homologous recombination event 
through TO transposon sequences inserts the construct from pFastBac into the bacmid 
DNA. Clones were selected by antibiotic resistance as described in Materials and 
Methods. Bacmid DNA purified from the selected clones showed the characteristic 
pattern of high molecular weight DNA on a 0.5% agarose gel (results not shown). 5 ; µl 
of bacmid DNA was used to transfect Sf9 insect cells using DNA-liposome complexes 
(Material and Methods). 
4.3.2 Expression of SPD-CD23 In Insect Cells. 
4.3.2.1 Expression 
Three days after transfection, the cells were harvested and the supernatant retained. 
Samples of supernatant were analysed by Western Blot. A band of the correct 
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approximate molecular weight was detected in a four fold concentrated sample of 
supernatant showing that SPD-CD23 was expressed and secreted by Sf9 cells. Some 
evidence of a dimer species was seen, possibly due to insufficient denaturing conditions 









Figure 4.3: Western Blot of Secreted SPD-CD23 from Sf9 Transfected Cells. 
CD23 expression in culture supernatants was analysed on a non-reducing, 4-20% SDS 
gel by Western blot using MHM6 (monoclonal anti-CD23). Lane 1 contained negative 
control supernatant and lane 2 contained a four fold concentrated sample of SPD-CD23 
supernatant from Sf9 cells. The major band was the correct approximate weight (22 
kDa). The minor band ran at about the dimeric weight of SPD-CD23. 
4.3.2.2 Selection Of Baculovirus Host Cell. 
The titre, plaque forming units (pfu) per ml, of the resulting baculovirus was estimated 
using a plaque assay (Materials and Methods). The titre of the primary infection was 
105 pfu/ml. This titre was amplified and the volume increased through sequential rounds 
of infection until 11 of virus at 5x 107 pfu/rnl was obtained. This baculovirus stock was 
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used to infect 11 Sf9 and Hi5 cells for expression of SPD-CD23 at a multiplicity of 
infection (MOI) of 10 i. e. 10 pfu/cell. 
The yield of `active' SPD-CD23 (i. e. that able to bind MHM6 and EBVCS-2 
monoclonal antibodies used in the sandwich ELISA) was quantified (Materials and 
Methods, 2.5.8.2). The active yields were quantified in triplicate by comparison to 
purified rCD23. Comparatively, Sf9 cells secreted twice as much SPD-CD23 as the Hi5 
culture (11 mg/1 and 5 mg/1, respectively; Table 4.1). 
Hi5 cells, derived from the eggs of Trichoplusia ni (Cabbage lopper) are reputed to be 
better protein expressing cells due to their larger cell size and superior post-translational 
modification machinery than either Sf9 or Sf21 cells from Spodoptera fruiperda. 
Differences in passage number and sub-optimal culture conditions or MOI would have 
an effect on recombinant protein expression in these host cells. For the culture 
conditions employed, Sf9 cells were selected for use in further expression cultures. The 
estimated yield suggests that a51 fermenter culture would provide enough protein for 
purification and characterisation purposes (around 50 mg). 
Table 4.1: Expression Of SPD-CD23 In The Supernatant Of Insect Cell Cultures 
Host Insect Cell Estimated Active yield in 3 day culture supernatant (mg/1) 
Hi5 5.0 (+/- 0.2) 
SO 11.4 (+/- 1.3) 
4.3.2.3 Expression of SPD-CD23 in 51 cultures. 
A51 bio-fermenter (Braun) was equilibrated overnight with 41 of Excell 420 serum 
free media at pH 6.2 (regulated by C02 addition); 02 levels set to 70% and incubated at 
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28 °C with stirring motor speed of 150 rpm. The addition of drops of 10% antifoam 
solution were added to improve gas exchange in the system. Sf9 cells were added at 0.8 
x 106 cells/ml. The following day the cells were counted and recombinant baculovirus 
was added at a MOI of 10. On the third day of infection the culture was harvested. 
4.3.3 Purification of SPD-CD23 From Insect Cell Media. 
4.3.3.1 Supernatant Treatments 
Following centrifugation for 20 minutes at 4000 rpm, the supernatant was filtered 
through 0.45 µm pore membrane (Millipore). The supernatant was concentrated using a 
minicassette ultrafiltration system to 1 1. The western blot analysis of these stages 
estimate the yield of SPD-CD23 in the concentrated supernatant was roughly 20 mg. 
0.05% azide and protease inhibitors (benzamidine, iodoacetamide, TLCK, PMSF and 
aminocaproic acid) were also added. 
4.3.3.2 Purification by Affinity Chromatography. 
Affinity Chromatography relies on the specific binding of an antibody or ligand to the 
target molecule. It is good method for the first step of purification because of its 
specificity and large volumes of protein solution that can be applied, especially 
advantageous for crude baculovirus or mammalian cell cultures. 10 mg MHM6 was 
coupled to Affiprep 10 via primary amines forming amide bonds with N- 
hydroxysuccinimide ester groups on a methacylate bead support. Concentrated SPD- 
CD23 supernatant was loaded at 1 ml/min, then washed with TBS-Ca buffer and eluted 
with 0.1 M glycine pH 2.5. The column had a low binding capacity (approximately 250 
µg) so the supernatant was reapplied several times. 
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Western blotting of the neutralised eluate showed a band of the correct size for SPD- 
CD23 (22 kDa). However, the presence of higher molecular weight complexes and 
aggregates of CD23 were also seen under non reducing conditions (Figure 4.4a). These 
bands disappear under reducing conditions (Figure 4.4b) suggesting they are mis-folded 
disulphide-linked CD23 multimers. SDS-PAGE analysis also showed that the eluted 
SPD-CD23 was contaminated with what appeared to be the 14 kDa breakdown product 
























Figure 4.4: Elution of SPD-CD23 from MHM6-Affiprep-10 Affinity Column 
a) SPD-CD23 eluted from MHM6-Affiprep lO was analysed under non-reducing, 
denaturing conditions by Western blot (using MHM6). Although SPD-CD23 was being 
eluted higher molecular weight complexes were also being detected. b) SDS-PAGE of 
reduced sample shows SPD-CD23 was degrading to smaller fragment (<16 kDa) and 
showed no higher molecular weight contaminants. 
Although no proteolysis of SPD-CD23 had been detected in the supernatant, this 
column was preferentially binding monomeric lectin domain. This is possible if 
trimerisation masks the MHM6 epitope or alternatively, MHM6 which has a very high 
affinity for CD23 disrupts the trimers making them susceptible to dissociation and 
degradation. 
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To investigate the oligomeric nature of SPD-CD23 purified by affinity chromatography 
it was run in its native form on a calibrated gel filtration column (Materials and 
Methods 2.4.3). The eluate was concentrated to approximately 1 mg/ml by ultrafiltration 
and applied to a Superdex 75 column. SPD-CD23 eluted as one major peak unresolved 
from a lower molecular weight peak and a smaller higher molecular weight maximum 
(Figure 4.5a). Fractions containing these maxima were reinjected and molecular weights 
estimated from a standard curve. A peak (-24 kDa = monomer) was still contaminated 
by the major product (-'14 kDa = breakdown product). The higher molecular weight 
peak ('54 kDa) was presumably some sort of oligomer. However, under non-reducing, 
denaturing conditions this fraction did not run as a monomer as expected but as a 
heterogeneous mixture of molecular weights between 30-40 kDa (Figure 4.5b). These 
bands may represent disulphide linked dimers of degradation products. Taken together, 
these results suggest that SPD-CD23 derived by this procedure was monomeric, 
degraded and mis-folded. 
The limitations of the MHM6 affinity column were similar to those experienced by 
Dierks et al., 1993. They observed murine CD23 purified by anti-CD23 affinity 
chromatography resulted in low levels of trimerisation, and subsequently, a reduced 
avidity to IgE adsorbent. To overcome the problem of binding monomeric CD23 the 
possibility of using IgE as an affinity ligand was investigated. It was hoped that an IgE 
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Figure 4.5: Analysis of MHM6 Affinity Purified SPD-CD23 by Size Exclusion 
Chromatography 
a) 0.25 mg SPD-CD23 was loaded onto a calibrated Superdex 75 (Appendix III) 
and run at 0.75 ml/min in 0.25 M Tris-C1,0.125 M NaCI, 1 mM CaCl2 b) Fractions 
1,2 and 3 were run under non-reducing conditions on a SDS gel and silver stained. 
Fraction 1 contained a mixture of mis-folded complexes (0), fraction 2 contained 




250 ml of SPD-CD23 infected S#'9 culture supernatant was loaded onto an IgE coupled 
affiprep 10 column and eluted with 0.1 M glycine pH 2.5. The elution was neutralised 
and analysed by SDS-PAGE and Western blot (results not shown). Very little protein 
was eluted and the major band ran at approximately 60 kDa (results not shown). This 
band did not show up by immunoblotting with MHM6. The 60 kDa protein was likely 
to be the highly expressed baculovirus coat glycoprotein gp64 that bound non- 
specifically. Thus, an IgE column was also unsuitable to purify SPD-CD23. Suspicion 
about SPD-CD23 inability to bind ligands was raised and consequently was investigated 
in a solid-phase binding assay. 
4.3.4 IgE Binding Assay of SPD-CD23 Expressed in Insect Cells. 
The IgE binding ability of SPD-CD23 present in the insect culture supernatant was 
investigated by sandwich ELISA. A monoclonal antibody (rnAb25) previously 
identified to only partially inhibit IgE binding (Wakai et al., 1993; section 5.2.2) was 
coated on to a microtitre plate to capture CD23 in the supernatant. A CD23 
quantification ELISA (2.5.8.2) was used to normalise the concentrations of SPD-CD23 
and a positive control (recombinant extracellular CD23 in blank supernatant). Both 
CD23 were added in serial dilutions to the mAb25 coated plate. A biotinylated form of 
IgE-Fc, followed by streptavidin-HRP was used to detect ligand binding. 
Figure 4.6 shows that full length CD23 was able to bind IgE-Fc (10 nM) at 
concentrations between 20 nM and 50 nM, whereas no binding to SPD-CD23 was 
detected within this range. Indeed, SPD-CD23 was not at a high enough concentration 
within the supernatant to obtain a complete sigmoidal curve. Thus, instead of having a 
higher affinity for IgE than rCD23, as predicted, unpurified SPD-CD23 either has a 
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Figure 4.6: Relative IgE binding activities of SPD-CD23 and rCD23 by ELISA 
Equivalent concentrations of recombinant rCD23 and SPD-CD23 in insect cell culture 
supernatants were captured by 2 µg/ml mAb25 coated onto a microtitre plate. 1 µg/ml 
IgE-Fc was added and interaction revealed by streptavidin-HRP. The curves suggest 
that rCD23 has a greater affinity for IgE-Fc than SPD-CD23 or that the proportion of 
`active' SPD-CD23 was much lower. 
4.4 Production of Chimeric CD23 Expressed by Bacteria 
It was established that SPD-CD23 from insect cells did not bind IgE with a high affinity 
as expected. It was not clear whether this was due to the fact that the chimera was not 
forming trimers or whether the chimera did form trimers that were not capable of ligand 
binding. Due to the difficulties of obtaining sufficient amounts of intact purified SPD- 
CD23 for accurate oligomerisation assessment, the construct was transferred to a 
bacterial expression system where large amounts of relatively pure protein can be made. 
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Through a collaboration with D. Conrad, a human CD23 fusion protein with an N- 
terminal isoleucine zipper and T7 tag (LZ-CD23) was available as solubilised inclusion 
bodies from E. coli expression. Thus, the CD23 chimeric designs could be compared. 
4.4.1 Construction of Recombinant SPD-CD23 Expression Vector 
Primers (PF3, PR3, Appendix I) were designed to produce a PCR product including the 
SPD-CD23 sequence, excluding the VK leader sequence from the original VK-SPD- 
CD23 pBluescript clone. The primers included a HindIIl and Bam-HI restriction sites for 
ligation into pBluescript for amplification and sequencing, and a Ndel site for excision 
and ligation into the MCS of pET5a. Sequencing of the insert in pBluescript confirmed 
no coding mutations were present. 
4.4.2 Expression of SPD-CD23 In E. Coli. 
The BL21 (DE3) (pLysS) host strain was transformed using the SPD-CD23 pET5a 
vector, as described in methods (2.3.1). Expression in 11 culture using M9 media was 
induced by 0.4 mM IPTG at an A600>O. 6. A time course of expression following 
induction was analysed by Western Blot, and the cells were harvested after 3 hours 
(Figure 4.7a). SPD-CD23 appeared to by expressed at high levels in the insoluble 
fraction of the cells. Extraction of inclusion bodies resulted in the solubilisation of 100 
mg protein from 11 of culture. SDS-PAGE analysis shows this extract to be of moderate 
























Figure 4.7: Denatured SPD-CD23 and LZ-CD23 from Expression in E. coli. 
a) SPD-CD23 expression in total cell protein was monitored after induction at time 0,1 
and 3 hours by Western blot using rb55 polyclonal antibody. b) SDS-PAGE analysis of 
SPD-CD23 (1) and LZ-CD23 (2) solubilised inclusion bodies, prepared for loading by 
TCA precipitation and stained by Coomassie Blue. 
4.4.3 Refolding of Chimeras from Solubilised Inclusion Bodies. 
10 mg batches were refolded using the optimised refolding method used to refold 
rCD23 (Reljic, 1996). This involved reduction, formation of a glutathione intermediate 
and dilution into cysteine buffer. Both refolded chimeras were concentrated to less than 
3 ml for purification by gel filtration. The recovery of protein from concentration by 
ultrafiltration was in the region of 60-70% for SPD-CD23 and 40-50% for LZ-CD23. 
Large amounts of aggregate and precipitate were occurring that may be attributed to the 
formation of the associated coiled coil before the stabilisation of the disulphide bonds in 
the lectin domain, thus, leading to intermolecular disulphide bonds. 
4.4.4 Purification of SPD-CD23 and LZ-CD23. 
In order to establish the most appropriate column for separation of oligomeric chimeras 
a series of column matrices were tested: Superdex 75, Superdex 200, Biosep 3000, 
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TSK4000 and Zorbax 250. The resolution of the desired matrix would be able to 
separate aggregated, mis-folded proteins from the correct size as well as breakdown 
material. The running buffer employed was strongly ionic (250 mM NaCI) and highly 
buffered (500 mM Tris) solely to prevent interaction of CD23 with ionic groups on the 
column matrix as had been observed previously for several recombinant proteins. The 
size of the pores in the matrix gives rise to the range of molecular masses the column is 
able to resolve. For both refolded SPD-CD23 (Figure 4.8a) and LZ-CD23 (Figure 4.9a) 
Biosep 3000 was selected for its ability to remove aggregate from the refolded material 
in the preparation. Superdex 200 also gave similar resolution and could also be used for 
purification. The columns were calibrated with protein molecular weight markers to 
form a standard curve (log MW against time) but the estimated molecular weights of the 
maxima did not correspond to the predicted molecular weights of the SPD-CD23 or LZ- 
CD23 oligomeric species. The fractions obtained had to be analysed by alternative 
methods in order to select the correctly folded protein. 
4.4.5 Characterisation of Fractions 
4.4.4.1 Western Blot Analysis 
Western blot analysis of fractions run on a SDS-gel under non-reducing conditions was 
able to show which fractions were mis-folded i. e. contained intermolecular disulphide 
bonds. The SPD-CD23 showed a large proportion of the refolded material contained 
high molecular weight aggregate (fractions 4-8, Figure 4.8b). Some protein of the 
correct size was identified in later fractions (fractions 11-12) which appeared to be well 
resolved from the mis-folded material. SDS-PAGE analysis confirmed this (results not 















ýº . -.... 
9101112 13 L 
44 
c 
5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0 9.5 10.0 
Fraction number 
-4- SPD-CD23 
elution time (mins) 
Figure 4.8: Analysis of Refolded SPD-CD23 by Gel Filtration 
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a) Elution profile (A280) of refolded SPD-CD23 on a calibrated Biosep 3000 column run at 
0.75 ml/min in 0.5 M Tris-C1 pH 7.2,0.25 M NaCl, 0.05% NaN3. Fractions were collected in 
0.5 minute intervals between 5 and 15 minutes. The two major peaks represent aggregated (2 
MDa) and a species estimated to be 150 kDa. b) Fractions and the protein loaded (L) were 
analysed under non-reducing conditions by Western Blot with MHM6. Fractions 4-8 
contained aggregated SPD-CD23 and represents the majority of the preparation. Fractions 
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Figure 4.9: Analysis of Refolded LZ-CD23 by Gel Filtration 
a) Elution profile of refolded LZ-CD23 on a calibrated Biosep 3000 column. Fractions were 
taken every 0.5 minutes from 5 minutes. Several species of different molecular weight were 
observed of estimated weights 260 kDa and 38 kDa presumably representing oligomer and 
monomer, respectively. b) The fractions and refolded protein loaded onto the column (L) 
were analysed under non reducing conditions by Western blot with MHM6. No aggregation 
of LZ-CD23 was detected in this preparation but LZ-CD23 appeared to 
be present in the 
oligomeric fraction only. 
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LZ-CD23 fractions that contained CD23 ran at the correct molecular weight (38 kDa), 
indicating that the fractions 8-12 appeared to be correctly folded and free of aggregate 
(Figure 4.9b). Non-reducing and reducing SDS-PAGE analysis agreed with this 
observation and that the fractions contained few contaminants (results not shown). 
4.4.4.2 IgE binding of Fractions 
The C-type lectin domain has a low proportion of secondary structure and a relatively 
high number of cysteines that bring together non contiguous parts of the backbone to 
form the calcium ion binding site (Figure 1.2). Therefore, incorrectly folded species are 
unlikely to retain the ligand binding site conformation. A ligand binding assay was used 
as a method to identify correctly folded protein. A CD23-IgE ELISA (Methods 2.5.8.4) 
was performed with the fractions obtained from gel filtration. The optimisation of this 
assay is described in Chapter 5. Briefly, the CD23 samples were coated onto a micro- 
titre plate in TBS-Ca, a biotinylated version of anti NIP-IgE or IgE-Fc was added and 
the interaction was detected by Streptavidin-horse radish peroxidase conjugate enzyme 
reaction. 
SPD-CD23 fractions (Figure 4.1 Oa) showed low IgE binding activity akin to that of 
monomeric lectin domain (e. g. Der-CD23). No interactions were detected with 
biotinylated IgE, only the IgE-Fc mutant would bind in this assay. The lower molecular 
weight fractions (fractions 13-15) had the greatest relative binding capacity in this 
assay. The higher molecular weight fractions (fractions 3-9) did not bind IgE-Fc 
because they contained aggregated and mis-folded CD23 oligomers. 
The IgE binding activity of the LZ-CD23 fractions was more promising with relative 
activities comparable to the full length CD23 construct (Figure 4.10b). 
Thus, fractions 
12-15 of SPD-CD23 and fraction 8-11 of LZ-CD23 were pooled as correctly folded, 
114 


















Figure 4.10: IgE Binding Activity of Chimeric CD23 Fractions. 
a) 55 nM of each SPD-CD23 fraction was coated in triplicate alongside 55 nM Der- 
CD23 positive control and a negative control (BSA). 1 pg/ml biotinylated IgE-Fc was 
added and revealed by streptavidin-HRP b) 100 fold dilutions of LZ-CD23 fractions in 
TBS-Ca were coated in triplicate. 1 µg/ml biotinylated anti-NIP IgE was added and 
revealed by streptavidin-HRP (assays described in Chapter 5). 
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active protein for further analysis. Further activity assessments and kinetic constants of 
ligand binding activity of trimeric CD23 are described in Chapter 5. 
4.4.4.3 N-terminal Sequencing and Mass Spectrometry of Selected Fractions 
The N-terminus sequence of protein contained in fraction 13 of SPD-CD23 and Fraction 
10 LZ-CD23 from the Biosep 3000 column was analysed by B. Smith at Celltech as 
described in the methods. The SPD-CD23 preparation gave a major sequence of 
PDVASLRQQVEALQG which represents the correctly processed N-terminal sequence 
(SPD neck region). However, there was a trace of additional sequence which could not 
be attributed to a degradation product but was more likely to be a contaminating E. coli 
protein. N-terminal sequence of LZ-CD23 gave a 15 amino acids representing the T7 
tag (Met processed) derived from the expression vector, pET24a: 
ASMTGGQQMGRGSEF. No additional sequences were detected. 
Positive Ion Electrospray Mass Spectrometry was performed on the SPD-CD23 fraction 
by L. King at Celltech, Slough. The predicted mass of SPD-CD23 is 22,325 calculated 
from sequence data and assuming no glycosylation or other post translational 
modifications other than the removal of the initiation Methionine. This was confirmed 
by the recorded mass of 22,320.34 +/-5.59. Together, these data demonstrate that the 
fractions selected from gel filtration were fully processed and did not contain 
degradation products which may interfere with oligomerisation and consequently 
activity. 
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4.5 Assessing the Oligomerisation State of Chimeric CD23 
Having established the contrasting IgE binding abilities of SPD-CD23 and LZ-CD23, it 
was necessary to determine their oligomerisation state. It was unclear as to whether the 
low affinity interaction of IgE-Fc with SPD-CD23 was due to the chimera being 
monomeric or for other structural factors. Chemical crosslinking and analytical size 
exclusion chromatography using a `physiological' buffer were used to define the 
oligomeric state of the chimeric CD23. 
4.5.1 Chemical Cross-Linking 
1-Ethyl-3-(3-dirnethylaminopropyl)carbodiimide Hydrochloride (EDAC or EDC) was 
utilised in a chemical cross-linking experiment to assess whether a SPD-CD23 and LZ- 
CD23 was forming oligomers in solution. This method, described in Methods (2.5.5.1) 
has previously been used to show the stalk region of CD23 fragment forms trimers 
(Beavil et al., 1995). 
A western blot (reduced conditions) in Figure 4.11 shows the products of cross linking 
SPD-CD23 and LZ-CD23 with a series of EDC concentrations. The reduced monomeric 
SPD-CD23 species decreases on addition of EDC, and a major trimeric species becomes 
visible especially with 25 mM EDC. On a longer exposure, small amounts of other 
oligomers are seen. These are approximate to the molecular mass of a hexamer and 
nonamer, suggesting SPD-CD23 forms stable trimers. 
The EDC crosslinking results of LZ-CD23 again show the reduction in monomeric 
species (37.5 kDa) and the appearance of a major band around 75 kDa, corresponding to 
a dimer. A small amount of trimeric LZ-CD23 (114 kDa) may be present, 
but could be 
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indistinguishable from a tetramer (150 kDa). At higher EDC concentrations LZ-CD23 
was aggregating and did not enter the separating gel. 
To confirm the presence of dimeric or trimeric LZ-CD23 species, di-fuoro di- 
nitrobenzene (DFDNB) was also used. This crosslinker also has a short `spacer arm' of 
0.3 nm and cross links primary amines (R-NH2) i. e. lysine residues. DFDNB has been 
used to demonstrate the oligomeric species of other animal C-type lectins e. g. rat 
asialoglycoprotein receptor (Halberg et al., 1997). A series of DFDNB concentration 
(0.1 mM, 1 mM and 10 mM) were used with 1 µg/m1 LZ-CD23 in carbonate- 
bicarbonate buffer pH 10 for 2 hours at room temperature. Despite the smeared 
appearance of the resulting western blot, two major bands (at <75 kDa and -105 kDa 
markers) replaced the monomeric species on addition of 1 mM DFDNB. These 
probably represent LZ-CD23 dimers and trimers. Again, excess crosslinker results in 
aggregation and consequently no detection of CD23 in the separating gel. 
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Figure 4.11: Chemical Cross-linking of CD23 Chimeras. 
a) 1 µg/ml SPD-CD23 was cross-linked with a range of EDC concentration 10-100 mM in 
25 mM acetate buffer pH 5.0 for 15 minutes. The reaction was stopped on addition of 
reducing SDS loading buffer. Western blot analysis using rb55 (polyclonal anti-CD23) 
showed the monomeric species decrease and the appearance of a major trimeric species (66 
kDa) and possibly further trimeric multimers indicated by arrows. b) Using identical 
conditions LZ-CD23 was also shown to cross link with EDC. Approximate dimeric 
species (-75 kDa) and a small amount of trimer (-110 kDa) were forming. c) This 
observation was confirmed using DFDNB at 1 mM, pH 10, for 2 hours. 
c) LZ-CD23 + DFDNB (M) 
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4.5.2 Analytical Gel Filtration HPLC 
The oligornerisation state of a protein can be determined simply by measuring its 
molecular weight in solution. Analytical gel filtration was performed using a running 
buffer closer to physiological conditions than previously employed for purification. 
Superdex 200 can resolve proteins over a wide range of molecular weights (20 kDa - 
500 kDa) and could identify larger oligomeric forms. Purified SPD-CD23 and LZ-CD23 
(-0.3 mg/ml) were dialysed against HBS-Ca and 20 µl was loaded onto a calibrated 
Superdex 200 column at 0.75 ml/min. 
The resulting profile (Figure 4.12) indicates that more than one species was being eluted 
from each purified protein. Two maxima were estimated to be 95 kDa and 37 kDa, 
which might corresponded to trimeric (66 kDa) and monomeric (22 kDa) SPD-CD23. 
This protein did not behave like the standard proteins, eluting earlier than expected, 
therefore appearing larger. A non-globular shape due to the SPD stalk could account for 
it appearing larger. Another maxima approximately 6 times the observed monomeric 
oligomeric weight may have represented a small fraction of the sample was forming a 
hexamer (2 sets of trimers). The LZ-CD23 preparation appeared to be largely trimeric, 
estimated to be 134 kDa (actual trimer size is 113 kDa). Here too, the long stalk of the 
molecule would cause the LZ-CD23 to behave like a larger protein. The was also 
evidence of a range of lower molecular weight species in the LZ-CD23 preparation, but 
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Figure 4.12: Analytical Size Exclusion Chromatography of Purified Chimeras 
The fractions selected in the previous section were analysed on a Superdex 200 size exclusion 
column. Samples were dialysed into HBS-Ca which was also used as a running buffer at 0.75 
ml/min. 20 µl of 0.4 mg/ml SPD-CD23 (a) and LZ-CD23 (b) were loaded. The column had 
previously been calibrated by protein molecular weight markers (also run in HBS-Ca). The 
extrapolated molecular weights corresponded only loosely to the predicted mass of the 
monomers (M) and trimers (T). 
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4.5.3 Stability of SPD-CD23 and LZ-CD23 Oligomers in Physiological Buffer 
A preparative run of the size exclusion chromatography in HBS-Ca was performed to 
determine the stability of the major species of oligomer. On reinjection of these 
fractions, a single maxima was obtained showing no evidence of aggregation or 
degradation (SPD-CD23 shown in Figure 4.13a). Furthermore, no equilibrium between 
trimer or monomer was detected within this time (hours). LZ-CD23 trimeric fraction 
was concentrated by ultrafiltration (YM10 membrane) the trimeric fraction in HBS-Ca 
was analysed on the Superdex 200 column. The majority 80% (calculated by integration 
under the curve) was still trimeric. However, a small amount, of aggregate (5%) and a 
shoulder (15%) on the major peak was seen (Figure 13. a). This was also noted when 
LZ-CD23 was dialysed into PBS. At higher concentrations (>0.3 mg/ml), precipitation 
was a problem in the LZ-CD23 preparation and planned analytical ultracentrifugation 
could not be undertaken. 
Following two weeks stored at 4 °C, the SPD-CD23 and LZ-CD23 trimeric fractions 
were analysed by SDS-PAGE to assess their stability. A silver stained gel (Figure 4.13) 
shows that little degradation had occurred (reducing conditions). Under non-reducing 
conditions the preparations are expected to run at monomeric molecular weight because 
trimers are supposed to be non-covalently associated. However, a significant proportion 
of both preparations (but especially SPD-CD23) behave like disulphide linked dimers or 
trimers. 
In summary, this section shows LZ-CD23 is forming dimers or trimers and SPD-CD23 
was mostly trimeric. However, in physiological buffer both chimeras have a propensity 
to aggregate and appear mis-folded. Using this method of refolding and purification, 
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Figure 4.13: Analysis of Purified Trimeric Species. 
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a) The oligomeric species (SPD-CD23 and LZ-CD23) identified by analytical HPLC 
(Section 4.52, Figure 4.12) were re-injected onto Superdex 200 in HBS-Ca. No 
monomer/dimeric/trimer equilibrium was observed. b) Purified SPD-CD23 (S) LZ-CD23 
(L) stored for 2 weeks was analysed by SDS-PAGE under reducing and non-reducing 
conditions to assess their stability. Little degradation was observed but the a proportion of 
the samples ran as intermolecularly bonded oligomers under non-reducing conditions. 
This suggests the samples are mis-folding with time. 
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4.6 Summary and Conclusions 
A leader-SPD sequence was made from overlapping oligonucleotides by PCR, which 
can be joined to any point of CD23 (or other target protein) sequence in a single PCR 
step. The 5' restriction sites (BamHI and Xmal) allow the chimera to be inserted into 
pFastBac and pEE 12 expression vectors and secreted by insect and mammalian cells. 
In this project the SPD sequence was fused to the '25 kDa' CD23 fragment including 
the neck, lectin domain and C-terminal tail. This region of CD23 supposedly contains 
the minimum requirements of ligand binding and the omission of the principal sites of 
proteolysis. Expression in insect cells resulted in the secretion of SPD-CD23 into the 
culture supernatant (10 mg/1). Although enough material could be expressed by 51 
fermentation, purification by affinity chromatography using anti-CD23 antibodies led to 
the isolation of a high proportion of mis-folded and degraded products. Antibodies to 
the SPD region would be an attractive alternative especially if they recognise SPD as a 
coiled coil. However, no such monoclonal antibodies were available. For future chimera 
purification an affinity tag at the N-terminus would be advisable, for instance, the 
commonly used His tag which would not interfere with ligand binding. 
Of concern was the inability of SPD-CD23 in the culture supernatant to bind an IgE 
coupled affinity column and its low affinity interaction with IgE-Fc in an ELISA. SPD- 
CD23 was transferred to a bacterial expression system to investigate this observation 
further. Large amounts were extracted (100 mg/1) to moderate purity and this was 
compared to another human chimera, LZ-CD23, also previously uncharacterised, but 
the human equivalent to a murine chimera which was demonstrated to inhibit high 
affinity receptor binding to IgE. 
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A sizeable proportion of the refolded SPD-CD23 and LZ-CD23 was aggregating and 
precipitating noticeably during concentration. Some effort could be made to reduce the 
intermolecular bonds forming during concentration by blocking free cysteines (with 
iodoacetate) or oxidising them (with copper phenanthroline). Initial attempts made little 
difference and complicated the further analysis (results not shown). 
Gel filtration was successful in separating mis-folded aggregate from the remaining 
preparation. IgE binding assays confirmed that the highest activities were in the non- 
aggregated fractions. Nevertheless, SPD-CD23 still showed a low affinity to IgE-Fc 
similar to that of lectin domain alone. Conversely, LZ-CD23 interacted with IgE to an 
extent similar to recombinant extracellular CD23, as expected (Chapter 5). N-terminal 
sequencing and mass spectrometry of the selected fractions demonstrated that both 
SPD-CD23 and LZ-CD23 were intact and correctly processed. 
The oligomerisation state was investigated by chemical crosslinking and analytical 
HPLC. Using EDC, cross-linked SPD-CD23 trimers were detected, and analytical 
HPLC confirmed the majority of purified SPD-CD23 was trimeric with evidence of 
multimers of trimers. On closer inspection the trimeric fraction had a tendency to form 
intermolecular disulphide bonds during concentration and dialysis into a lower ionic 
strength solution. Crosslinking LZ-CD23 with EDC and DFDNB resulted in dimers and 
trimers. The estimation of molecular mass of the oligomeric species by analytical HPLC 
was difficult due to the non-globular shape of the LZ-CD23 molecule which did not 
behave like the standard proteins of the calibration curve. With time, LZ-CD23 also 
formed intramolecularly bonded multimers (notably dimers), and tended to aggregate at 
high concentrations. 
The refolding of the cysteine rich lectin domain was complicated 
by the trimeric 
association because this may have encouraged aberrant 
disulphide bonds forming 
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between domains. It is possible that the SPD motif forced the lectin domains into an 
orientation that brought cysteine residues on neighbouring domains closer together than 
the native arrangement. This is supported by crystallography evidence of trimeric SPD 
(Hakansson et al., 1999). The SPD lectin domains are asymmetrically arranged because 
of the packing of a tyrosine side-chain in the coiled coil. Altered orientation or `pitch' of 
the CD23 lectin domains may also account for the poor affinity of SPD-CD23 for IgE- 
Fc. Although the SPD motif was effective at forming trimers, SPD-CD23 was 
unsuitable for use in the intended biological and biophysical studies because of its poor 
ligand binding ability. 
Perhaps LZ-CD23 benefited from having the CD23 stalk region to orient and stabilise 
the lectin domains. Dimer/trimer stability may have contributed to effective IgE binding 
of LZ-CD23 and possibly a reduction in proteolysis along the stalk. Enough of the final 
LZ-CD23 was prepared to quantify its affinity for IgE and investigate its effect in a 
biological assays (Chapter 5). 
126 
CHAPTER 5: FUNCTIONAL CHARACTERISATION OF 
RECOMBINANT 16 kDa AND OLIGOMERIC CD23 
5.1 Introduction 
Soluble CD23 was identified as the IgE binding factor from B-cell cultures responsible 
for the enhancement of IgE production (Sarfati and Delespesse, 1988). Since then, 
CD21 was discovered as the counter structure for sCD23 which is postulated to up- 
regulate IgE synthesis (Aubry et al., 1992). There are several possibilities to explain 
how sCD23 fragments >25 kDa mediate up-regulation of IgE. In addition to a 
stimulatory signal upon ligation of CD21, the production of sCD23 causes a loss in cell 
surface CD23, thereby diminishing negative signals mediated by membrane CD23-IgE 
complexes (Sherr et aL, 1989). Also, negative feedback may be abrogated by 
competition between sCD23 and membrane CD23 for binding soluble IgE. It is still 
unclear whether up regulation of IgE synthesis by CD23 is a result of B-cell 
proliferation, a directed switching event or B-cell differentiation to plasma cells. 
To investigate these possibilities, an in vitro system using stable CD23 was developed. 
LZ-CD23 produced in Chapter 4 was intended for this purpose. Less is known about the 
mechanism of IgE suppression mediated by smaller CD23 fragments, i. e. 16 kDa 
(Sarfati et al., 1992). Der-CD23 characterised in Chapter 1 should be a useful molecular 
tool to study IgE suppression in vitro. 
This Chapter compares the ligand binding properties and kinetic binding data of 
oligomeric sCD23 (LZ-CD23) and CD23 lectin domain (Der-CD23) with 
IgE Fc in an 
attempt to rationalise the opposing regulatory properties of native 
29-37 kDa and 16 
kDa sCD23. ELISA and surface plasmon resonance (SPR) studies were carried out 
using the recombinant components listed in Table 5.1 and shown 
in Figure 5.1. 
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Table 5.1: List of Recombinant Proteins Included in Functional Assays. 
Recombinant Protein Structure Expression 
System 
MW 
Anti-NIP IgE Soluble IgE NSO 185 kDa 
Der-CD23 Lectin domain E. coli 16 kDa 
IgE-Fc (bIIgII) IgE Fc double 
glycosylation mutant 
NSO 42 kDa 
(dimer = 84 kDa) 
LZ-CD23 Extracellular chimeric 
trimer 
E. coli 37.5 kDa 
(trimer = 113 kDa) 
rCD23 Extracellular E. coli 31 kDa 
(trimer = 93 kDa) 





















Figure 5.1: Silver Stained SDS-PAGE of Recombinant Proteins. 
250 ng of each recombinant protein was analysed by SDS-PAGE under reducing 
conditions. A small proportion of degradation product was observed in rCD23 and LZ- 
CD23 samples. BSA and baculovirus gp64 are the likely contaminant in 1gE-Fc and 
sCD21, respectively. 
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5.2 CD23-Ligand Binding by Enzyme-Linked Immunosorbent Assay. 
5.2.1 CD23-IgE Interaction 
A rapid and reproducible ELISA was required for simple assessment of CD23 activity. 
An assay using recombinant extracellular CD23 coated on a microtitre plate followed by 
the addition of anti-NIP-IgE and anti IgE-HRP conjugate had previously been described 
by J. Shi (1997). Variations of this assay were investigated using biotinylated IgE 
fragments in order to improve sensitivity. Optimisation of the steps were also carried 
out. 
From a screen of five buffers (50 mM glycine, 50 mM glycinate, pH 6.0; PBS pH 7.2; 
TBS, 2 mM CaC12, pH 7.5; 100 mM sodium carbonate, 100 mM sodium hydrogen 
carbonate, pH 8.4 and pH 9.0) TBS-Ca was selected as the most efficient coating buffer 
for the IgE binding ELISA, using the conditions described in section 2.5.8.4 (Figure 
5.2a). BSA in TBS-Ca was selected for the blocking buffer and assay buffer because it 
produced a greater signal than the milk protein mixture (Figure 5.2b) and still 
maintained a low background signal. Chicken egg Ovalbumin (46 kDa) was also an 
improvement. 
Both biotinylated IgE (anti-NIP) and IgE Fc bound CD23 in the functional assay. Figure 
5.2c shows IgE and IgE-Fc titrated on 80 nM (250 ng/ml) rCD23. IgE-Fc produced a 
greater signal, either because reduced steric hindrance allows more IgE-Fc to bind, or 
perhaps, because IgE-Fc was more efficiently labelled with biotin. This IgE 
concentration range was used to compare the relative binding abilities of the soluble 
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Figure 5.2: Optimisation of an IgE Binding Assay by ELISA (CD23 coated directly 
onto plate). 
a) rCD23 was coated directly onto a microtitre plate using buffers of varying ionic 
strength and pH. TBS-Ca (pH 7.5,125 mM NaCl) was selected. b) Different blocking 
agents were tested in the assay. BSA and chicken egg ovalbumin were preferable to the 
milk protein mixture. c) Biotinylated IgE and IgE-Fc were serially diluted to select a 




5.2.2 IgE binding Sandwich ELISA 
An anti-CD23 capture antibody was sought to improve the presentation of CD23 to IgE. 
The adsorption process causes CD23 to be largely denatured and the high 
concentrations used to coat CD23 directly to the plate may mimic multimeric molecules 
and result in artificially strong interactions. Using an anti-CD23 monoclonal antibody it 
was hoped that orientation, fold and concentration of captured CD23 would be constant 
and hence the IgE interactions comparable. A capture monoclonal antibody also allows 
activity of CD23 in non-homogeneous samples to be assessed and at lower 
concentrations than direct coating. 
From published competition assays (Wakai et al., 1995; Bonnefoy et al., 1997; 
summarised in Table 5.2) some anti-CD23 monoclonal antibodies have a low capacity 
for IgE binding inhibition e. g. EBVCS-1,2 and 5. It was hoped that one would be 
appropriate for use as a capture antibody. A screen of several antibodies (Figure 5.3) 
were coated at 2 µg/ml in Bicarbonate-carbonate buffer pH 9.8. Using full length rCD23 
and biotinylated IgE and IgE-Fc, only mAb25 was found to be suitable for use in the 
sandwich ELISA under these conditions. The protocol for this ELISA is outlined in 
Chapter 2 (2.5.8.5). 
5.2.3 Comparison of LZ-CD23 and Der-CD23 Interactions with IgE by ELISA 
Recombinant CD23 constructs (listed in Table 5.1) were included in both optimised 
ELISAs added to the wells in equal molar quantities. Serially diluted biotinylated IgE 
and streptavidin-HRP was added as before. The resulting curves in Figure 5.4 show that 
biotinylated IgE bound LZ-CD23 and rCD23 but was unable to interact with Der-CD23 
significantly above the negative control (BSA). The inability to detect Der-CD23-IgE 
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B6 Partial n/d IgG2b Bonnefoy et al., 1987 
BU38 Yes n/d IgG 1 Bonnefoy et al., 198 7 
EBV-CSI No 0 IgGI Wakai et al., 1993 
EBV-CS2 Partial 16 IgGI Wakai et al., 1993 
EBV-CS4 n/d n/d IgM 
EBV-CS5 Partial 17 IgGI Wakai et al., 1993 
IOB8 n/d n/d IgG 1 
mAb 25 Partial 20-50 IgGI Wakai et al., 1993 
MHM6 Yes 90 IgG1 Wakai et al., 1993 
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Figure 5.3: Selection of a Capture Antibody for IgE binding Assay 
Cý 
Q) 
2 pg/ml of each anti-CD23 monoclonal antibody was coated onto a microtitre plate 
(incubated overnight at 4 °C). After standard blocking and wash procedures (Materials 
and Methods 2.5.8.5) 1 pg/ml rCD23 (positive control protein) and blank samples (no 
CD23) were incubated at room temperature for 2 hours. 1 µg/ml biotinylated IgE was 
added and the assay continued as normal. Results are blank subtracted averages of the 
triplicate samples (+ 1 standard deviation error bar). 
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Figure 5.4: Comparison IgE binding to Recombinant CD23 fragments. 
Biotinylated IgE was titrated over 80 nM of CD23 fragments a) directly coated in TBS- 
Ca or b) captured by 2 µg/ml mAb25. IgE-CD23 interaction was revealed by 
streptavidin-HRP and the enzyme reaction developed with OPD. Der-CD23 did not 
bind significantly above background levels (negative control, BSA) whereas the 
trimeric LZ-CD23 appeared to have a greater binding ability than the full length 
recombinant CD23. 
0.1 1 10 
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binding may be due to the disruption of the weak interaction during washing steps of the 
ELISA. 
Despite being applied to the wells in equal molar quantities, the maximum signal 
obtained for LZ-CD23 and rCD23 were different. This is not necessarily a reflection on 
affinity, instead, this suggests that the concentration of active molecules was different 
for each recombinant CD23. Possibly the rCD23 sample contains more mis-folded or 
degraded molecules (evident in Figure 5.1). Alternatively, as two lectin domains are 
involved in the IgE interaction, the greater the proportion of oligomeric species in the 
CD23 sample, the more IgE binding sites are available. Thus, the increased stability of 
the CD23 trimer by the LZ fusion could be responsible for the greater number of IgE 
binding sites. 
Affinity constants can be derived from ELISA data, either directly through Scatchard 
plot construction (r/[L] vs. r) or by an indirect method (Friguet et a!., 1985), but are not 
as informative as SPR, which would also be able to determine the binding constants for 
the weaker interaction of Der-CD23 and IgE (section 5.3). However, the ELISAs can 
provide a comparison of binding ability of CD23 in fractions or batches, particularly 
useful in the purification of CD23. 
5.2.4 Inhibition of CD23-IgE binding with Der-CD23 
In the previous ELISAs no specific interaction was detected between Der-CD23 and 
biotinylated IgE. Der-CD23 will bind biotinylated IgE-Fc in an ELISA (as used in 
Figure 4.10). The interaction occurs when Der-CD23 is coated at high concentration (> I 
µg/ml) which may mimic an oligomeric situation as the 
interaction can not be 
demonstrated when Der-CD23 is captured by mAb25. As an alternative, an indirect 
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Figure 5.5: Competitive Inhibition of the CD23-IgE Interaction 
-ý LZ-CD23 
Der-CD23 
Serial dilutions (starting from 10 µg/ml) of the CD23 and IgE constructs were made in 
assay buffer containing 2 µg/ml biotinylated IgE. These mixtures were added to 3 µg/ml 
rCD23 coated plates and assay completed as previously described. Absorbance values 
were corrected for IgE and CD23 blanks. Percentage inhibition was calculated from the 
% Inhibition = (Ao - Ai/)Ao x 100 where Ao is the absorbance at 492 nm with no 
inhibitor and Ai with inhibitor (averages of triplicate readings). 
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Der-CD23 at several concentrations was incubated with biotinylated IgE and added to 
rCD23 coated mitrotitre plates. Der-CD23 IgE interactions should reduce the amount of 
IgE binding to rCD23. Figure 5.5 shows the percentage inhibition of the rCD23-IgE 
interaction with LZ-CD23 and Der-CD23. As predicted, LZ-CD23 showed a 
concentration dependent inhibition maximal at -250 nM. However, Der-CD23 even at 
high concentrations (600 nM) did not show any significant competition for IgE binding. 
The controls for the assay included an irrelevant IgG 1 (negative control, no inhibition at 
all concentrations), IgE-Fc (90% at 10 µg/ml), EDTA (80% at 10 mM) and mAb25 (an 
anti-CD23 mAb) which partially inhibited IgE binding (60% at 10 µg/ml), confirming 
the observations from sandwich ELISA optimisation (Figure 5.3). 
5.2.5 CD23-CD21 Interaction 
A CD21 binding assay has been described by Fremeaux-Bacchi et al., 1996. Their 
protocol was adapted for use with the recombinant proteins and monoclonal antibodies 
available in the laboratory. In the following experiment, sCD2 1, expressed by insect 
cells and purified by affinity chromatography (HB5 coupled Affi-prep 10) was added to 
CD23 coated plates. Anti-CD21 monoclonal antibody HB5 (also IF8 or BU32) could be 
used to reveal the interaction, followed by an anti-mouse Fc-HRP conjugate. Molar 
equivalents (300 nM) of rCD23, Der-CD23, BSA (negative control) and iC3b (positive 
control) were coated directly onto microtitre plates. sCD21 was titrated from 10 µg/ml 
to 0.125 µg/ml. Figure 5.6 shows that the full length extracellular CD23 was the most 
effective CD23 structure to bind sCD21, albeit much at less extent than iC3b. Binding 
of sCD21 to Der-CD23 was barely detected above the negative control. 
These results may be a reflection of the oligomeric state of the recombinant CD23. Full 
length extracellular CD23 can form dimers and trimers (R. Relj ic, 1996) and may have 
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an increased affinity due to multivalent interactions. Unfortunately, no LZ-CD23 was 
available at this time to support this observation. Experiments are ongoing in this 
laboratory to characterise the LZ-CD23/CD21 interaction. The lectin domain construct 
would have the molecular requirement to establish the protein-protein interaction 
between CD23 and the first SCR domain of CD2 1, but was probably too weak to detect. 
The weak CD23-CD21 interaction detected in this assay may also be a result of non- 
physiological glycosylation of sCD21 by insect cells. Baculovirus expression systems 
synthesise proteins with N-linked carbohydrate rich in mannose and are unable to 
process proteins with complex carbohydrate containing sialic acid or galactose. 
Kijirnoto-Ochiai and Uede (1995) demonstrated that CD23 acts as a galactose-binding 
lectin in the cell aggregation of EBV-transformed human B-cell lines. Mannose and 
other sugars not found on complex carbohydrate termini did not inhibit the CD21-CD23 
interaction (Pochon et al., 1992). It is probable that the baculovirus expressed sCD21 
was insufficiently glycoslyated to demonstrate high affinity carbohydrate recognition by 
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Figure 5.6: Demonstrating the CD23-CD21 Interaction by ELISA 
C3bi 
- - rCD23 
Der-CD23 
100 nM rCD23 (-10 µg/ml), Der-CD23, C3bi and BSA were coated directly onto a 
microtitre plate in TBS-Ca. Dilutions of sCD21 were applied and interaction revealed 





5.3 Measurement of CD23-IgE Fe Binding Constants by Surface Plasmon 
Resonance (SPR). 
5.3.1 Principles of SPR 
Although ELISA based functional assays are helpful in qualitative studies, they provide 
no information on the kinetics of the interaction and cannot detect weak interactions 
(<106 M-1). Surface plasmon resonance has been used to provide additional data; 
association and dissociation rate constants (ka and kd) and hence, the affinity constant, 
KA. In SPR kinetic experiments, ligands are permanently bound to dextran chains 
attached to the thin gold surface of up to four flowcells on a sensor chip, either through 
covalent EDC coupling or, as in this project, very high affinity streptavidin-biotin 
interactions (KA = 10-14 M-1). Ligand-analyte interactions are detected by a change in 
refractive index (RI) at the sensor chip surface measured by an optical technique. The 
binding response is measured in response units (RU) and is particularly sensitive (100 
RU is the equivalent of 100 pg mm 2) therefore, little protein is consumed and weak 
interactions can be detected. Molecular interactions are followed in real time (10 
measurements per second) thus, association and dissociation rates can be measured. 
Evaluation software can be used to fit models of kinetic parameters to the sensorgrams 
produced. 
5.3.2 Flowcell Preparation and Regeneration 
In contrast to ELISA, the IgE component (biotinylated IgE-Fc) was bound to the chip 
surface and soluble CD23 analyte was passed over. This gives a fairer comparison of 
affinities of the soluble recombinant CD23 fragments. Sparsely 
biotinylated IgE-Fc was 
used in preference to IgE because previous attempts at tethering 
IgE led to poor 
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responses on CD23 binding. The unusual bent shape of IgE may allow only a limited 
number of favourable orientations and coupling may be preferred on the convex side 
(also the Fe receptor binding site). A flowcell containing 447 RU and 900 RU of bound 
IgE Fc were prepared and a blank flowcell with unbound streptavidin was used as a 
negative control. 
Due to the calcium dependent nature of the CD23-IgE interaction HBS containing 2 
mM Ca2+ was used as the running buffer at 10 µl/min. The sensorgram in Figure 5.7 
shows the binding response following injection of rCD23 and suggests that the bound 
ligand was not adversely altered by attachment to the chip surface. A series of three 
regeneration buffers were tested to optimise the removal of bound analyte (CD23) 
without damaging the ligand (IgE-Fc). Buffers of lowered pH and high salt 
concentration are often used to disrupt interactions, but 100 mM sodium acetate (pH 5) 
with and without 0.5 M NaCl, were ineffective for this system even after several 
injections (Figure 5.7). 10 mM EDTA in HBS was efficient at removing the majority of 
the remaining analyte. This is a very mild regeneration, able to remove CD23 by 
disrupting the calcium dependent binding site in the lectin domain. Further optimisation 
demonstrated 3 two minute injections of 25 mM EDTA were required and maintained 
identical responses to duplicate injections of CD23 (not shown). 
5.3.3 Measurement of Binding Kinetics of Der-CD23 and LZ CD23 
The affinity constant of the interaction of IgE-Fc with LZ-CD23 and Der-CD23 was 
obtained by SPR. Experiments were performed at a flow rate of 10 , 
d/min in HBS-Ca, 
collecting association and dissociation phase data for 6 minutes (at 10 Hz). Serial 
dilutions of analyte protein were injected over the IgE-Fc flowcells and the blank 














Figure 5.7: Regeneration of the IgE-Fc Flowcell 
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Following a1 minute injection of 440 nM rCD23, three regeneration buffers (RBI-3) 
were tested to select the mildest buffer that could remove CD23 bound to IgE Fc. RB 1 
(100 mM sodium acetate, pH 5) initially removed 22% but did not dislodge on repeat 
injections. RB2 (100 mM sodium acetate, pH 5,0.5 M NaCI) was also ineffective 
(10%). RB3 (HBS, 10 mM EDTA) was the most efficient regeneration buffer able to 
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Figure 5.8: BlAcore Sensorgrams of Recombinant CD23 Binding to IgE-Fc 
In a single experiment, serial dilutions of rCD23 (- 440, - 220,110,55 nM); LZ-CD23 (- 
166,83,42, - 21, nM) and Der-CD23 (- 1000, - 500,250, - 63 nM) were injected through 
a flowcell containing 445 RU or 920 RU of bound IgE-Fc at 10 pl/min in HBS-Ca. 
Association and dissociation phases occurred for 6 minutes. The representative sensorgrams 
shown here are the result of subtracting the response from the blank flowcell negative 
control. 
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subtracting the blank flowcell data. The start of the association was adjusted to 0 RU, 
t=0 as shown in Figure 5.8. All of the recombinant CD23s bound IgE-Fc specifically, 
although the Der-CD23 sensorgram appears quite different from rCD23 and LZ-CD23. 
The large shift in RU on association and dissociation is the bulk response, indicative of 
a difference in refractive index due the high concentration of protein or a change in 
buffer. 
Analysis of the data was performed using a 1: 1 Langmuir association/dissociation 
model in the BlAevalution 3.0 software (Pharmacia). Although the CD23-IgE 
interaction is theoretically a 2: 1 interaction, we assume one trimer (LZ-CD23) binds one 
immobilised IgE-Fc. The Der-CD23 contains no stalk region and should, therefore, 
interact as a monomer, satisfying the Langmuir equations. 
The rate of formation of a complex AB from components A and B can be written as: 
d[AB]/dt = ka [A] [B] - kd [AB] 
Where ka is the association rate constant (M-ls 1) and kd is the dissociation rate constant 
(s-1). When one of the reactants [B] is substituted for [B]o - [AB], where [B]a is the total 
concentration of reactant B, the equation is written as 
d[AB]/dt = ka [A]([B]o - [AB]) - kd [AB] 
The analyte, A is continuously replenished in the flowcell, therefore the free analyte 
concentration remains constant, C. The response, R, corresponds to the amount of AB 
complexes formed and Rm will be proportional to the surface concentration of 
immobilised ligand [B]o. Therefore: 
dRlät=kaC(Rma-R)-kdR 
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Rearranging the rate equation: 
dR/dt = ka CRmax - (kaC + 1) R 
Plots of dR/dt vR for a range of concentrations of free analyte will have a gradients of 
-(kaC+kd). When these values are plotted versus concentration a line is obtained whose 
slope is equal to ka and y intercept corresponding to -kd. 
After the association phase the concentration of free analyte drops to zero therefore: 
dRldt= -kdR 
or 
1n(RoI) = k(tn - to) 
where Rn is the response at time t,,. The dissociation rate is calculated from the slope of 
the plot ln(RO/Rn) versus (tn - to). 
In these analyses the dissociation constants were derived from the data first using at 
least 200 s of the 360 s dissociation time, then these values were used to derive the ka 
constant for each concentration.. The software calculates, or fits, the ka and Rm locally 
(i. e. for each concentration) for at least 200 s of the association phase (selected 
manually). This calculation is fitted to the observed response curves, whose accuracy is 
assessed by a residual plot (Appendix IV). Values were accepted whose residuals 
(deviation of experimental data from the proposed curve) were less than 2.5 and 
distributed evenly. The results are displayed in Table 5.3, the Chi2 values give a 
statistical indication of closeness of fit, values below 2 are considered acceptable. 
Chi2 = ý(rf-rx)2/n 
Where rf is the fitted value, rX is experimental value and n is the number of data points. 
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(x 10-4 s 1) 
ka 
(x 103 M-IS-1) 
KA 
(x 106 M-l) 
Chi2 Number of 
experiments 
Trimeric 4.3 ± 0.8* 23.2 ± 11.3* 52.8 ± 19.9* 0.317 3 
LZ-CD23 
Trimeric 2.6 ± 0.6 14.1 ± 4.2 57.0 ± 18.91: r 0.315 1 
rCD23 
Monomeric 10.1 ± 3.0* 9.1 ± 4.4* 9.0 + 2.6* 0.333 3 
Der-CD23 
* The mean of the kinetic constants derived from 10 concentrations ±1 standard 
deviation. I The mean of the kinetic constants derived from 4 concentrations ±1 
standard deviation. 
The 1: 1 Langinuir model fitted well to each recombinant CD23 data, shown by small, 
well distributed residuals (Appendix IV) and low Chi 2 values (< 0.4). The association 
constants rates of trimeric CD23 (ka = 1.4 - 2.3 x 104 M-ls-) appeared to be higher than 
the monomeric CD23 (ka, = 9.1 x 103 M-ls-) however, the standard deviations were 
large. The dissociation rate, of Der-CD23 (kd _10-3 s-) was more than double that of 
rCD23 and LZ-CD23 (2.6 and 4.0 x 10-4 s 1, respectively). These ka and kd differences 
were reflected in the affinity constant KA, 
KA = ka/ka 
which would suggest that the affinity of rCD23 and LZ-CD23 (5.7 and 5.3 x 107 M-1, 
respectively) approximately six times greater than Der-CD23 (KA = 9.0 x 106 M-'). 
When taking into account the deviations for the affinity constants (KA) the affinities of 
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monomeric and trimeric CD23 remain distinct (0.7 - 1.2 M-1 and 3.3 - 7.6 x 10' M-1, 
respectively). These experiments also show that LZ-CD23 does not appear to differ in 
affinity from the rCD23 construct, assuming both interact as trimers. 
Large standard deviations would be due to errors in concentration estimation, 
particularly if there is a proportion of the sample that is not active. The dissociation 
constants, which are not a function of concentration, are considered to be a good 
comparative indicator of affinity between similar molecules. Focussing on dissociation 
rates, the Der-CD23 lectin domain has an affinity for IgE three-fold lower than full 
length CD23. 
5.3.4 The Effect of Flow Rate on the Der-CD23-IgE Fc Dissociation Rate Constant. 
ELISA data described earlier suggests that Der-CD23 weakly interacts with IgE. 
Binding was improved when using IgE-Fc and SPR data would suggests the affinity of 
this interaction was actually fairly high (KA = 107 M"1). It is possible that SPR was over- 
estimating the apparent affinity. The high concentration used in kinetic experiments 
may encourage rebinding during dissociation and would cause the kd to be under- 
estimated. This potential problem was assessed with a faster flow rate (30 µl/min). 
A concentration series of Der-CD23 (from 1000 nM) was applied to the 
flowcells at 
30 µl/ml for 6 minute association and dissociation period. The measured 
kd displayed in 
Table 5.4 were calculated as before and represent the mean 
kd from a number of 
experiments. The standard deviations were quite 
high but no significant difference in kd 
was found at 30 µl/min. Therefore, no mass transfer effects were occurring at 
10 µ1/min 
and the dissociation rate of 1x 10"3 s-1 was a reliable estimation. 
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Table 5.4: Effect of Experimental Flow Rate on Dissociation Rate Constant for the 
Der-CD23 IgE-Fc Interaction. 
Flow Rate (µl/min) kd (x 10ý s )* n Chi 
10 1.0 + 0.3 16 0.341 
30 0.9 ± 0.3 7 0.339 
* mean kd ±1 SD calculated from n number of analyses. 
It is likely that the ELISAs are at the limits CD23-ligand affinity detection, with the 3-6 
fold greater affinity of the trimeric constructs being sufficient to form stable 
interactions. The shorter `lifetime' of Der-CD23-IgE complexes inferred by faster 
dissociation rates (kd) may be the crucial factor that results in the lack of detection by 
ELISA techniques. 
5.4 Preliminary IL-4 stimulated IgE Synthesis Assay 
The CD23 lectin domain (Der-CD23; Chapter 3) and oligomeric CD23 (LZ-CD23; 
Chapter 4) were included in an in vitro IgE synthesis assay (Zhang et al., 1991) to test 
whether they had the predicted inhibitory and stimulatory effects, respectively (Sarfati 
et al., 1992). Peripheral blood mononuclear cells (PBMC) from uncharacterised, non- 
symptomatic donors, were purified on a Ficoll gradient and cultured in the presence of 
IL-4 and an anti-CD40 antibody which induces IgE synthesis (kindly performed by N. 
McCloskey and D. Fear; section 2.5.9). In order to assess the effect of the recombinant 
CD23 without interference from endogenous sCD23 which can be as high as 200 ng/ml 
in IL-4 anti-CD40 stimulated tonsillar B cell cultures (N. McCloskey, unpublished data) 
the following conditions were investigated: 
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1) an excess of purified recombinant CD23 was included in the assays (sections 5.4.1 
and 5.4.2) 
2) Batimastat, the metalloprotease inhibitor which prevents the 37 kDa and 33 kDa 
sCD23 being released from the cell surface (Marolewski et al., 1998) was also 
employed to eliminate any stimulatory effect of these endogenous products (section 
5.4.3). 
Each condition was performed in triplicate (Der-CD23) or duplicate (LZ-CD23). After 
12-13 days in culture IgE in cell supernatants were quantified by ELISA, also in 
duplicate or triplicate. 
5.4 .1 IgE Production Suppression by Der-CD23 
The presence of IL-4 and anti-CD40 stimulated PBMC to synthesise approximately 25 
ng/ml IgE (Figure 5.9). Low IgE levels (<4 ng/ml) were detected in controls not 
containing IL-4 and anti-CD40. The addition of 1 µg/ml Der-CD23 inhibited IgE 
synthesis by approximately 40% to 15 ng/ml. Adding a greater excess (10 µg/ml) did 
not inhibit IgE synthesis further. 
Previous studies by Sarfati et al. (1992) demonstrated the suppressive activity of 16 kDa 
CD23 using PBMC from atopic donors (-30%). Data presented here showed higher IgE 
levels (more than tenfold) were obtained from uncharacterised donor PMBC, and 
observed similar suppression of IgE production, albeit at much greater concentrations of 
Der-CD23 (50 and 500-fold). It will be necessary to determine whether Der-CD23 was 
toxic at high concentrations. Cell viability can be measured by trypan blue staining of 
dead cells. Examination under a light microscope indicated that cultures including Der- 
CD23 were similar to controls not containing Der-CD23. 
148 
Further titration of Der-CD23 in stimulated PBMC cultures will be analysed in future 
experiments (on-going in this laboratory) to investigate the concentration dependence 
and obtain an inhibitory constant (IC50) for Der-CD23. Ideally, assays will be carried 
out in tonsillar B-cell cultures so the cellular mechanism of suppression can be readily 
elucidated. This has not been possible here because of recent changes to tonsillectomies 
following detection of prions in tonsils and on sterilised operating equipment. Disposal 
surgical instrumentation has allowed procedures to be resumed (June 2001). 
5.4.2 The Effect on IgE Production by LZ-CD23 
In this experiment, PBMC from a different blood donor produced almost tenfold more 
IgE (255 ng/ml) than the previous donor, on stimulation with IL-4/anti-CD40. 
Unstimulated PBMC had similar low IgE levels (less than 3 ng/ml). Although the donor 
was non-symptomatic, the B cells may have been activated in vivo. On addition of an 
excess amount of LZ-CD23 at 800 ng/ml, stimulated cells produced approximately 110 
ngiml IgE, a 56% reduction. Adding further LZ-CD23 (8 µg/ml) produced an even 
greater inhibition of IgE production of 82% (45ng/ml), more potent than Der-CD23. 
This was not expected; from several studies fragments >25 kDa CD23, recombinant and 
native have been shown to enhance IgE synthesis (summarised in Chapter 1; Table 1.1). 
It was possible that the LZ-CD23 preparation had been degraded during culture to 
suppressive fragments less than 25 kDa. Potent inhibition of IgE synthesis was observed 
by Sarfati et al. (1992) with a 1: 1 (w/w) mixture of 29 kDa and 16 kDa CD23. The 
possibility was investigated by Western blot. Figure 5.11 shows that no 
breakdown 
product was apparent in culture supernatants at day 13 using a polyclonal antibody. 
Undetectable amounts of degradation product at optimal concentration for suppression 
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Figure 5.9: Effects of Recombinant sCD23 on IgE Production by IL-4 induced 
PBMC 
Excess amounts of recombinant CD23 were added to purified peripheral blood 
mononucleic cells (PBMC) stimulated by IL-4 (200 IU/ml) and anti-CD40 (1 µg/ml) or 
PBMC in culture media (CM) alone. After 12 days of culture, cell supernatants were 
analysed for secreted IgE by ELISA. Both Der-CD23 and LZ-CD23 were effective 

































Figure 5.10: Western Blot of LZ-CD23 after 13 days in PBMC culture. 
8 µg/ml LZ-CD23 was included in PBMC cultures containing IL-4/anti-CD40 (+) or culture 
media alone (-). 20 µl of supernatant in reducing and non-reducing loading buffer were run 
on a SDS-gel. Following blotting, the nitrocellulose was probed with polyclonal anti- 
CD23, rb55. No breakdown product was detected and LZ-CD23 appeared to remain the 
correct MW (-3 8 kDa). Aggregation was evident under non-reducing conditions. 
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conditions LZ-CD23 in day 13 supernatants appears to be aggregating as it can be 
detected in the stacking region of the SDS-gel. 
Titrations of recombinant sCD23 are needed to establish any dose dependent regulation 
of IgE production. Analysing the effects of titrations of recombinant sCD23 will be 
complicated by the release of endogenous CD23 on stimulation. For this reason the use 
of Batimastat that prevents 37 kDa and 33 kDa sCD23 release was investigated. 
5.4.3 Effects of Batimastat on sCD23 and IgE Production by PBMC 
The addition of 10 µM Batimastat was expected to have a profound inhibitory effect on 
IgE production by IL-4/anti-CD40 stimulated PBMC (Christie et al., 1997). Despite the 
IgE levels being quite different in the two experiments performed, 10 µM Batimastat 
produced a 55-65% inhibition of IgE production (Figure 5.11). The inhibition observed 
was not as pronounced as reported by Christie and co-workers with 10 .M Batimastat 
(-90%). Differences in IgE synthesis inhibition may be attributed to slightly differing 
culture conditions and different solvent used to make Batimastat stock solutions 
(ethanol c. f. DMSO). 
As Batimastat will be used to evaluate the effects of recombinant CD23 it was 
necessary to show that the inhibition observed was due to a decrease in sCD23 levels. 
Analysis of sCD23 in the culture supernatants showed the expected induction of sCD23 
with the presence of IL-4/anti-CD40 to approximately 20-40 ng/m . The effect of 10 
µM Batimastat on sCD23 detected were inconsistent (<5% and 35% inhibition) in the 2 
experiments performed (Table 5.5 and Figure 5.11). Although generation of 37 kDa and 
33 kDa fragments may be inhibited by Batimastat (Marolewski et al., 1998), the 25 kDa 
fragment is produced by a different proteolytic mechanism and can be cleaved directly 
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from the cell surface (Moulder et al., 1993). Due to the indiscriminate nature of the 
sCD23 ELISA, the size of sCD23 detected could not be determined and detection of 25 
kDa sCD23 may account for no apparent difference in sCD23 levels. It is possible to 
quantify 29-37 kDa CD23 by ELISA (Katira and Gordon, 1995) and analyse the size of 
CD23 by immunoprecipitaton and Western blot. These methods will be used in future 
studies. 
It is expected that addition of LZ-CD23 to Batimastat treated (stimulated) PBMC 
should restore or enhance IgE synthesis by providing B-cells with an alternative source 
of sCD23 to trigger the stimulatory signal through binding CD21 (as depicted in Figure 
1.4, Chapter 1). 
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Table 5.5: Effects of Batimastat on IgE and sCD23 Production in IL-4/anti-CD40 
Stimulated PBMC Cultures. 
IgE in culture 
supernatant (ng/ml) 
sCD23 in culture 
supernatant (ng/ml) 
Culture Conditions DONOR 1 DONOR 2 DONOR 1 DONOR 2 
Unstimulated 2.4 ± 0.1 2.6 ± 1.5 2.9 + 0.0 3.1 ± 0.2 
IL-4 + anti-CD40 25.0 ± 5.6 255.7 ± 30.0 22.3 + 4.8 38.5 ± 1.9 
Unstimulated 
+10µM Batimastat 
1.8 ± 0.1 1.6 ± 0.8 3.0 ± 0.1 2.8 ± 0.0 
IL-4 + anti-CD40 
+ 10µM Batimastat 












- 0 IgE CD23 
Assayed Molecule in Supernatant 
  DONOR 1 
  DONOR 2 
Figure 5.11: Effects of 10µM Batimastat on IgE and sCD23 in PBMC cultures 
10 µM Batimastat was added to in vitro PBMC cultures (from 2 different donors) 
stimulated with IL4 and anti-CD40. The resulting IgE and sCD23 concentrations in Day 
12-13 cultures were measured by ELISA. Percentage inhibitions were calculated using 




This chapter characterises the ligand binding properties of the recombinant CD23 
molecules expressed and purified in Chapters 3 and 4 and their effect on IgE 
production. Der-CD23, a 16 kDa recombinant CD23 lectin domain protein, was 
compared to LZ-CD23, an extracellular CD23 containing an LZ motif to encourage 
trimer stabilisation (Kelly et al., 1998, Harbury et al., 1994). 
IgE binding to LZ-CD23 was demonstrated by two optimised ELISAs; with CD23 
coated directly to the solid phase and when captured by a monoclonal antibody mAb25, 
which only partially inhibits IgE interactions (Wakai et al., 1993, Bettler et al., 1989 
and Bonnefoy et al., 1987). No specific interaction was detected between Der-CD23 
and biotinylated IgE in either assay format. The interaction was too weak to be detected 
and the complex may be disrupted during the wash steps. Specific interactions were 
observed in an ELISA with Der-CD23 and biotinylated IgE-Fc glycosylation mutant, 
whose affinity for CD23 is similar to melanoma IgE (Young et al., 1995). The apparent 
higher affinity of Der-CD23 for IgE-Fc than IgE in these ELISAs may be attributed to 
lack of steric hindrance from the Fab and glycosylation structures on the IgE Fc mutant. 
The position and number of biotin labels would also effect the relative signals obtained 
for the two IgE molecules used. 
Weak CD23-CD21 interactions were also detected by ELISA (described by Fremeaux- 
Bacchi et al., 1996). Again, only the full length extracellular CD23 fragment (rCD23) 
was able to bind above background levels, possibly enhanced by avidity effects from 
being dimeric or trimeric, or from possessing additional interaction sites not present in 
Der-CD23. No LZ-CD23 was available at this time to confirm this observation. It is 
difficult to envisage how monomeric Der-CD23 could physically interact with 2 distant 
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sites (SCR1-2) and (SCR 5-8) of the CD21 molecule (Aubry et al., 1994). Therefore. 
only a single weak interaction may have been detected. The signal obtained with the 
CD21 ELISA was unsatisfactory. There was concern that if CD23 behaves like a 
galactose specific C-type lectin as demonstrated by Kijimoto-Ochiai and Uede (1995) 
then the recombinant sCD21 expressed by baculovirus would not be appropriately 
glycosylated. Native or sCD21 expressed by mammalian cells would be needed to 
resolve this problem. The CD21/CD23 interaction is likely to be pivotal in regulation of 
IgE production so an improvement in ELISA and SPR kinetic data will be 
advantageous. 
BlAcore experiments using IgE-Fc tethered to the sensorchip, were able to determine 
kinetic binding constants for the recombinant CD23s. By fitting a 1: 1 Langmuir 
association/dissociation model to resulting sensorgrams the following affinity constants, 
KA were obtained: LZ-CD23 (5.3 x 107 M-1) and Der-CD23 (0.9 x 107 M"1). This 
suggests that the affinity of trimeric LZ-CD23 for IgE is approximately 6 fold greater 
than monomeric Der-CD23. The possibility that the Der-CD23-IgE-Fc affinity was 
over-estimated of due to mass transfer effect was assessed by increasing experimental 
flow rate to 30 pd/min, but no increase in dissociation rate was observed (from 1.0 x 103 
S-1 to 0.9 x 103 s-1). The affinity of Der-CD23 for IgE Fc (Cs2-Cc4) is considerably 
higher than the KA of the lectin domain interaction to a different IgE Fe construct (Cc3- 
Cc4) which was estimated to be 10-5 M-1 by analytical ultracentiiugation (Shi et al., 
1997). Barlett et al., (1995) also estimated the affinity of the murine monomeric sCD23- 
IgE interaction to be to between 105 - 106 M-1. The IgE-Fc mutant used in these 
BlAcore experiments has a 10 fold higher affinity than wild type IgE-Fc attributed to 
the removal of two N glycans (Young et aL, 1995) which may explain the discrepancy 
between these monomeric affinities. Alternatively, the high concentrations of Der-CD23 
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used (as high as 90 µg/ml) may promote trimerisation and the Der-CD23-IgE complex 
may be stabilised by additional head-head interactions. Although, Der-CD23 contains 
no stalk region, cross-linking evidence (section 3.5.7; Beavil et al., 1995) suggests 
oligomers may occur. 
This BlAcore data for the LZ-CD23 and IgE-Fc interaction (KA = 5.3 x 107 M-1) 
corresponds well to cell binding assays data with membrane bound CD23 on B-cell 
lines (i. e. trimeric) and this IgE Fc glycosylation mutant (3.2 x 107 M-1, Young et al., 
1995). The LZ-CD23 affinity constant compares well to wild type IgE and CD23: 4.2 x 
107 M-1 (Anderson and Spiegelberg, 1981), 7x 107 M"1 (Bettler et al., 1992) and 5.3 x 
107 M-' (Sato et al, 1997). The LZ fusion with mouse CD23 (also containing mutated 
proteolysis sites) inhibited IgE binding to the high affinity receptor (FccRI) implying 
that chimeric CD23 has the potential to possess even higher affinities (Kelly et al., 
1998). Any inactive or mis-folded LZ-CD23 in the sample is difficult to detect which 
could lead to an underestimation the affinity constant. Thus, the KA for the LZ-CD23 
IgE Fc interaction may be greater than estimated by BlAcore. Perhaps a higher affinity 
constant of the human chimera could be obtained with improvements to refolding and 
purification techniques (as discussed in Chapter 4). 
The in vitro IgE synthesis assays were carried out with human PBMC cultures 
stimulated with IL-4 and anti-CD40, which mimic B cell activation signals by cognate 
T cells (reviewed by Gordon and Pound, 2000). The suppressive effect of Der-CD23 on 
IgE synthesis appeared to agree with the results obtained by Sarfati et al., 1992 and 
1984. LZ-CD23 suppressed IgE production to an even greater extent (84% with 8 
µg/ml). Excess amounts of recombinant CD23 were included to prevent 
interference 
with endogenous sCD23, which were quantified in these experiments to 
be 20-40 ng/ml 
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in stimulated cultures. It is possible that the mechanism of IgE enhancement occurs over 
a narrow range of sCD23 concentrations. This hypothesis is supported by Chretien et 
al., 1990 who obtained enhancement of IgE synthesis in IL-4 stimulated human 
peripheral blood lymphocytes using 10-1000 pg/ml recombinant 33 kDa sCD23, above 
less pronounced enhancement of IgE occurred. Furthermore, soluble CD23 may only 
enhance IgE synthesis in sub-optimal IL-4 conditions (10-20 IU/ml) as used in previous 
studies (Pene et al., 1988, Chretien et al., 1990). These conditions would have resulted 
in lower endogenous sCD23. 
Many variables to this in vitro assay need to be assessed; not only concentration 
dependence of sCD23 and the IL-4/anti-CD40 stimulus but also the alternative strategy 
to eliminate endogenous sCD23 with matrix metalloproteinase inhibitors. Preliminary 
studies with Batimastat, which prevents the release of 37 kDa and 33 kDa sCD23 from 
the cell surface (Marolewski et al., 1998), suppressed IgE synthesis in accordance with 
Christie et aL, 1997. It is expected that the addition of LZ-CD23 to Batimastat treated 
B-cells will overcome IgE suppression. This strategy may be preferable to adding 
excess concentrations of recombinant CD23 as it is likely that high concentrations of 
LZ-CD23 were affecting other cells and cellular mechanisms, e. g. cell proliferation and 
differentiation. Work is continuing in our laboratory to investigate the mechanisms 
underlying IgE regulation by CD23 using purified B-cells from tonsils. 
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CHAPTER 6: EXPRESSION OF RECOMBINANT, SOLUBLE 
INTEGRIN, CDllb/CD18. 
6.1 Introduction 
The interaction of CD23 with the X32 integrins CD 11 b/CD 18 and CD 11 c/CD 18 has been 
partially characterised on the cell surface of monocytes and transfected CHO cells 
(Lecoanet-Henchoz et aL, 1995). Further characterisation of the receptor-ligand 
interaction will require binding assays to be carried out with the receptors in a 
homogeneous environment. Ideally, a soluble form of the integrin is needed to be 
included in biophysical studies to elucidate binding kinetics and stoichiometry of the 
CD23 binding. Furthermore, purification of soluble heterodimer leads to the possibility 
of attaining a high resolution structure of the integrin. Therefore, the feasibility of 
expressing CD 1l b/CD 18 (aMß2, CR3, Mac-1) as a soluble heterodimer was explored. 
Soluble receptor can be attained through recombinant DNA technology in preference to 
the use of detergents or proteolytic release from the membrane. Dana et al., 1991, 
demonstrated that recombinant aMß2 lacking the transmembrane and cytoplasmic 
domains was secreted by COS cells as a heterodimer and still retained specific ligand 
binding. Other integrins have also been expressed as active soluble heterodimers in this 
system, (Table 6.1). However, the yields were generally too low for purification and 
further studies. 
To improve yields an alternative expression system could be investigated. The choice of 
expression system for recombinant soluble integrin is limited to cells which will fold, 
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large complex integrin subunits would be unglycosylated, potentially insoluble and 
difficult to renature, as experienced by Schroeckh et al., 2000. 
Some success has been attained with the baculovirus expression system (Table 6.1). 
There are several benefits of this method over mammalian cell cultures particularly the 
faster and simpler selection of recombinant clones than co-transfection of mammalian 
cells. Furthermore, insect cells minimise contamination with endogenous integrins and 
the cultures use serum free media without the need for enriched carbon dioxide 
atmosphere. Potential pitfalls of the baculovirus system are that O-linked glycosylation 
can not be processed in insect cells and high mannose type N-linked carbohydrate 
replaces any complex glycosylation. Although integrins are highly glycosylated (25 N- 
linked sites on aMß2) it is unclear whether complex carbohydrate is essential for CD23 
binding. The removal of sialic acid by neuraminadase did not have any effect on CD23 
binding to CD 11 b or CD 11 c transfected CHO cells (Lecoanet-Henchoz et al., 1995). 
This chapter describes the cloning and expression of a truncated recombinant aMß2 
using the baculovirus expression system and preliminary ligand binding studies with 
recombinant soluble integrin expressed in mammalian cell cultures (Stephens et al., 
2000). 
6.2 Production of Recombinant CD11b/CD18 Baculovirus 
The DNA sequence used for cloning of the soluble integrin subunits included the whole 
of the extracellular domain up to the transmembrane sequence N700 
(CD 18, numbering 
by Kishimoto et al., 1987) and NI 104 (CD 11 b, Arnaout et al., 1988). Truncation of the 
subunits was achieved through sub-cloning fragments 
from the cDNA using PCR 
techniques. 
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To assist the detection of expressed product, the alpha subunit was cloned with a 
aspartate rich octapeptide FLAG epitope (DYKDDDDK) placed at the C-terminus. In 
addition, an accessible, non-interfering epitope could be used as a tag for purification 
and immunoprecipitation studies to assess heterodimerisation of the subunit chains. 
Cloning of each subunit was achieved by PCR in several steps as outlined in Figures 6.1 
and 6.2 and Table 6.2. By constructing each subunit sequence in parts, the future 
addition of alternative leader sequences and optional epitope tags can be added by PCR 
without having to re-sequence the whole construct. This will be particularly useful for 
these large constructs of 3.3 kb (aM, CD11b) and 2.1 kb (p2, CD18). 
6.2.1 Constructing Extracellular CD11b 
The first fragment was produced by PCR using the primers and conditions outlined in 
Table 6.2. The fragment denoted aN1 (the first alpha subunit fragment including its 
native leader sequence) was ligated into the Hindill and EcoRV sites of pBluescript. 
One positive clone (pBS-aN 1) was identified and sequenced with primers listed in 
Appendix I (sequence data of the selected clone are detailed in Appendix II). 
The second fragment a2 was more problematic to clone. It was a larger fragment -1.7 
kb with one blunt end restriction site and a high content of repeat sequences. Low yields 
of PCR product were obtained and attempts at cloning directly into pB S-aN 1 were 
unsuccessful using standard methods. Therefore, a new primer with a HinduI site 5' to 
EcoRV was used to produce fragment a2, which was ligated into pBluescript vector 
used for amplification of the insert and sequencing. Several clones obtained from PCR 
with Taq polymerase contained several substitutions leading to coding mismatches. 
The 
PCR was subsequently performed using High Fidelity/proof-reading polymerase 
(Pwo). 
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When a pBS-a2 clone of correct sequence was identified (Appendix II), it was excised 
using EcoRV and Xbal and ligated into pBS-aNl. An improved transformation 
efficiency was observed and several clones (denoted pBSaN2) were identified, all 
presumed to have correct sequence as no further PCR was involved. 
The third fragment (a3E) with a FLAG epitope sequence was also cloned into the 
BamHI and SacI sites of the pBiuescript shuttle vector. Sequence analysis of pBS-a3E 
identified no errors. The final fragment was excised by Ndel and SacI and ligated into 
the same sites of pBS-aN2. 
Finally, the completed CD11b construct in pBS-aN3E was excised with HindII1 and 
ligated into pFastBac and named pFB-CD 11 bNE (Figure 6.1). Insert identification and 
correct orientation in selected clones were checked with a series of restriction digests 
Ncol and HindIIl (released 0.7,2.7 and 4.7 kb fragments) and Notl and Ndel (released a 
3 kb fragment). 
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Figure 6.1: Construction of Truncated CD11b DNA Sequence. 
a) Sequence coding for the truncated CD 11 b (Ml -N 1104) contained native leader 
sequence and an epitope tag. It was constructed from the sequential ligation of three 
cloned fragments in pBluescript. b) The final construct was excised using Hindill and 
ligated into the site in the baculovirus expression vector, pFastBac 1. 
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a) 
BgIII EcoRI HindIll 
pSP-3Nl or- - 
EcoRl HindIII 
P2 (PCR product) 














Figure 6.2: Construction of Truncated CD18 DNA Sequence 
a) The sequence coding for extracellular CD 18, including the native leader sequences 
and truncated at the transmembrane domain (M1-N700) was constructed in pSP73 
from two PCR fragments. b) The completed construct was excised by BgIII and 
HindIII and ligated into the BamHI, HindIII sites of pFastBac I. 
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6.2.2 Extracellular CD 18 
The first beta subunit fragment containing the native leader sequence (ßN1,0.9kb) 
produced by PCR conditions outlined in Table 6.2 was inserted into the pSP73 shuttle 
vector using BgIII and EcoRl restriction sites (Figure 6.2). Sequencing using Primers 
listed in Appendix I were used to sequence three colonies identified by analytical 
restriction digest. The second PCR product of the ß subunit (ß2) was then inserted into 
the EcoRI and HindIII sites of one of the clones (pSP73-ßN1). Positive clones of the 
completed construct were sequenced including the internal fragment joint. Sequencing 
showed the second fragment in (pSP73-ßN2) contained no coding errors but a single 
point mutation in the first fragment was later identified which lead to aK 194 -R amino 
acid change (Appendix 11). 
The completed construct was excised using BglII and HindIII and ligated into the 
BamHI and HindlH sites of pFastBac (pFB-CD 18N). BamHI and BglII have compatible 
overhang sequences (GATC) which can be ligated together but both sites are lost so 
another combination of restriction enzymes are used to identify the inserted fragment in 
the recombinant vector. 
6.2.3 Dual Vector Construct. 
In order to engineer a recombinant bacmid capable of inducing dual expression of the 
truncated subunits, further cloning steps were necessary but no PCR. CD 18N was able 
to be transferred into the Ban Hl and HindIIl as in the single promoter vector (Figure 
6.3). Due to the size of the CD 18 and CD 11 b constructs, many of the unique restriction 
sites of the multiple cloning sites of vector were unsuitable. Consequently, the CD 11 b 
HindIII fragment had to be inserted into a new pBluescript vector (in the orientation 
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shown in Figure 6.3). Once excised with Xbal and Sall, the fragment could be ligated 
into the Nhel and Xhol sites of the second cloning site by virtue of the complementary 
overhang sequences of these digested ends. This final step proved problematic, possibly 
due to the increasing size of the vector (10.6 kb) and difficulties in separating cut vector 
from fragment after excision. Only 4 out of 96 colonies proved positive in a PCR screen 
and of these, only 2 gave the correct restriction digest pattern. No PCR was involved in 
the creation of the dual vector, therefore, it was assumed the sequence would remain 
unchanged (see 5.3). 
6.2.4 Virus Amplification 
Recombinant CD 18N and CD 11 bNE bacmids were produced from the pFastBac 
expression vector as described in the methods. The titre of the recombinant baculovirus 
(rbv) was low for rbvCD 18N and rbvCD 11 bNE (detailed in Table 6.4). Only the dual 
expression baculovirus stock was sufficient for standard infections for protein 
expression studies. Despite several rounds of infection to increase viral titre, these 
plaque forming unit estimates were never improved upon. Although it is difficult to 
assess why, it is possible that the integrin subunits were interfering with the baculovirus 
infection cycle. 
Table 6.3: Recombinant Baculovirus Titres as Estimated by Plaque Assay. 
Recombinant Baculovirus Stock Viral Titre 
(pfuml) 
Vol. Required for 2x 106 
cell infection, MOI-5 (ml) 
rbvCD 11 bNE 6x 10 1.7 
rbvCD 18N 2x 10 50.0 





Nhel Xhol (BamHIBg1II) EcoRI 
MCSII MCSI 
HindIIl 
Sall HindIll EcoRV Ndel HindIII Xbal 
b) pFastBacDual-CD11bNE/CD18N 
(Xbal/Nhel) 
















Figure 6.3: Construction the CD11b/CD18 Baculovirus Co-expression Vector 
a) The extracellular CD 18 coding sequence (pSP-ßN2 in figure 6.2) was excised with 
BglII/Hindlll and ligated into the BamHI/HindIII site of the first multi-cloning site 
(MCSI) of pFastBacDual. The Hindill extracellular CD 11 b fragment was cloned into 
pBluescriptKS in the orientation shown. The fragment was excised with Xbal and Sall 
and ligated to Nhel and Xhol sites of second multi-cloning site (MCSJI) by virtue of 
complementary overhang sequences. b) The completed recombinant dual vector had 
CD 11 b under the control of a strong early p 10 promoter whereas CD 18 was upstream of 
the polyhedron promoter. 
(Sall/Xhol) (BglII/BamHI) 
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6.3 Expression Results 
Clearly with poor viral titres, the required volume of rbvCD 18N (50 ml) could not be 
added directly to cells plated in a6 well plate. Alternatively, 2x 106 Sf9 cells were 
incubated in 50 ml of the virus for 1 hour at room temperature on a slowly rotating 
wheel. In this time it was envisaged that the virus would be adsorbed onto the cell 
surface. The cells were pelleted upon gentle centrifugation, resuspended in 2 ml fresh 
media and plated. 
The viral stocks were produced from 5 day culture supernatants, by which time essential 
nutrients are depleted and toxic cell by-products and debris from infected cells increase 
to a level which makes it unsuitable for further cell culture. Therefore, due to the high 
volumes of rbvCD 11 bNE needed, the virus was allowed to adsorb onto plated cells for 
1 hour, then carefully removed and replaced by 2 ml fresh media. All infections were 
allowed to proceed for 3 days and the cultures were harvested for analysis. 
6.3.1 Single infections 
Infected cell cultures were harvested, and the supernatant and cellular proteins were 
analysed by immunoblot techniques. Recombinant CD 11 b protein of the correct 
approximate molecular weight was detected in the cell extract of rbvCD 11 
bNE infected 
cells by using an anti-FLAG mAb in a western blot (Figure 6.4a) 
CD 1I bNE was not 
detected in the culture supernatant. This result is similar to the observations by 
Bennett 
et aL, 1993, where the aIIb subunit was expressed without the 
ß3 subunit was found 
retained within the COS cells. This also appears to 
be the case for aMß2 expression in 
leukocytes but, Berman et al., (1993) established that heterodimer formation was not 
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required for the export of CDl lb in human kidney cell line (293) or from COS cells 
(Dana et al., 1991). This was not the finding in the baculovirus expression system. 
Cells infected with the CD 18N baculovirus showed secretion of the recombinant protein 
of the correct size in the supernatant using a `wet' transferred western blot with anti- 
CD 18 mAb, KIM89 (Figure 6.4b). Several attempts were made to demonstrate CD 18 
within the cell by western blotting with an array of anti-CD18 monoclonal antibodies, 
but no specific binding could be detected. A dot-blot technique did show the presence of 
CD 18 in cell extracts (section 5.3.2). The antibodies were apparently sensitive to the 
native fold of the protein and the solubilisation and denaturation of total cell protein 
during SDS-PAGE may have prevented the epitope being recognised. 
a) 
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Figure 6.4: Western Blot Analysis of Expression of Single Subunits in Insect Cells 
a) The cellular fraction of four 2 ml Sf9 cell infections with three CD 11 bNE baculoviral 
clones (and one negative control infection) were suspended in 2 ml PBS and 5 µl was 
loaded onto a 4-20% SDS gel in non-reducing buffer. Protein was transferred to 
Imobilon-P by the `wet' method, detailed in Chapter 2 and probed with M2 anti-FLAG 
monoclonal antibody. b) A four fold concentrated sample of 
CD18 infected cell culture 
supernatant was run on a 4-20% SDS gel under non-reducing conditions alongside a 
negative control supernatant. Following wet transfer, 
the CD 18 was detected by anti- 
CD 18 monoclonal antibody (KIM89). 
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6.3.2 Co-infections 
A dot blot immuno-technique was used to analyse the results of co-infections of the 
recombinant integrin subunits because of the difficulty of detecting CD 18 within the 
cell fraction by western blot. The cell extract was applied directly to nitrocellulose. 
Although this technique does not give any information on the size of the protein 
detected, it was shown with negative controls (SPD-CD23 and CD 1lb infected cells) to 
be a stringent detection method. When CD 18N was co-infected with CD 11 bNE, a 
reduction in the amount of CD 18 in the supernatant was detected. No CD 11 b was 
detected through the FLAG epitope in the co-infection culture supernatants, even at 
tenfold concentrations of the supernatants. This would be indicative of either the alpha 
subunit sequestering the beta subunit intracellularly or heterodimerisation concealing 
both epitopes (Figure 6.5). 
6.3.3 Dual Expression 
Earlier work carried out by Peterson et aL, 1998, demonstrated good expression of 
soluble alIbß3 using a dual vector with different promoters in baculovirus. It was 
conceived that with CD 11 b under the control of a stronger earlier polyhedron promoter 
it would associate with CD 18 (p 10 promoter), therefore neutralising any inhibitory 
effect the single beta subunit may have on the infection cycle. An increased virus titre 
would improve co-infection experiments, increasing the likelihood of heterodimer 
formation and transport out of the cell. 
Unfortunately, expression of heterodimer was not detected. The beta subunit expressed 
similarly to the single construct baculovirus, in that it was detected by anti-CD 18 mAb 
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Figure 6.5: Dot Blot Analysis of CD11 bNE/CD18N Co-infections in Sf9 cells 
2x 106 Sf9 cells were infected with recombinant baculovirus at a MOI of 5. Following 3 
days culture, I pl of culture supernatant (Sup) and cell extract (Pel, cells suspended in I ml 
PBS) were transferred directly to nitrocellulose. Recombinant CD 11 b and CD 18 protein 
were detected by M2 anti-FLAG and KIM89 anti-CD 18. Co-infections were performed in 
duplicate alongside single transfections and a negative control (SPD-CD23). 
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analysis of the infected cells and supernatant with an anti-FLAG monoclonal antibody 
(Figure 6.6). 
On sequencing the dual expression vector used in the transfection it was discovered that 
these clones were found to have several deletions and mismatches which explains the 
lack of CD1lb expression. A co-infection with the dual expressing baculovirus and 
CD 11 bNE single construct baculovirus gave the same intracellular expression pattern as 
observed with the co-infections. 
anti-FLAG anti-CD18 
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Figure 6.6: Dot Blot Analysis of Infection with Dual Expression Baculovirus 
1 µl of Sf9 culture supernatants infected (MOI = 5) with recombinant baculovirus were 
directly blotted onto nitrocellulose and probed with anti-FLAG to detect CD 11 b 
expression and KIM89 to detect CD 18. The following infections were analysed: (1) ten 
fold concentration of rbvCD 11 bNE/CD 18N; (2) ten fold concentration of negative 
control supernatant (SPD-CD23); (3) CD18N positive control supernatant (4) 
CD 11 bNE positive control cell extract. CD 18 was detected in the supernatant of the 
dual expression infection but not CD 11 b. 
Table 6.4: Summary of Expression of Integrin subunits. 
Baculovirus Location Size 
CD18N Secreted into media -8OkDa, some oligomerisation 
CD 11 bNE Cellular - 120kDa 
CD 11 bNE/CD 18N 
Co-infection 
CD 1lb and CD 18 in 
cellular fraction 
Not determined 
CD 11 bNE/CD 18N 
Dual Expression 
CD 18 in media 
No CD 11 b detected 
Not determined 
(CD 11 b DNA rearrangements) 
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6.4 Integrin binding Assays by ELISA 
Expression of recombinant soluble aM02 using the baculovirus expression system was 
unproductive. Therefore, an alternative source of recombinant integrin was used for 
initial CD23 interaction studies. Soluble recombinant integrins (truncated at the 
transmembrane domain) have been successfully expressed in mammalian cells (CHO 
and COS cells) at Celltech (Stephens et al., 2000). The alpha and beta subunits are 
secreted into the culture medium with a mouse-IgG Fc (mFc) or human IgG-Fc (hFc) 
fusion on the carboxy terminal end of the extracellular subunit. Fc promotes 
heterodimerisation in solution and aids purification and quantification, as well as being 
a useful additional epitope for ligand binding assays. Although the expression levels 
were fairly low (200 ng/ml), interactions with control proteins have been detected by 
ELISA. Table 6.5 details the recombinant integrins used and control ligands. 
Table 6.5: Soluble recombinant integrins used in the following assays. 
Integrin Expression System Control Ligand 
aM j32-mFc CHO iC3b 
avß 1-mFc COS Fibronectin 
avß3-hFc COS Fibronectin RGD peptide 
avß5-mFc COS Vitronectin RGD peptide 
6.4.1 alpha m beta 2 (CD11b/CD18, Mac-1, CR3) 
A ligand binding assay for aMß2 interactions was established with iC3b by B. 
Sweeney, Celltech (described in Materials and Methods 2.5.8.7). Microtitre plates were 
coated overnight at 4 °C with 5 µg/ml Der-CD23 (Chapter 1), 5 µg/ml control ligand 
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iC3b and a BSA negative control. The culture supernatant and supernatant from mock 
transfected CHO cell was serially diluted and added to the wells. After three hours 
incubation at room temperature, the binding of the recombinant integrin was detected by 
an anti mouse Fc -HRP conjugate. Der-CD23 appeared to bind to the recombinant 
soluble a1ß2, above background levels, but was a much weaker interaction than the 
positive control (Figure 6.7a). A630 measurements greater than 1.0 could be obtained for 
the Der-CD23-integrin interaction by developing the enzyme reaction for longer (15 
minutes). 
To test the validity of the interaction, a serial dilution of anti- aMß2 antibodies was 
incubated with a1 in 5 dilution of uMß2 supernatant for 1 hour and added to Der-CD23 
coated wells. Any inhibition of binding would confirm that the interaction was 
occurring specifically via the integrin. Ab44 (anti aM) was reported to partially inhibit 
CD23 (in liposomes) binding to activated blood monocytes (Lecoanet-Henchoz et al., 
1995). This was also observed in these experiments (Figure 6.7b). KIM170, 
(recognising the heterodimeric receptor) and 6.5E (recognising the ß2 subunit) appeared 
to completely block binding at 1 . g/ml 
(antibodies mapped by Stephens et al., 1995). 
The blocking of CD23 interactions with anti-132 antibodies demonstrates the 
requirement of the 0 subunit for ligand binding in the alpha subunit. 
6.4.2 alpha v beta 3 (Vitronectin Receptor) 
Another reported integrin to bind CD23 is avß3/CD47 complex on monocytes 
(Hermann et al., 1999). A similar ELISA (materials and methods) was used to 
investigate whether CD23 was able to interact with the avß3 
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Figure 6.7: Recombinant Soluble aMI32 Interaction with CD23 
a) 5 p. g/ml of ligand iC3b, Der-CD23 and BSA were coated on a microtitre plate. Serial 
dilutions of CD 11 b/CD 18 CHO cell supernatants (and mock-transfected supernatant) 
were applied. Interactions were detected by an anti-mouse IgG-Fc HRP conjugate. No 
background signal was detected for either BSA or mock-transfected CHO culture 
supernatant. b) Dose dependent inhibition of the CD23-CD 11 b/CD 18 interaction was 
seen with by incubation of supernatants with anti-CD 11 b/CD 18 antibodies. 
0 0.2 0.4 0.6 0.8 1 1.2 
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expressed by COS cells (Celltech). Although the recombinant av1i3 integrin interacted 
with the control RGD peptide, no binding to Der-CD23 was detected. 
Some effort was made to improving the avß3 ligand binding assay but no interaction 
significantly greater than background was recorded. Measures included: using a 
different transfected COS cell clones; concentrating CD23 and avß3; reversing the 
order of the assay, i. e. capturing av 3 to the plate with anti-human Fc mAb and 
detecting any interaction with an anti-CD23 mAb; using alternative buffers (with and 
without manganese or calcium) and with other recombinant CD23s. 
There are many reasons why this interaction might not have been demonstrated. The 
hazard of using recombinant protein in culture supernatant is that the integrin is 
heterogeneous, of unknown degree of heterodimerisation or activation state and also 
serum supplemented media may contain factors that interfere with specific binding. 
Alternatively the CD23 lectin domain may be insufficient to bind the integrin. Hermann 
et al., 1999, demonstrated binding with the 25 kDa fragment which contains the C- 
terminal tail, which could be required. Finally, the affinity of the interaction maybe so 
weak that it could not be detected and may require the presence of CD47 to increase the 
affinity. 
6.4.3 Alpha v beta 5 (Vitronectin receptor) 
Hermann et al., 1999, mapped the CD23 interaction to the alpha subunit, and they also 
demonstrated binding to purified av. This lead to an investigation of CD23 interactions 
with other av integrins, in particular the closely related vitronectin receptor avß5. 
Matheson et al., 1999, identified avß5 as a CD23 binding structure expressed on pre-B 
cells. In an attempt to support this evidence, CD23 was included in an avßl aß-ß5 
ligand binding assay previously established at Ceiltech. 
a 
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As before, 5 µg/ml CD23 was coated onto the plate, dilutions of recombinant integrin 
supernatants added and binding detected by anti-mouse IgG Fc HRP conjugate. All 
control proteins showed the integrins were active but specific binding to Der-CD23 was 
detected only with the recombinant avß5 (Figure 6.8). In order to establish optimum 
component concentrations for further experiments, Der-CD23 and avß 5 supernatant 
were titrated against each other. Der-CD23 concentrations greater than 1.25 µg/m1 were 
required to obtain A630 >1.0 with 4 fold dilutions of avß5 supernatant in TBS-Ca-Mn 
(results not shown). 
To test whether the CD23 interaction was specific to avß5 in the culture supernatant, 
three anti-avß5 monoclonal antibodies were used to inhibit the soluble integrin binding 
to a CD23 coated plate. A serial dilution of the antibodies were made in a4 fold dilution 
of avß5 supernatant (in TBS-Ca-Mn) and incubated at room temperature for 1 hour. 
The samples were added to CD23 coated plates (1.25 pg/ml Der-CD23) and interactions 
detected by an anti- mouse IgG Fc-HRP. Figure 6.9 shows that each antibody to some 
degree inhibited the interaction by blocking the ligand binding site in the alpha subunit 
or causing an unfavourable ligand-binding conformation. Furthermore, 2 mM EDTA 
was effective at inhibiting Der-CD23 avfß5 binding. Divalent ions chelated by EDTA 
must be important for the ligand binding sites of CD23 or the integrin, or both. 
Although the recombinant integrin supernatant may have been a heterogeneous, non 
purified mixture of subunits, the inhibition studies suggest that the interactions detected 
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Figure 6.8: Interaction of Der-CD23 with Recombinant av Integrin Supernatants 
Serial dilutions of recombinant soluble av integrins with IgG-Fc fusion (x I, x2, x4, x8) 
were added to Der-CD23 coated wells (5 µg/ml). Following a three hour incubation, 
interactions were detected by an anti-IgG Fc-HRP conjugate developed by TNB for 5 
minutes. Each recombinant integrin bound their control ligand but only the avß5-Der- 
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Figure 6.9: Inhibition of the CD23-avß5 Interaction. 
5 pg/ml anti-av(35 monoclonal antibodies (Ab1961, Ab1980 and L230) were incubated 
in a 4-fold dilution of recombinant avß5-mouse IgG-Fc cell culture supernatant and 
blank supernatant (diluted into TBS-Ca-Mn). After 1 hour incubation, the samples were 
added to wells coated with 1 µg/ml Der-CD23.5 mM EDTA was also effective at 
inhibiting the CD23-avß5 interaction. 




The purpose of this study was to synthesise a recombinant soluble ß2 heterodimer 
ultimately for characterisation of the CD23 - ß2 integrin interaction. Attempts to 
express recombinant soluble aMß2 in insect cells were made following the success of 
Dana et al., 1991, who produced an active soluble truncated aMß2 secreted by COS 
cells, and the improved yields of allbß3 achieved by Peterson et al., 1998, using the 
baculovirus expression system. Fermenter cultures at this expression yield (1 mg/1) 
could provide enough material to purify and included in informative experiments such 
as surface plasmon resonance. 
Using PCR techniques truncated CD 11 b and CD 18 with their native leader sequences 
(N} were constructed in fragments, in doing so, an alternative leader and optional 
epitope tag (E) could be added. The assembled subunits termed CD 18N and CD 11 bNE 
were cloned into pFastBac and recombinant baculovirus (rbv) containing each subunit 
were produced. 
Analysis of transfected Sf cells by western blot show secretion of CD 18 in the culture 
supernatant. The CD 11 b construct was present only in the cellular protein fraction. 
These findings were similar to those observed by Bennett et aL, 1993, where the 
presence of the ß subunit of platelet cdIbP3 was essential for the transport of the 
heterodimer to the membrane. Both CD 18N and CD 11 bNE were the correct 
approximate molecular weight. 
Unfortunately, co-infection of rbvCD 18N and rbvCD 11 bNE resulted in neither 
construct being detected in the culture supernatants. This observation may be consistent 
with the heterodimer forming complexes within the cell that are insoluble or unable to 
be exported. There is a possibility that the optimal co-infection conditions were not 
0 
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achieved, factors include: multiplicity of infection (MOI), infection time, temperature. 
media and host cell. The optimal MOI for CD 11 b fragments in one study was as low as 
0.1 (Xia et al., 1999) although the standard range is between 1-10. It was difficult to 
assess optimum conditions because of the low titre of rbvCD 18N (1 x 105 pfu/ml) and 
large volumes required. The reason for low titre was not apparent but likely that the ß2 
subunit was interfering with the infection cycle of the baculovirus. 
A dual expression baculovirus was used to overcome low titres and co-infection 
difficulties. By having the alpha subunit under the control of an earlier promoter, it was 
envisaged that less beta subunit would be free to able to interfere with subsequent 
rounds of infection. Indeed, a higher virus titre was achieved with dual expression 
baculovirus (5 x 107 pfu/ml). CD18 was secreted into the media, as before. However, 
the difficulties experienced in cloning the alpha subunit into the dual vector were 
reflected in the discovery of a rearrangement event that lead to the production of 
frameshifts and deletions in the CDl lb DNA. This accounted for the lack of detection 
of the C-terminal FLAG epitope. 
The baculovirus expression system using these subunit constructs failed to produce 
recombinant soluble aMß2. The extracellular regions of the subunits are relatively 
complex for recombinant expression, with several domains of unknown structure or 
function, different activation conformations and many glycosylation sites. For our 
purposes the recombinant integrin can not be simplified. The CD23 binding site was 
mapped to the alpha subunit (Lecoanet-Henchoz et al., 1995). Expressing alpha subunit 
alone has resulted in a recombinant subunit unable to bind ligand or was retained within 
the cell, as demonstrated with aIIb (O'Toole et al., 1989; Bennett et al., 1993 and also 
observed with these results). Simplifying the integrin further, for instance, expression of 
the aM I domain (Fairbanks et al., 1995) was also not an option 
because it is unclear 
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whether the CD23 binding site is wholly encompassed in this region. Factor X has been 
shown to be the most effective inhibitor of CD23 binding to CD 11 b/c CD 18 transfected 
COS cells of the 132 ligands tested by Lecoanet-Henchoz et al., 1995. Although most 
CD 11 b/CD 18 ligands map to the I domain, Factor X appeared to be only partially 
recognised by the I domain (Zhou et al., 1994). This evidence could imply that other 
structural features (e. g. P subunit or the putative P propeller) are required for Factor X 
and, by extension, CD23 binding. 
In collaboration with Celltech (Slough, UK) recombinant, soluble integrins expressed 
by mammalian cells were available for use in preliminary ligand binding assays with 
soluble CD23. These integrins contain an IgG Fc fusion to enhance heterodimerisation, 
aid purification and serve as a useful epitope in ligand binding assays (Stephens et al., 
2000). Interactions were detected Der-CD23 (CD23 lectin domain) and recombinant 
aMß2 and avß5 culture supernatants. The interactions were shown to be integrin 
dependent because binding was inhibited by three integrin specific monoclonal 
antibodies. The interaction between Der-CD23 and avß5 was also metal ion dependant 
established by its inhibition with EDTA. Furthermore, these results stress that neither 
the stalk region nor the C-terminal tail (containing a reverse RGD sequence) of CD23 
are essential for aMß2 or av(35 binding. These studies support the findings of 
Lecoanet-Hencoz and Matheson et al., 1999 and provide a basis for future detailed 
mapping and binding properties once the recombinant integrins are purified and 
characterised. 
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CHAPTER 7: GENERAL DISCUSSION 
The work presented in thesis was intended to elucidate the structure of the CD23 C-type 
lectin domain and provide recombinant CD23 molecules to study the functions of 
human soluble CD23 fragments. To achieve these aims two novel recombinant proteins 
were expressed and characterised. Chapter 3 described the production of large yields of 
correctly folded CD23 lectin domain in E. coli. By using a different approach to 
purification, replacing size exclusion chromatography with hydrophobic interaction 
chromatography, pure folded CD23 was attained in a single step and losses were 
reduced. This domain was shown to bind an IgE Fc glycosylation mutant with an 
appreciable affinity (KA = 0.9 x 107 M-) and had a low affinity for sCD21. Labelled 
preparations of Der-CD23 were made (15N and 15N/13C) and the assignment of residues 
in 2D and 3D NMR spectrometry is currently being carried out by J. McDonnell at the 
University of Oxford. 
If successful, CD23 will be the first animal C-type lectin whose structure has been 
determined by NMR techniques. Using this data, the identification of the ligand binding 
sites can be also be elucidated without the delays generally encountered with co- 
crystallisation. The homology model based on mannose binding protein A (Weis et al., 
1991) shows large areas of charged residues and hydrophobicity (Figure 7.1). These are 
potentially important for forming ligand binding and additional trimer/dimer 
stabilisation to the stalk region. CD23 is a particularly interesting subject for ligand 
binding site analysis with respect to its many ligands and its ability to form protein- 
carbohydrate and protein-protein interactions. 
1$3 
Figure 7.1: Models of CD23 C-type Lectin Domain 
Top, shows a ribbon diagram ofthe secondary structure elements. The space filling model (by 
J. McDonnell), below, shows regions of hydrophobicity (blue) and charged residues (red). 
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Chapter 4 described the production of two designs for chimeric CD23 to provide a 
stable trimeric CD23 for molecular and biological studies. A surfactant protein-D 
trimerisation region (Hoppe et al., 1993) was fused to the 25kDa CD23 fragment thus 
omitting the stalk region and its many sites of proteolysis. Chemical cross-linking and 
analytical HPLC evidence suggest the SPD motif was effective at forming trimers. 
However, the resulting IgE binding activity of the molecule was not enhanced by its 
trimerisation as expected. The crystal structure of trimeric SPD shows that the packing 
of a tyrosine sidechain in the alpha helical coiled coils causes asymmetric orientation of 
the lectin domains (Hakansson et al., 1999). The wrong orientation of the CD23 lectins 
caused by the SPD motif was likely to contribute to the weak IgE interaction of this 
chimeric protein. Similar finding were obtained with other C-type animal lectin fusions: 
MBP-CD23 and CD72-CD23 (Kelly et al., 1998). SPD-CD23 also readily degraded to 
16 kDa and aggregated on purification from baculovirus and E. coli expression systems 
and therefore was not suitable for further studies. 
It was not possible to determine definitively whether the LZ motif resulted in dimeric or 
trimeric CD23 when expressed in E. coli and refolded from inclusion bodies. The 
presence of the endogenous stalk region may have benefited the orientation of the lectin 
domains and therefore its IgE binding activity. BlAcore data estimates the LZ-CD23 - 
IgE Fc (glycosylation mutant) affinity constant to be 5.3 x 107 M-' which was similar to 
the cell binding data with membrane bound CD23 and this Fc mutant (KA= 3.2 x 107 M- 
1, Young et al., 1995). This recombinant chimera appeared to be stable in culture 
conditions for two weeks without any evidence of detectable breakdown product. This 
made LZ-CD23 a suitable molecular tool for functional assays. 
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Many anti-CD23 antibodies have been shown to inhibit IL-4/CD40L induced IgE 
production (Wakai et al., 1993, Bonnefoy et al., 1987, Bettler et al., 1987) yet the 
mechanism of CD23's role in IgE regulation is not fully understood. The inclusion of 
Der-CD23 and LZ-CD23 in an in vitro IgE synthesis assay was hoped to demonstrate 
the reported suppression and enhancement of IgE synthesis of the l6kDa and >25kDa 
sCD23, respectively (Sarfati et al., 1992 and Chretien et al., 1990). Using excess 
amounts of each recombinant protein resulted in the inhibition of IgE production, 
particularly LZ-CD23. It is likely that LZ-CD23 in high concentrations was effecting 
other cellular mechanisms and possibly on cells other than B cells in the PBMC 
preparation e. g. monocytes. Work is ongoing in our laboratory to optimise the 
concentrations of the components in the in vitro system with human PBMC and tonsillar 
B cells. 
The molecular details of the activity of sCD23 on monocytes was explored using 
recombinant integrins in cell free binding assays. The integrins aM02, aXß2, (i. e. 
CD 11 b and CD 11 b integrins, Lecoanet-Henchoz et al., 1995) and av ß3 (Hermann et 
al., 1999) have been identified as sCD23 binding receptors on monocytes, and avß5 on 
a pre B cell like cell line (Matheson et al., 1999). In Chapter 6 work was presented on 
the construction of a recombinant soluble integrin (aMß2) using the baculovirus 
expression system. Expression of both subunits was detected but no heterodimer was 
secreted. Considering the complexity and uncharacterised nature of the integrin subunits 
recombinant expression remains an ambitious task. 
Alternatively, binding assays were carried out in a using recombinant soluble integrin 
successfully expressed in mammalian cells (in collaboration with 
Celitech, Slough). 
Interactions between Der-CD23 and aMß2 and avß5 were detected. Inhibition of these 
interactions with an array of anti- aMß2 and anti- av135 antibodies and 
EDTA suggest 
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these experiments are first evidence of CD23-integrin binding without the presence of 
other membrane proteins. Interactions with the lectin domain protein (Der-CD23) show 
that the inverse RGD integrin binding motif in the C-terminal tail is not required for 
binding. To date no RGD peptides or anti RGD monoclonal antibodies have been 
demonstrated to inhibit CD23 ligand binding. The ELISAs described are a good basis 
for future characterisation and inhibition of interactions using purified recombinant 
soluble integrin. 
The ability of the 16 kDa fragment to bind certain integrins may provide an explanation 
to how these sCD23 fragments are able to suppress IgE synthesis in vitro PBMC 
cultures. Monomeric CD23 triggers the release of pro-inflammatory cytokines by 
monocytes through CD 11 bCD 18, CD 11 cCD 18 and avß3 (Armant et al., 1994; 
Lecoanet-Henchoz et al., 1995; Hermann et al., 1999; Aubry et al., 1997; Rezzonico et 
al., 2000). In particular, the inflammatory cytokine IFN-y has an antagonistic effect on 
IL-4 stimulated IgE production (Chretien et al., 1990). The bias toward of TH 1 
immunity through the hypothetical binding of Der-CD23 to 02 or av integrins could be 
investigated further using PBMC cultures. 
High sCD23 serum levels are found in IgE independent chronic inflammatory diseases. 
The importance of CD23 in inflammatory mechanisms was demonstrated by the 
alleviation of symptoms in the collagen induced mouse model of rheumatoid arthritis 
with anti-CD23 monoclonal antibodies (Plater-Zyberg and Bonnefoy, 1995). 
Ultimately, the structural details of the CD23 lectin domain and well characterised 
interactions with its ligands will aid the understanding of the biological role of CD23 
and benefit the development of potential therapies 
for allergic, certain B cell 
lymphomas and inflammatory diseases. 
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APPENDIX I: LIST OF OLIGONUCLEOTIDES 
Primers for the Construction of H-CD23 
HF TAG TAG AAG CTT CAT ATG GAG TTG CAG GTG TCC AG 
HR TAG TAG GGA TCC TTA TCA TCA GCA TGT GGC GAC CCG G 
Primers for the Construction of Der-CD23 
DF TAC TAC AAG CTT CAT ATG AGC GGC TTT GTG TGC AAC AC 
DR TAC TAC GGA TCC TTA TCA TCA CTC CGC GGA ACC TTC GCT 
Primers for the Construction of SPD-CD23 
01 TAG TAG GGA TCC CCC GGG ATG AGT GTG CCC ACT CAG GTC 
CTG GGG TTG CTG CTG CTG TG 
02 GAA GCA ACA TCT GGG ATG TCA CAT CTG GCA TCT GTA AGC 
CAC AGC AGC AGC AAC CCC AG 
03 GAC ATC CCA GAT GTT GCT TCT CTG AGG CAG CAG GTT GAG 
GCC TTA CAG GGA CAA GTA CAG C 
04 CTG CTG CTC GAG CTT ATA CTG AGA GAA AGC AGC CTG GAG 
GTG CTG TAC TTG TCC CTG TAA GG 
PF1 TAG TAG GGA TCC CCC GGG AT 
PR1 CTG CTG CTC GAG CTT ATA CTG 
CD23FF TCT CAG TAT AAG ATG GAG TTG CAG GTG TCC AG 
SPDFR CTG CAA CTC CAT CTT ATA CTG AGA GAA AGC AG 
PF2 ACT AGT GGA TCC CCC GG 
PR2 TAG TAG GAA TTC TTA TCA TCA AGA GTG GAG AGG GGC 
AGA 
PF3 (E. coli) CTA CTA AAG CTT CAT ATG CCA GAT GAT GTT GCT TCT 
CTG AG 
PR3 (E. coli) TCG TCG GGA TCC GAA TTC TTA TCA TCA AGA GTC 
Primers for the Construction of CD11b 
aNF ATG TAG AAG CTT ATG GCT CTC AGA GTC CTT C 
aNR TGTGCT GAT ATC GAG GTG CC 
a2F' CAC CTC GAT ATC AGC ACA T 
a2R TAG TAG TCT AGA CAT ATG ACA GTC TGG TTC AG 
OF GAC TGT CAT ATG GGA CCG CC 
OR TAG TAG GAG CTC AAG CTT TTA TCA TCA CTT GTC ATC 
GTC GTC CTT GTA GTC GTT GGG GAC CTC GAA CG 
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GAG GCC CT 
AAC TTC TG 
CCA AGC CG 
GAT GGT AT 
ACA TGA CC 
GCA GAC CC 
GCA TCA CA 
CTG AGT GG 
TAC TGG CT 
TGA GAC AA 
CAA GTC TG 
CTG GAC TG 
GTC CTC CA 
GGC TTC CC 
ßNF TAG TAG AGA TCT ATG CTG GGC CTG CGC C 
(3NR GTA GTC GAA TTC GTT GCT C 
(32F AGC AAC GAA TTC GAC TAC CC 
(32R TAG TAG AAG CTT TTA TCA TCA GTT GGG GCC TGC CAC AC 






































GGA ATG TC 
GTC ATC AA 
TCC ATT TC 
CTC CAG GG 
ACT CCA TT 
TGA CAC TG 
ATG GAG TT 
GTG GTC GT 
CAG GGT GA 
pBluescript KS T7 GTA ATA CGA CTC ACT ATA GGG 
T3 AAT TAA CCC TCA CTA AAG GG 
pET5a RpET5a CCG AAA AGT GCC ACC TGA CG 
pSP73: FpSP73 CAC CAT ATG GAC 
ATA TTG TCG 
C 
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APPENDIX II: SEQUENCE DATA OF RECOMBINANT PROTEINS 
H-CD23 (E. soli) 
1 MELQVSSGFV CNTCPEKWIN FQRKCYYFGK GTKQWVHARY ACDDMEGQLV 
51 SIHSPEEQDF LTKHASHTGS WIGLRNLDLK GEFIWVDGSH VDYSNWAPGE 
101 PTSRSQGEDC VMMRGSGRWN DAFCDRKLGA WVCDRLATC 
Der-CD23 (E. coli) 
1 SGFVCNTCPE KN7INFQRKCY YFGKGTKQWV HARYACDDME GQLVSIHSPE 
51 EQDFLTKHAS HTGSWIGLRN LDLKGEFIWV DGSHVDYSNW APGEPTSRSQ 
101 GEDCVMMRGS GRWNDAFCDR KLGAWVCDRL ATCTPPASEG SAE 
SPD-CD23 (baculovirus) 
1 MSVPTQVLGL LLLWLTDARC DIPDVASLRQ QVEALQGQVQ HLQAAFSQYK 
51 MELQVSSGFV CNTCPEKWIN FQRKCYYFGK GTKQWVHARY ACDDMEGQLV 
101 SIHSPEEQDF LTKHASHTGS WIGLRNLDLK GEFIWVDGSH VDYSNWAPGE 
151 PTSRSQGEDC VMMRGSGRWN DAFCDRKLGA WVCDRLATCT PPASEGSAES 
201 MGPDSRPDPD GRLPTPSAPL HS 
SPD-CD23 (E. coli) 
1(M)PDVASLRQQV EALQGQVQHL QAAFSQYKME LQVSSGFVCN TCPEKWINFQ 
51 RKCYYFGKGT KQWVHARYAC DDMEGQLVSI HSPEEQDFLT KHASHTGSWI 
101 GLRNLDLKGE FIWVDGSHVD YSNWAPGEPT SRSQGEDCVM MRGSGRWNDA 
151 FCDRKLGAWV CDRLATCTPP ASEGSAESMG PDSRPDPDGR LPTPSAPLHS 
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CD11b- Translated aN1 Fragment Sequence Data 
CDllb MALRVLLLTALTLCHGFNLDTENAMTFQENARGFGQSVVQLQGSRVVVGAPQEIVAANQR 60 
segdata MALRVLLLTALTLCHGFNLDTENAMTFQENARGFGQSVVQLQGSRVVVGAPQEIVAANQR 60 
************************************************************ 
CD11b GSLYQCDYSTGSCEPIRLQVPVEAVNMSLGLSLAATTSPPQLLACGPTVHQTCSENTYtIK 120 
seqdata GSLYQCDYSTGSCEPIRLQVPVEAVNMSLGLSLAATTSPPQLLACGPTVHQTCSENTYVK 120 
CD11b GLCFLFGSNLRQQPQKFPEALRGCPQEDSDIAFLIDGSGSIIPHDFRRMKEFVSTVMEQL 180 
seqdata GLCFLFGSNLRQQPQKFPEALRGCPQEDSDIAFLIDGSGSIIPHDFRRMKEFVSTVMEQL 180 
************************************************************ 
CD11b KKSKTLFSLMQYSEEFRIHFTFKEFQNNPNPRSLVKPITQLLGRTHTATGIRKVVRELFN 240 
seqdata KKSKTLFSLMQYSEEFRIHFTFKEFQNNPNPRSLVKPITQLLGRTHTATGIRKVVRELFN 240 
************************************************************ 
CD11b ITNGARKNAFKILVVITDGEKFGDPLGYEDVIPEADREGVIRYVIGVGDAFRSEKSRQEL 300 
seqdata ITNGARKNAFKILVVITDGEKFGDPLGYEDVIPEADREGVIRYVIGVGDAFRSEKSRQEL 300 
************************************************************ 
CD11b NTIASKPPRDHVFQVNNFEALKTIQNQLREKIFAIEGTQTGSSSSFEHEMSQEGFSAAIT 360 
seqdata NTIASKPPRDHVFQVNNFEALKTIQNQLREKIFAIEGTQTGSSSSFEHEMSQEGFSAAIT 360 
CD11b SNGPLLSTVGSYDWAGGVFLYTSKEKSTFINMTRVDSDMNDAYLGYAAAIILRNRVQSLV 420 
seqdata SNGPLLSTVGSYDWAGGVFLYTSKEKSTFINMTRVDSDMNDAYLGYAAAIILRNRVQSLV 420 
************************************************************ 
CD11b LGAPRY 426 
seqdata LGAPRY 426 
One DNA point mutation, but no coding error 
CD11b- Translated a2 Fragment 
CDllb YQHIGLVAMFRQNTGMWESNANVKGTQIGAYFGASLCSVDVDSNGSTDLVLIGAPHYYEQ 60 
alpha2 YQHIGLVAMFRQNTGMWESNANVKGTQIGAYFGASLCSVDVDSNGSTDLVLIGAPHYYEQ 60 
************************************************************ 
CD11b TRGGQVSVCPLPRGRARWQCDAVLYGEQGQPWGRFGAALTVLGDVNGDKLTDVAIGAPGE 120 
alpha2 TRGGQVSVCPLPRGRARWQCDAVLYGEQGQPWGRFGAALTVLGDVNGDKLTDVAIGAPGE 120 
************************************************************ 
CD11b EDNRGAVYLFHGTSGSGISPSHSQRIAGSKLSPRLQYFGQSLSGGQDLTMDGLVDLTVGA 180 
alpha2 EDNRGAVYLFHGTSGSGISPSHSQRIAGSKLSPRLQYFGQSLSGGQDLTMDGLVDLTVGA 180 
************************************************************ 
CD11b QGHVLLLRSQPVLRVKAIMEFNPREVARNVFECNDQVVKGKEAGEVRVCLHVQKSTRDRL 240 
alpha2 QGHVLLLRSQPVLRVKAIMEFNPREVARNVFECNDQVVKGKEAGEVRVCLHVQKSTRDRL 240 
************************************************************ 
CD11b REGQIQSVVTYDLALDSGRPHSRAVFNETKNSTRRQTQVLGLTQTCETLKLQLPNCIEDP 300 
alpha2 REGQIQSVVTYDLALDSGRPHSRAVFNETKNSTRRQTQVLGLTQTCETLKLQLPNCIEDP 299 
************************************************************ 
CD11b VSPIVLRLNFSLVGTPLSAFGNLRPVLAEDAQRLFTALFPFEKNCGNDNICQDDLSITFS 360 
alpha2 VSPIVLRLNFSLVGTPLSAFGNLRPVLAEDAQRLFTALFPFEKNCGNDNICQDDLSITFS 360 












CD11b PISLVFLVPVRLNQTVI 557 
alpha2 PISLVFLVPVRLNQTVI 557 
***************** 
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CD11bNE- Translated a3E Fragment Sequence Data 
alpha3E IWDRPQVTFSENLSSTCHTKERLPSHSDFLAELRKAPVVNCSIAVCQRIQCDIPFFGIQE 60 
CdllbNE IWDRPQVTFSENLSSTCHTKERLPSHSDFLAELRKAPVVNCSIAVCQRIQCDIPFFGIQE 60 
************************************************************ 
alpha3E EFNATLKGNLSFDWYIKTSHNHLLIVSTAEILFNDSVFTLLPGQGAFVRSQTETKVEPFE 120 
Cdl1bNE EFNATLKGNLSFDWYIKTSHNHLLIVSTAEILFNDSVFTLLPGQGAFVRSQTETKVEPFE 120 
alpha3E VPNDYKDDDDKKLEL 135 
Cd11bNE VPNDYKDDDDKKLEL 135 
*************** 
CD18N- Translated Construct 
seqdata MLGLRPPLLALVGLLSLGCVLSQECTKFKVSSCRECIESGPGCTWCQKLNFTGPGDPDSI 60 
CD18 MLGLRPPLLALVGLLSLGCVLSQECTKFKVSSCRECIESGPGCTWCQKLNFTGPGDPDSI 60 
seqdata RCDTRPQLLMRGCAADDIMDPTSLAETQEDHNGGQKQLSPQKVTLYLRPGQAAAFNVTFR 120 
CD18 RCDTRPQLLMRGCAADDIMDPTSLAETQEDHNGGQKQLSPQKVTLYLRPGQAAAFNVTFR 120 
seqdata RAKGYPIDLYYLMDLSYSMLDDLRNVKKLGGDLLRALNEITESGRIGFGSFVDKTVLPFV 180 
CD18 RAKGYPIDLYYLMDLSYSMLDDLRNVKKLGGDLLRALNEITESGRIGFGSFVDKTVLPFV 180 
seqdata NTHPDKLRNPCPNREKECQPPFAFRHVLKLTNNSNQFQTEVGKQLISGNLDAPEGGLDAM 240 
CD18 NTHPDKLRNPCPNKEKECQPPFAFRHVLKLTNNSNQFQTEVGKQLISGNLDAPEGGLDAM 240 
seqdata MQVAACPEEIGWRNVTRLLVFATDDGFHFAGDGKLGAILTPNDGRCHLEDNLYKRSNEFD 300 
CD18 MQVAACPEEIGWRNVTRLLVFATDDGFHFAGDGKLGAILTPNDGRCHLEDNLYKRSNEFD 300 
************************************************************ 
seqdata YPSVGQLAHKLAENNIQPIFAVTSRMVKTYEKLTEIIPKSAVGELSEDSSNVVHLIKNAY 360 
CD18 YPSVGQLAHKLAENNIQPIFAVTSRMVKTYEKLTEIIPKSAVGELSEDSSNVVHLIKNAY 360 
************************************************************ 
seqdata NKLSSRVFLDHNALPDTLKVTYDSFCSNGVTHRNQPRGDCDGVQINVPITFQVKVTATEC 420 
CD18 NKLSSRVFLDHNALPDTLKVTYDSFCSNGVTHRNQPRGDCDGVQINVPITFQVKVTATEC 420 
seqdata IQEQSFVIRALGFTDIVTVQVLPQCECRCRDQSRDRSLCHGKGFLECGICRCDTGYIGKN 480 
CD18 IQEQSFVIRALGFTDIVTVQVLPQCECRCRDQSRDRSLCHGKGFLECGICRCDTGYIGKN 480 
************************************************************ 
seqdata CECQTQGRSSQELEGSCRKDNNSIICSGLGDCVCGQCLCHTSDVPGKLIYGQYCECDTIN 540 












CD18 TCKERDSEGCWVAYTLEQQDGMDRYLIYVDESRECVAGPN 700 
**************************************** 




APPENDIX III: CALIBRATION OF SIZE EXCLUSION COLUMNS 
a) Superdex 75. 









Standards Mw (Da) log Mw time (min) 
acetone 50 1.70 27.00 
c ctochrome c 10500 4.02 18.29 
carbonic anhydrase 29000 4.46 14.70 
BSA 66000 4.82 12.03 
BSA dimer 132000 5.12 11.25 
alcohol deh dro enase 150000 5.18 11.05 
Blue dextran 2000000 6.30 10.80 
b) Biosep 3000. 







8.00 9.00 10.00 11.00 12.00 
Time (min) 
Standards MW log MW time min 
c ochrome c 10500 4.02 11.65 
carbonic anh drase 29000 4.46 10.95 
BSA 66000 4.82 9.81 
alcohol deh dronase 150000 5.18 9.37 
y=-0.210x+7.512 
z R=0,979 
IJ GU L3 
time (min) 
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c) Superdex 200 




" y=-0.1412x+7.5356 5.2 -" R2=0.981 
5 





10 12 14 16 18 20 22 24 26 
time (min) 
Standards MW lo MW time min 
c ochrome c 12000 4.08 24.92 
carbonic anh drase 29000 4.46 21.77 
bovine serum albumin 66000 4.82 18.52 
BSA dimer 132000 5.12 16.15 
am lase 200000 5.30 16.24 
apoferritin 443000 5.65 14.03 
th ro lobulin 669000 5.83 12.31 













Standard Protein MW l0 10 MW time min 
c ochrome c 12.40 1.09 23.60 
carbonic anh drase 29.00 1.46 21.80 
BSA 66.00 1.82 18.50 
b-am lase 200.00 2.30 16.39 
a oferritin 443.00 2.65 14.10 
th ro Iobulin 669.00 2.83 12.25 
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APPENDIX IV: EXAMPLES OF BIACORE KINETIC 
EVALUATION 
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